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Preface 
Preface 
In developed countries like the Netherlands health care for patients with chronic diseases is of 
a high standard compared with many other, less fortunate countries around the world. The 
typical structure of the Dutch health care system, with general practitioners (GPs) as the 
gatekeepers towards medical specialist and paramedical care facilities provides a rather 
transparent and efficient health care infrastructure.1 The GP gatekeeper structure is intended 
to reduce costs while maintaining or improving the quality of care by increasing coordination 
and preventing and reducing duplicative or inappropriate care.2 This is especially important 
for patients with chronic diseases, many of whom are dependent on medical care and seek 
contact with health care providers on a regular basis. 
Two chronic diseases that are highly prevalent in the population are asthma and chronic 
obstructive pulmonary disease (COPD).3,4 Until about 1997, the two conditions were often 
described jointly by the overarching term chronic non-specific lung disease (CNSLD, or 
‘CARA’).5,6 Nowadays, asthma and COPD are recognized as two separate disease entities, 
although individual patients may well exhibit features of both diseases.7 Even specific 
histopathological features in endobronchial biopsy specimens are not always sufficient to 
discriminate between COPD and asthma.8 This means that –even with extensive diagnostic 
testing- the two conditions cannot always be strictly separated, which may complicate the 
appropriate choice of treatment. Moreover, underdiagnosis in the general population appears 
to substantial for both conditions.3,9 
The subdivision of CNSLD into asthma and COPD has had (and still has) important 
consequences for the way patients in the Netherlands are diagnosed and managed by GPs. 
Over the next few years it is expected that in many countries a sharp increase will occur in the 
prevalence of both asthma and COPD. Especially patients with COPD will make steadily 
increasing demands on available primary and secondary health care services10. One of the 
major challenges for the near future is to achieve efficient use of available health care services 
for patients with COPD and asthma. This means propagating effective treatment in patients 
for whom this is indicated, while at the same time reducing unnecessary and ineffective 
treatment and counteracting barriers that restrain optimal delivery of care. These goals should 
preferably be attained on the basis of scientific evidence, to which this thesis makes a modest 
contribution. 
The thesis contains chapters that pertain to COPD, to asthma, or to both conditions 
simultaneously. The Introduction consists of the summary of a comprehensive literature 
review regarding the efficacy and (cost-)effectiveness of a range of health care interventions 
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for COPD and asthma, which was performed as a part of the 1997 Public Health Status and 
Forecasts (PHSF) project enforced by the National Institute of Public Health and the 
Environment (RIVM)11. Possible barriers towards attaining optimal health care for patients 
with COPD and asthma were also identified and discussed in this PHSF contribution. The 
subsequent chapters mainly comprise two topics that were also considered in the PHSF, and 
which are particularly relevant for the primary care management of patients with COPD and 
asthma, i.e. (1) spirometric testing in the general practice setting, and (2) treatment with 
inhaled corticosteroids in different study populations of subjects with -or at high risk of- 
chronic respiratory disease. Chapter 1 is a review of the literature on different aspects of 
spirometry in general practice. Because the accessibility of spirometry for GPs has 
substantially improved over the last couple of years, evidence-based information needs to be 
established in order to critically assess the applicability of spirometry as a tool for diagnosis 
and monitoring in the general practice setting. In Chapters 2 through 4 the results of two 
original studies regarding the validity of spirometric tests performed in Dutch general 
practices are reported. Chapter 5 explores the impact of spirometry on GPs’ diagnostic 
differentiation and decision making, whereas Chapter 6 reflects on the current status and 
organisation of spirometry in primary care. Chapter 7 reports a qualitative study in which the 
views of pulmonologists with regard to efficient referral and consultation in patients with 
COPD or asthma are explored. In chapters 8 to 11 the effects of regular treatment with inhaled 
corticosteroids, one of the most prescribed classes of drugs in COPD and asthma, is studied in 
three different populations: adult patients with asthma (Chapters 8 and 9), subjects with early 
signs and symptoms of COPD (Chapter 10), and patients with COPD or chronic bronchitis 
(Chapter 11). In asthma the position of inhaled corticosteroids is no longer a matter of 
dispute.12 However, the role of inhaled steroids in the management of COPD is less clear13, 
although evidence is accumulating that supports a preventive effect on the occurrence of acute 
exacerbations14-16, deterioration of health status14, and maybe the progression of airflow 
limitation.16 Finally, Chapter 12 focuses on the occurrence and costs of acute exacerbations in 
patients with COPD or chronic bronchitis. Prevention of exacerbations is generally considered 
as one of the main treatment goals in these patients18,19, because exacerbations are known to 
have a significant impact on the quality of life20,21 and are responsible for the majority of 
COPD-related health care costs.22,23 Moreover, exacerbation rate is increasingly used as an 
outcome measure in long-term clinical COPD studies.24 The data presented in Chapters 11 
and 12 are from a randomised controlled trial, the COOPT (‘COPD on Primary Care 
Treatment’) study, in which the long-term effects of regular treatment with N-acetylcysteine 
11
and the inhaled corticosteroid fluticasone propionate are investigated in a primary care 
population of patients with COPD. The results of this study were not timely available for 
inclusion in this thesis. 
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Introduction 
 
 
 
 
 
 
Published as: The Public Health Status and Forecast 1997. 
Chapter 8. Chronic Non-Specific Lung Disease, 
National Institute of Public Health and the Environment (RIVM), 1997  
CHRONIC NON-SPECIFIC RESPIRATORY DISEASE (CNSLD) 
 
1. Introduction 
 
This chapter gives a summary of a comprehensive literature review on the efficacy and 
effectiveness of health care interventions for COPD and asthma and barriers associated with the 
primary process of care delivery. These barriers comprised: contact with the health care system, 
diagnosis of the disease, indications for intervention, the execution of care and treatment 
compliance (Schermer et al. 1997). To justify the contents and the majority of literature 
references, the reader is referred to the background report. 
In contrast with the usual approach taken in the 1997 Public Health Status and Forecasts 
(PHSF), this literature study categorized chronic non-specific respiratory disease (CNSLD) into 
chronic obstructive pulmonary disease (COPD, chronic bronchitis and emphysema) and asthma. 
Chronic bronchitis is characterised by the hypersecretion of mucus in the bronchial tree that 
manifests itself as a chronic or recurrent productive cough. By definition, these symptoms must 
be present on most days, for a minimum of three months per year and for at least two consecutive 
years. Emphysema is defined as anatomical changes in the lungs, characterised by abnormal 
enlargement of the air-containing spaces distal to the terminal, non-respiratory bronchioli, 
without any evidence of fibrosis. Asthma is described as inflammation of the respiratory tract that 
is accompanied by reversible narrowing of the bronchi and increased bronchial responsiveness to 
various trigger factors. 
COPD and asthma have different pathogeneses and pathophysiologies. In this chapter, it is 
particularly important to distinguish between COPD and asthma, because there are diagnostic and 
therapeutic consequences and also consequences regarding the outcome of the disease processes. 
In section 1.2, this distinction receives further elaboration. 
 
1.1 Methods 
A literature review was performed in which the efficacy of health care interventions was 
judged on the basis of systematic literature reviews, meta-analyses and original studies, such 
as randomised clinical trials (RCTs). Information was obtained via the Cochrane 
Collaboration, MEDLINE (period 1981-1996), references in relevant literature, the 
Nederlands Tijdschrift voor Geneeskunde, Huisarts & Wetenschap, Tijdschrift voor Sociale 
Geneeskunde and Dutch theses. The quality of the original reports was assessed using the 
criteria formulated by Guyatt et al. (Guyatt, et al., 1993). Preference was given to randomised 
controlled studies. When these were unavailable, use was made of non-randomised studies. 
Information on the effectiveness of interventions and the primary process of care was 
obtained from the same sources, except for the Cochrane Collaboration. When necessary, 
additional information was obtained from experts in the fields of COPD and asthma. 
To review the literature on economic evaluations of COPD/asthma, extensive searches were 
made in MEDLINE (1968-1996), diverse bibliographies, editions of journals on health 
economics and cross-references. 
 16
 
1.2 Epidemiology, pathogenesis, disease course and prognostic factors 
On the basis of general practice registries, it was estimated that 172,500 persons were suffering 
from asthma in 1994, while 290,000 persons were suffering from COPD (see Theme Report I, 
Part B2, Section 4). In that year, an estimated 60,500 persons were newly diagnosed with asthma, 
while 34,600 were newly diagnosed with COPD. In 1994, data showed that 54 patients died from 
asthma, while 5643 died from COPD. This means that approximately 50,100 years of life were 
lost (see Theme Report I, Part B1, Section 3.1). 
COPD is characterised by pathophysiological changes in gas exchange, ventilation and 
pulmonary circulation. Chronic bronchitis is associated with increased numbers of mucus-
producing goblet glands, while these glands, in contrast with the normal situation, can also be 
found in the more peripheral airways. Cellular inflammatory infiltrates are present in the mucus 
membrane and also around the goblet glands. Inhalation of cigarette smoke and viral or bacterial 
respiratory infections cause increases in mucus production and decreases in mucus drainage. 
Viral infections and inhalation of tobacco smoke, ozone, nitrogen dioxide and other irritating 
agents are largely responsible for the increases in oxygen radical level and enzymes that are 
harmful to lung tissue. It is assumed that the natural anti-oxidative protection mechanisms of the 
body against these oxygen radicals fails in COPD patients. The combination of the relative excess 
of harmful enzymes and damaged support tissue of the lungs and alveolar walls ultimately leads 
to emphysema. Interaction between oxygen radicals and immune defence cells may increase the 
risk of recurrent respiratory infections in COPD. 
Asthma is characterized by infiltration of various types of inflammatory cells into the walls 
of the bronchi, which damages the bronchial mucosa and causes oedema and thickening of the 
basal membrane. The combination of increased mucus production and contraction of the smooth 
muscle in the bronchial walls leads to bronchial constriction. An important difference between 
asthma and COPD is that the bronchial constriction in asthma is reversible, either spontaneously 
or due to treatment. The bronchial hyperresponsiveness (BHR) typical of asthma is caused by 
genetic factors and environmental factors (such as exposure to allergens). BHR is a strong 
determinant of the severity and degree of bronchial constriction. 
Although the natural course of COPD cannot be followed in its pure form, because diverse 
care interventions will have already been applied, it is possible to make an approximation of lung 
function deterioration over time by recording sequential measurements of the forced expiratory 
volume in 1 second (FEV1). The results of various epidemiological studies performed within this 
framework on COPD patients indicated irreversible deterioration of the FEV1 of 48-91 ml per 
year (Burrows, 1991). This decrease is about two to three times more rapid than in healthy 
persons of the same age and sex. Owing to the fairly gradual deterioration in lung function and 
the only moderate correlation between FEV1 and symptoms, many patients do not consult their 
GP until they are in a rather advanced stage of the disease (Van Weel 1996). 
A wide range of prognostic factors determine the (clinical) course in individual COPD and 
asthma patients. A number of these prognostic factors might form suitable targets for health care 
interventions. These include: failure to quit smoking, continuous use of/poor response to 
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bronchodilatory medication (Van Schayck & Van Herwaarden 1993), airway infections and 
hypersecretion of mucus in the lungs, hypoxaemia and nocturnal desaturation, malnutrition, poor 
functional status, reduced exercise tolerance, cardiac dysfunction and congestive heart failure, 
alpha-1-antitrypsin deficiency, bronchial hyperresponsiveness, occupational exposure factors. 
Outcome measures that are relevant to COPD and asthma are: mortality, quality of life, 
functional status, illness-related absenteeism from work or school and incapacity to work. All 
these aspects are less favourable than in the general population. Intermediary outcomes for 
COPD and asthma are: FEV1 (as predictor of mortality and functional status) and BHR (as 
indicator of the severity of bronchial inflammation), respectively. Peak flow measurements can 
be used in asthma patients to monitor treatment effects. 
 
2. Outcomes and process assessment 
 
2.1 Contact with the health care system 
Dutch screening programmes on the general population revealed that 306 per 1000 persons aged 
25-70 years, after exclusion of patients with congestive heart failure and chronic pulmonary 
diseases other than COPD or asthma, had symptoms or lung function abnormalities consistent 
with COPD or asthma (Tirimanna et al., 1996a). In 65%, the GP was not aware of this, while in 
the group with severe symptoms or severely compromised lung function, the GP was not aware 
in 7%. As mentioned above, many patients do not consult their GP until a late stage of the 
disease. Explanations for this are the gradual deterioration in lung function, the moderate 
correlation between lung function (FEV1) and symptoms, and different perceptions of dyspnoea 
(Tirimanna et al., 1996b); Tirimanna, 1997; Van Weel, 1996). 
 
2.2 Diagnosis 
One year after the primary diagnosis of asthma had been made by the GP, the diagnosis was still 
recorded by the GP in only 60% of the cases; ten years later, this was only 20% (Bottema 1993). 
Apparently, the symptoms had diminished to such an extent that the diagnosis was no longer 
justifiable. It is possible that over-diagnosis played a role. Besides evidence of over-diagnosis, 
there is also evidence of under-diagnosis (Bottema 1993). Furthermore, it has been suggested that 
the ineffectiveness of health care interventions in a proportion of the patients can be attributed to 
insufficient differentiation between asthma and COPD. This differentiation can be made to a 
certain extent using lung function tests, while the (clinical) course of asthma and COPD can be 
monitored by recalling the patient for regular lung function tests. 
 
2.3 Health care interventions 
Tables 1 and 2 give overviews of health care interventions for COPD and asthma, their efficacy, 
effectiveness, indications, barriers reported in relation with their administration and (if 
applicable) treatment compliance. 
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The tables show that a large number of health care interventions are effective. These 
interventions influence outcomes such as symptoms, physical functioning, quality of life, FEV1 
and mortality. The size of the effects and the outcome measures differed between studies. 
Judgements of efficacy were chiefly made on the basis of randomised controlled trials. However, 
for a number of health care interventions, no data were available from such trials. For example, 
no experimental research was available on influenza vaccination in COPD patients, but 
assessments of efficacy were derived from studies on the elderly; in the case of lung 
transplantation, judgement was based on comparisons between patients who had undergone a 
lung transplant and the patients on the waiting list who acted as controls. 
Information on the effectiveness of health care interventions was often lacking, or 
effectiveness assessments were made on the basis of research from other countries. 
Consequently, it was impossible to draw any conclusions about the health benefit that might be 
gained from specific health care interventions by comparing studies on efficacy under ideal 
circumstances to studies performed in daily practice. 
Information about barriers in the process of care was scarce and partly based on foreign 
research. Nevertheless there were indications that some of the barriers also applied to the Dutch 
situation (see table 1). Solving these problems can lead to greater health benefit. 
 
COPD 
By solving the barriers in treatment indications for COPD, more health benefit can be achieved 
if: 
• GPs advise more patients to quit smoking and repeats this advice often 
• more patients are vaccinated against influenza 
• more consideration is given to anticholinergic medication as the first choice instead of β2-
agonists 
• oral corticosteroids are indicated more often as experimental treatment for severe, stable, 
therapy-resistant COPD 
• fewer prescriptions are written for antibiotics and are based more on further diagnostics into 
the cause of exacerbation. A short course of corticosteroids might form an alternative 
• more indications are recognised for (outpatient) pulmonary rehabilitation or home care 
• ventilatory support with oxygen is started at home at an earlier stage and is based more often 
on existing indication criteria 
• non-invasive ventilatory support is offered (at home) to the small subgroup of COPD 
patients who might benefit from it 
• more attention is paid to (preventive) measures and advice relevant to the working 
environment of patients who are active in the employment process. 
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Table 1. Health care interventions for COPD: efficacy, effectiveness and barriers in the process 
of care delivery. 
 
Health care 
interventiona 
Efficacyb Effectivenessb Indication 
for 
treatmentc  
Executionc Treatment  
compliancec 
Comment 
Smoking cessation 
 
+ + + + + Trials in smokers 
Influenza vaccination 
 
? to + ? + ? n.a. No trials specifically in COPD, 
but in healthy/elderly subjects 
Preventive measures 
with surgical 
interventions 
 
? ? ? ? ? No trials in COPD, but in major 
(abdominal) surgery, 
recommendation according to 
guideline 
Anticholinergics 
 
+ ? + + + Preferred above β2-agonists 
β2-agonists 
 
+ ? + + +  
Methylxanthines 
 
+ ? ? ? + Compared to placebo 
Inhaled 
corticosteroids 
 
? ? ? ? + Trials with probable case-mix 
with asthma 
Oral corticosteroids 
 
+ ? + + + Compared to placebo, not to 
inhaled corticosteroids 
N-acetylcysteine 
 
+ ? ? ? + Reduced risk of exacerbation, 
anti-oxidative effect is being 
investigated 
Mucolytics and 
cough preparations 
 
? to + ? ? ? + One trial for one drug 
Antibiotics 
 
- to + ? + ? + Not effective compared to oral 
steroid courses, effective 
compared to placebo. Cause of 
exacerbations often unclear in 
trials 
(Outpatient) 
pulmonary 
rehabilitation 
+ + + + +  
(Multidisciplinary) 
home care, after-care, 
transmural care 
+ ? + ? ? In other countries effect on 
mortality by deploying 
respiratory nurses 
Physiotherapy 
 
- to + ? ? ? ? Depending on the nature of the 
treatment 
Home oxygen 
therapy 
 
+ + + + +  
Chronic intermittent 
ventilatory support 
- to + ? + + +  
Lung transplants and 
lung volume 
reduction surgery 
? to + ? ? ? n.a. Before-after comparison or 
waiting list controls, mixture of 
pulmonary diseases 
Patient education and 
self-management 
 
- - + ? + Effect on hospital admissions 
a) efficacy unknown for pneumococcal and staphylococcal vaccination, alpha1-antitrypsine supplementation and nutritional 
supplementation. 
b) + = proven, - = inefficacious or ineffective, ? = unknown or unclear, … to …= dependent on subgroup or specific intervention.  
c) + = barrier present, ? = unknown. 
n.a. = not applicable. 
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The execution of health care interventions for COPD can be improved by: 
• providing more intensive guidance and after-care following smoking-cessation advice 
• giving better instruction about the inhalation technique of diverse respiratory drugs 
• monitoring the effects and side-effects of a trial treatment with corticosteroids more closely 
• providing adequate supervision and after-care following outpatient or clinical pulmonary 
rehabilitation in order to prevent relapse 
• prescribing oxygen at home for a sufficiently long duration, providing better instruction 
about its use, supplying modern equipment and making closer evaluations of the treatment 
effect 
• improving the feasibility of ventilatory support treatment and its administration by means of 
intermittent ventilatory support at home 
• increasing the uptake of influenza vaccination, for instance by providing better patient 
education and organising special vaccination consulting hours. 
 
Improvements in treatment compliance to a large number of health care interventions for COPD 
can also lead to greater health benefit. 
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Table 2.Health care interventions for asthma: efficacy, effectiveness and barriers in the process 
of care delivery. 
 
Health care interventiona Efficacy b Effectiveness b Indication for 
treatment c 
Execution c Treatment 
compliance c 
Smoking cessationd + + + + + 
Influenza vaccination + ? + ? n.a. 
Domestic allergen avoidance 
measures 
+ ? + ? + e 
Allergen immunotherapy + + + ? + 
Preventive measures in case 
of surgical interventions 
? f ? ? ? ? 
Anti-cholinergics  - to + g ? + + ? 
β2-agonists + + h + + + 
Methylxanthines - to + i ? + + + 
Inhaled corticosteroids + j + + + + 
Oral corticosteroids + k + l + ? ? 
Nedocromil and cromones + ? + ? + 
(Multidisciplinary) home 
care, after-care, transmural 
care 
? m ? ? + + 
Physiotherapy + n + ? ? ? 
Patient education and self-
management 
- to + o + + ? + 
 
a) for pneumococcal and staphylococcal vaccination the preventive efficacy has not been established sufficiently in clinical trials; no placebo-controlled 
trial has been reported for antibiotics. 
b) + = proven, - = ineffective, ? = unknown or unclear, … to … = depends on the subgroup ore type of intervention. 
c) + = barrier present, ? = unknown, n.a = not applicable. 
d) trials in smokers. 
e) proportion that takes avoidance measures is rather limited; it is unknown to what extent advices given by physicians or paramedical professionals are 
followed. 
f) no trials in patients with asthma, but from preventive measures in major (abdominal) surgical procedures. 
g) in adults no long-term additional value compared with β2-agonists; in children additional value when combined with β2-agonists in exacerbations. 
h) in a foreign region with a low β2-agonists prescription rate more asthma-related hospital admissions. 
i) no additional value in treating exacerbations compared with β2-agonists and systemic corticosteroids, short-term effect of regular treatment. 
j) in a foreign region with a low prescription rate more asthma-related hospital admissions. 
k) short course in case of exacerbation; reduction of hospital admissions and improved exacerbation recovery. 
l) in a foreign region with a low prescription rate more hospital admissions for asthma 
m) multidisciplinary home care efficacious in a randomised trial in CNSLD; no effect of CNSLD-nurse supervision at home in a randomised study. 
n) relaxation exercises. 
o) in adults  not in children. 
 
 
ASTHMA 
Determining treatment indications for asthma can be enhanced by: 
• improving the diagnosis of allergies and causes of exacerbations 
• encouraging patient education and self-treatment/self-management in adult patients 
• advising more patients to quit smoking and repeating this advice more often 
• making more recommendations about domestic allergen avoidance measures following 
adequate allergy diagnostics 
• conducting more allergen-immunotherapy in specific subgroups (after adequate allergen 
diagnostics) 
• prescribing more prophylactic medication, such as nedocromil, cromoglycine acid or inhaled 
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corticosteroids 
• prescribing inhaled corticosteroids (if necessary in higher dosages) instead of systemic 
corticosteroids 
• giving more consideration to β2-agonists than to anticholinergics for bronchodilatory 
treatment 
• limiting the use of methylxanthines as regular treatment 
• using systemic corticosteroids and β2-agonists more often and at an earlier stage during 
exacerbations and avoiding the use of methylxanthines 
• using systemic corticosteroids more often for therapy-resistant asthma 
• exercising moderation in the prescription of antibiotics during asthma exacerbations 
• encouraging relaxation training 
• paying more attention to (preventive) measures and advice in relation with the work situation 
of patients who are active in the employment process. 
 
The execution of health care interventions for asthma can be improved by: 
• providing more intensive guidance and after-care following smoking-cessation advice 
• encouraging the use of β2-agonists "as required" instead of continuously 
• emphasizing "continuous" use of inhaled corticosteroids 
• monitoring serum concentrations after the prescription of methylxanthines 
• closely monitoring patients on oral corticosteroids for early detection of side-effects. 
 
Encouraging treatment compliance to achieve health benefit also applies to asthma patients. 
 
3. Economic evaluations 
 
Table 3 shows the results of a literature study on economic evaluations of health care 
interventions for COPD and asthma. Not all health care interventions were subjected to economic 
evaluation. A total of 87 studies were traced that applied to 24 health care interventions, 
including several cost-of-illness studies and partial economic evaluations. No studies at all were 
found on seven health care interventions. In ten of the health care interventions, it was possible to 
make some degree of judgement about cost-effectiveness, albeit with the greatest of caution. 
Another important finding was that the study designs varied widely, which made mutual 
comparisons practically impossible and no conclusions could be drawn on actual differences in 
cost-effectiveness between health care interventions. 
 
 
 
 
 
23
Table 3. Literature review on economic evaluations in COPD and asthma 
 
Intervention No. of 
studies 
Results Comments C-E 
Smoking cessation 6 2xLYS, 1xQALY, 
1xCOI, 2xother 
Various interventions, non-CNSLD 
specific, mainly modelling studies 
?+ 
Influenza vaccination 7 2xLYS, 3xQALY, 
2xCBA 
mainly modelling studies, on high-risk 
populations probably cost-effective 
+ 
Pneumococcal vaccination 4 3xLYS, 1xCBA Results of modelling studies differed 
substantially, not all relevant cost was 
included 
?+ 
Allergen immunotherapy 1 CBA Only part of direct cost was estimated ? 
Anticholinergics 4 1xCVM, 1xCBA, 
2xO 
Compared to various alternatives, not C/E 
in asthma or in case of acute exacerbation 
?+ 
β2-agonists 8 1xEFD, 3xO, 
2xCMA, 2xCBA  
Differences in study design, perspective 
and outcome measures 
? 
Methylxanthines 2 1xCFM, 1xO Limited indication ?- 
Inhaled corticosteroids 
(children) 
3 1xO, 1xSFD, 
1xCBA 
Dutch study regarding costs and savings, 
good quality design 
?+ 
Inhaled corticosteroids 
(adults) 
5 1xCOI, 3xO, 
1xCBA 
Dutch study regarding costs and savings, 
good quality design, asthma only, increase 
of dose not C/E 
?+ 
Systemic corticosteroids 1 1xO Insufficient data ? 
Cromones 1 1xCBA Insufficient data ? 
Alpha-1 antitrypsine 
supplementation 
1 1xLYS Modelling study, appears to quite 
expensive 
?- 
Pulmonary rehabilitation 3 1xWY, 1xCBA, 
1xO 
Probably C/E in a selected target 
population, insufficient good-quality data 
?+ 
Home care, after-care, 
transmural care 
5 1xO, 4x CBA Improved integration between care 
echelons may be C/E, additional good-
quality studies are needed 
?+ 
Home oxygen therapy 9 9xO None of the traced studies were full 
economic evaluations 
? 
Home mechanical 
ventilation 
6 6xO None of the traced studies were full 
economic evaluations 
? 
Lung transplantation 2 2xQALY Good-quality Dutch study, results positive 
compared with other studies 
?- 
Patient education and self-
management (children) 
5 3xCBA, 2xO Diverse interventions, different cost 
categories included 
?+ 
Patient education and self-
management (adults) 
8 7xCBA, 1xO Mainly asthma, diverse interventions and 
cost categories, no cost-effectiveness 
analyses 
?+ 
a  no economic evaluations could be traced for: allergen avoidance measures, prophylactic measures in surgery, 
N-acetylcysteine, expectorants, antibiotics, nutritional interventions, physiotherapy 
 
Abbreviations used:    
CEA = Cost-effectiveness analysis EFD = CEA based on Episode-Free Day 
CBA = Cost-benefit analysis SFD = CEA based on Symptom-Free Day 
CMA = Cost-minimisation analysis WY = CEA based on Well Years 
LYS = CEA based on Life Years Saved O = Other CEAs or cost studies 
QALY = CEA based on Quality Adjusted Life Years C/E = Cost-effective 
COI = Cost of Illness study     
CFM = CEA based on Complication-Free Month    
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4. Future developments 
 
Over the next few years, it will become clear whether early detection of COPD and/or asthma is 
desirable. Diagnostic procedures to discriminate COPD from asthma will undergo further 
refinement. In the field of pathophysiology, the role of free radicals will become more definite. In 
the longer-term, more insight into the pathophysiology of asthma and COPD might yield new 
medication that focuses specifically on the pathogenetic mechanism. The effect of inhaled 
corticosteroids on COPD should become apparent in the short-term, as well as insight into the 
effect of N-acetylcysteine (NAC) on COPD. In the field of patient care, pulmonary rehabilitation 
will gain importance and it will be necessary to pay more attention to after-care. 
 
5. Discussion 
 
A large number of health care interventions exist for COPD and asthma. These interventions 
have proved to be efficacious in improving a wide range of outcome measures, such as 
respiratory complaints, exacerbations, physical functioning, quality of life, FEV1 and mortality. 
Studies vary strongly on the size of the effects and the type of outcomes for which effects have 
been demonstrated. 
Only limited knowledge is available on the degree to which existing health care 
interventions yield health benefits in daily practice. It was impossible to calculate the level of 
health benefit that could be gained on the basis of direct comparisons between studies on 
effectiveness in daily practice and studies in which the intervention was applied under ideal 
circumstances. 
Economic evaluation studies proved to be limited in number, quality, comparability and 
applicability to the Dutch situation. There is a particular need for more, better quality studies that 
are relevant to Dutch health care practice. 
Insight into barriers in the primary process of care is partly based on foreign study data and 
partly lacking. Nevertheless a large number of barriers have been demonstrated in areas such as: 
patient contact with the health care service, diagnostic procedures, determination of treatment 
indications, execution of health care interventions and treatment compliance. 
A large proportion of persons with (mild) COPD or asthma never consult health care 
services about these complaints. There are indications that health benefit can be achieved in this 
group. A randomised, double-blind trial was conducted on the effects of inhaled corticosteroids in 
subjects with respiratory complaints and impaired lung function and/or bronchial 
hyperresponsiveness (BHR) (Tirimanna, 1997). These subjects were detected in the general 
population and were not registered as having COPD or asthma by their GP. After one year of 
treatment with an inhaled corticosteroid, improvements in lung function and BHR were observed. 
The diagnosis can be improved by making use of lung function tests, so that COPD can be 
distinguished from asthma. Assessment of treatment indications also requires supplementary 
investigations, such as allergy testing and evaluation of the cause of exacerbations. It seems likely 
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that improvements can be made in the determination of indications for preventive health care 
interventions, regular treatment and treatment for exacerbations. In addition, health benefit may 
be achieved by broadening the indications to enable non-invasive and non-pharmaceutical-based 
health care interventions, in particular patient education and self-management. Greater health 
benefit can be achieved not only through better determination of treatment indications, but also 
through better execution of the health care interventions by professionals. Treatment compliance 
to many health care interventions is far from perfect, which offers further scope for improving 
health benefit. It is difficult to quantify the amount of health benefit that can be gained by 
overcoming these barriers. One reason for this is that the relationship between the current process 
of care in practice and the outcomes has received little or no research attention. Another reason is 
that selection occurs in the determination of treatment indications. For example, the group of 
patients with severe asthma will be the first to receive inhaled corticosteroids. Broadening the 
indications for inhaled corticosteroids will indeed lead to health benefit, but it cannot be expected 
that the health benefit achieved in the remainder of the patients with milder asthma will be as 
high as that in the more severe group. 
In the overview of barriers, suggestions have been made regarding aspects that need to be 
improved within the primary process of health care delivery. Ways in which to achieve these 
improvements have never been studied, although a few recommendations were made in the report 
by Schermer et al. (1997). To achieve improvements, standards or guidelines are required such as 
those of the Dutch College of General Practitioners (NHG). These guidelines present state of the 
art health care management recommendations that are easily accessible for GPs. Some 
improvement will be achieved by simply applying these guidelines in a consistent manner. New 
guidelines for COPD/asthma have been published fairly recently (Geijer et al., 1997a; Geijer et 
al., 1997b; Geijer et al., 1997c). 
Besides providing information for health care professionals and endeavouring to apply the 
NHG guidelines in a consistent manner, it is also necessary to provide further education for GPs 
and practice assistants. In particular, it is important that they refine their skills in giving advice, 
encouraging self-management and giving instructions about inhalation technique and medication 
use. From an organizational perspective, it should be possible to improve the ‘tuning’ of care 
within primary health care (GPs and home care organisations), and also between primary care 
(GPs) and secondary care (pulmonologists). Furthermore, lung function testing could be 
stimulated in general practice and the GP should have direct access to lung function laboratory 
facilities. In this way, better distinction can be made between COPD and asthma, which will also 
mean more adequate treatment targeting. 
We recommend concentrating responsibilities and registration of data on patients who 
receive special treatments, such as the oxygen treatment at home and chronic intermittent 
respiratory support. 
Owing to the lack of knowledge on the process of care and outcomes, we also recommend 
that relevant parameters are recorded in general practice registration systems so that evaluations 
can be made of these processes and outcomes. These parameters might include patient 
characteristics that predict the prognosis, or characteristics that form an indication for health care 
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intervention (such as symptoms, severity of the respiratory disorder, etc.), health care 
interventions that have already been applied and relevant outcomes (such as number of 
exacerbations and lung function test results). The value of this approach will increase further if 
the routine is incorporated into a quality improvement structure that can include audit and 
feedback. 
In the future, it is expected that health benefit will be achieved in COPD patients by means 
of medication that affects the role played by free radicals in the pathophysiology and in asthma 
patients by means of medication that specifically influences the mechanism of the underlying 
inflammation process. In addition, it will become clear whether it is desirable to detect COPD 
and asthma at an early stage. 
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The value of spirometry for primary care: Asthma and COPD
TRJ Schermer, HTM Folgering, BJAM Bottema, JE Jacobs, CP van Schayck and C van Weel
INTRODUCTION
The use of spirometry is a topic of discussion among
general practitioners (GPs).  At least one third of 
general practices in the UK either own a spirometer or
have easy access to external spirometry services,1 and
recent contributions to this journal have debated its
value in primary care.2,3
In the 1997 COPD guidelines of the British Thoracic
Society (BTS), spirometry was assigned a central role
in diagnosing and monitoring COPD.4 Since 
management of patients with mild to moderate COPD
usually takes place in primary care, these guidelines
certainly apply to general practice.
The aim of this paper is to review the added value of
spirometry for GPs, the quality of spirometric tests
performed in general practice, and the economic
consequences of large-scale application of spirometry
in primary care.  The evidence from the literature 
(collected by Medline search), recent dissertations and
the three latest annual conference proceedings of th
European Respiratory Society (ERS) and American
Thoracic Society (ATS) annual conferences is 
summarised.
THE VALUE OF SPIROMETRY FOR GPS
Spirometry can benefit primary care in several ways
(Table 1).  Recent studies indicate that the number of
undetected cases with asthma or COPD may be
reduced significantly by spirometry screening in 
general practice.5-8 Based on FEV1, FVC, FEV1/FVC
ratio and reversibility after  bronchodilatation, asthma
can be differentiated from COPD and severity of 
airway obstruction assessed.  Choice of reference
equations appropriate for the local population is
important, since different reference  values may lead
to dissimilar conclusions in terms of normal and
abnormal values and therefore diagnosis.9
When spirometry was introduced in one general 
practice, Spann demonstrated a significant reduction
of the underdiagnosis of COPD in high-risk 
populations, as well as improved differentiation
between reversible and irreversible airway 
obstruction.10 After bronchodilator treatment had been
adjusted on the basis of spirometry results, 25% of
patients reported a significant improvement in 
respiratory symptoms.  More recently, Pinnock et al.
found 56% of the cases referred to a primary care
asthma clinic had the diagnosis modified after 
spirometry.2 However, GPs can be inconsistent in
choosing to perform spirometry when chronic airway
disease is suspected.  Kesten t al. found that only 5%
(4/75) of Canadian GPs requested a pulmonary 
function test when consulted by an individual with
clear signs of COPD.11 Access to spirometry 
facilities was not a limiting factor, since the majority
(2/3) of the GPs involved had access to such services.
Although he did not consider COPD, Jones
demonstrated that availability of spirometry facilities
in itself does not guarantee integration of spirometry
in the GPs’ management of asthma.12 Moreover, the
author concluded that further consideration and 
clarification on a wider scale is required before limited
resources, whether in terms of time or money, are
committed to spirometry testing in asthma in primary
care.
INTERPRETATION
Although the practice of expressing FEV1 values as a
percentage of the predicted value is widely used, there
is evidence that using 80% of the predicted FEV1
value as a consistent lower limit of normal is not the
best method of assessment.  This method could lead to
more elderly and shorter individuals being classed as
abnormal than the original regression equations would
support.  Although the use of standardised residual
scores (SRS) would obviate this problem,13 this
method is far more complicated and therefore 
impractical for use in general practice.
Assessment of exacerbation severity and recovery is
another useful application of spirometry, especially in
patients with COPD.14 Monitoring of annual FEV1
decline – a typical feature of COPD – may be a less
ABSTRACT
In this paper, the need for widespread use of
spirometry in primary healthcare is appraised
through a literature review.  The added value of
spirometry for and the quality of measurements
made by general practitioners (GPs), and the 
economic consequences of greater use of 
spirometry in primary care are discussed.
Appropriate application of spirometry in general
practice may lead to improved health status of
patients with chronic obstructive pulmonary disease
(COPD) or asthma, but consistent attention to 
quality assurance measures is vital.  If good quality
cannot be guaranteed in the general practice setting,
the reliability and validity of the tests is uncertain.
Pulmonary function laboratories, nurse-run asthma
clinics, primary care group (PCG)-commissioned
and mobile community-based spirometry services
may be other choices, but it depends on local 
availability as to which choice is most suitable for
organising primary care spirometry.  It is concluded
that spirometry is a potentially useful and feasible
tool for GPs, provided that test results are easily
integrated into the GP’s usual management of
patients with obstructive lung disease.  At this time,
the health costs of widespread application of
spirometry in primary care are unknown.
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useful indication for primary care spirometry.
Although serial measurement of FEV1 provides
valuable information on disease progression, changes
over periods of less than a few years are difficult to
detect because the annual rate of FEV1 decline is small
relative to measurement variability.  This problem 
cannot be overcome by increasing measurement 
frequency.15Moreover, recent work by den Otter et al.
suggests that annual FEV1 decline rates measured in
general practice are not interchangeable with rates
based on pulmonary function laboratory 
measurements, the latter tending to be higher.16
ACCURACY, LINEARITY AND 
REPRODUCIBILITY OF ELECTRONIC
SPIROMETERS
In recent years, spirometers have become more and
more manageable and affordable, and therefore 
attractive, for use in primary care.  The first question
that emerges, however, is how these modern electronic
spirometers perform compared to a ‘gold standard’ – 
a conventional spirometer or computer-driven 
calibration equipment.  Linearity and reproducibility
are also essential characteristics.17 Since the 
performance of different types of spirometers varies
considerably, no general statements on these 
characteristics can be made,18 but they have have been
evaluated for several spirometers.19-23Correlations
between parameters as measured by electronic 
spirometer and a gold-standard are generally high.19,20,23
Nonetheless, it has been shown that FEV1 nd F C
values measured with rotary vane spirometers or 
pneumotachographs may be systematically lower than
gold-standard values.19,20,22,23This deviation seems to
increase with higher values of the respective 
parameters (‘non-linearity’).19,20,23Short-term 
reproducibility of electronic spirometers appears to
be quite acceptable for both FEV1 and FVC,19,22,23and
there is some evidence that electronic spirometers
keep  producing valid measurements in the long
term.22,23
Quality control of spirometry needs to be checked 
regularly. Although manufacturers test each new type
of spirometer to ATS-standards,17 in ividual 
spir meters of a particular brand may deviate 
substantially. As flow calibration or control requires
sophisticated test equipment, this is not feasible in
primary care. Calibration with a syringe provides
information on volume accuracy, and does not 
guarantee accurate volume or flow readings during
forced breathing manoeuvres.25F quent ‘biological
calibration’ by a healthy test subject may be a valid
alternative for primary care,26 but more studies on this
matter are needed.
TRAINING AND QUALITY ASSURANCE
A prerequisite for sufficient test quality in primary
care is training of the professionals responsible for the
xecution of spirometry.17 The consequences of 
inadequate expertise have recently been revealed in a
New Zealand study by Eaton et al.27 In this study,
experienced lung function technicians scored several
quality aspects of spirometric tests performed by
tra ned GPs. Sixty-seven percent (16/24) of the GPs
scored above standard, compared to 16% (4/25) in a
non-trained reference group. However, measurement
quality dropped considerably after a few months,
which stresses the importance of consistent attention
to test procedures. In the same study, the practice 
nurses of the same general practices were also
trained.27 Although the nurses’ performance scores
were initially lower compared to the GPs, test 
performance became equal several months later. Work
by our own research group showed that instruction 
and coaching of patients before and during forced 
expiratory manoeuvres were generally insufficient in
general practice.28
RELIABILITY AND VALIDITY
Fo  valid spirometric test results, the measurements
must be reliably performed. When measurement 
quality is insufficient, the error term and the ‘true’
Detection
l Screening of subjects ‘at risk’ for developing chronic airway diseases
Smokers
Occupational exposition to dust and/or irritants
Subjects with recurring respiratory infection
In routine physical examinations
Diagnosis
l Evaluation of
Respiratory symptoms (cough, dyspnoea, dyspnoea during exercise, wheezing or non-specific chest pain)
Physical signs (hyperinflation, cyanosis, chest deformation, crepitations during auscultation)
Abnormal laboratory findings (e.g. chest X-ray)
l Nature and underlying mechanism of airway obstruction by reversibility testing
l Determination of the influence of (worsening of) diseases on the lung function 
l Assessment of prognosis
Monitoring
l Determining the effect of therapeutic interventions
Bronchodilatators
Inhaled and oral corticosteroids
l Providing information on the course of lung function decline
* Adopted and modified from reference 8
Table 1. Relevant indications for spirometry in general practice*
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lung function of the patient will each contribute to the
test result, thus hindering good interpretation.29Criteria
are available for judging the reliability of spirometric
tests in two aspects: 
l assessment of single breathing manoeuvres
(judged by full inspiration, rapid onset of forced
expiration, smooth course of the forced expiration,
and duration of expiration Ž6 s or to an adequate
completion)
l reproducibility after repetition of the manoeuvre
(i.e. FEV1 of the two highest acceptable 
manoeuvres differing by <5% or 100 ml [BTS] 
or 200 ml [ATS]).
In ideal circumstances, reliability of spirometry can be
very high. Two large clinical trials performed in the
USA showed that a high proportion of spirometry tests
complying with ATS criteria can be achieved by 
pulmonary function laboratories (approximately
95%),30,31but it is unclear whether this can be achieved
in day-to-day situations. Eaton et al. investigated the
reliability of spirometric tests in 15 New Zealand 
general practices.27 Four months after completion of a
two-session training programme for GPs and practice
nurses, one-third of the spirometric tests conducted
were found to meet the ATS criteria. In the referenc
group of non-trained GPs and nurses, only 13% of all
tests were reliable. So it may be difficult to guarantee
sufficient reliability of spirometric tests when they ar
performed in general practices.
It is also important to know how spirometric tests in
general practice compare to tests performed in 
pulmonary function laboratories. A group of 52 people
with asthma, selected by 20 GPs who had previously
attended a spirometry training session, were studied by
van der Molen et al.32FEV1, as well as FVC, values
measured by the GPs were on average 280 ml lower
than laboratory values. In a similar study, den Otter et
al. evaluated spirometric tests of 68 subjects with 
respiratory symptoms.33 On average, FEV1 was 110 ml
lower, to the disadvantage of the measurements
obtained in general practice. In both studies, however,
GPs and lung function technicians used different types
of spirometers, which may explain an unknown part of
the observed differences.
Recently, Woolhouse et al. reported results of a study
in which two patients with severe, but stable, COPD
visited 14 general practices for spirometry.34Compared
with measurements by a lung function technician, 86%
of the GP-based FEV1 values measured were judged
acceptable (i.e. <160 ml difference from the 
technician’s value). Of the FVC values, 54% were
acceptable (FVC difference <330 ml). However, 
interpretation of these results is complicated by the
fact that only two patients were involved, both with
ample experience in undergoing spirometry.
INTERPRETATION OF SPIROMETRY TEST
RESULTS
Interpretation of spirometry requires specific expertise,
which can be expected from chest physicians, but not
necessarily from GPs. Eaton et al. took a random 
sample from the spirometry records of the 15 trained
N w Zealand GPs to address this issue.27The GPs had to
label spirometric tests of some of their own patients out
of seven pre-defined diagnoses (such as ‘normal’,
‘obstructive disorder’, ‘inadequate test performance’).
Two chest physicians judged the interpretation of the GPs
as c rrect in 53% of the cases, an almost similar 
percentage to that in a reference group of non-trained GPs.
These results need to be put in perspective. For
instance, Hnatiuk et al. showed that internists in the
US interpreted one out of every four screening 
spirometric tests incorrectly as normal, and one out of
every three cases incorrectly as abnormal.35 Quadrelli
et al. showed significant variation within a group of
15 Italian chest physicians in interpretation of
spirometric tests.36 There was a substantial inter-
obs rver variability between chest physicians (40%
disagreement), particularly in the assessment of
presence and severity of airway obstruction. However,
it should be noted that Eaton’s GPs were provided
with clinical data and indications for spirometry on
their own patients, while Quadrelli’s chest physicians
did not have such data, and were further required to
agree on severity classifications as well as diagnosis.
HEALTH ECONOMIC CONSEQUENCES
Currently, little is known about the impact on 
heal hcare cost of widespread application of 
spirometry in primary care. The only information
available comes from Canada, where Chan et al.
analysed trends in declared expenses for lung function
te ti g by GPs.37 (In the Ontario area from which the
data were derived, GPs could declare C$31.90 for a
flow–volume curve examination and C$16.20 for a
spirogram.) In this cost evaluation study, the possible
health enefits were not included. When the total costs
for spirometry by GPs for the periods 1989–90 and
1994–95 were compared, costs had increased by 37%
(from C$10.3 to 14.1 million). A quarter of this
increase could be explained by a rise in the total 
number of tests, attributable to the fact that in the
1994–95 period, 47% more GPs declared spirometric
tests than in the earlier period, while the average 
umb r of declared tests per GP remained unchanged.
Undoubtedly, the concurrent introduction of affordable
electronic spirometers will have contributed to the
increased costs.
DISCUSSION
From the evidence discussed above it is concluded that
spirometry can be a valuable additional instrument to
care for patients with obstructive airway disease in
general practice. However, although the use of 
spirometry is disseminating fast among GPs, several
aspects of primary care spirometry (especially GP
surgery-based spirometry) deserve critical 
consideration. An important finding is that the 
reliability of modern electronic spirometers does not
limit their use in general practice. Although these
spirometers may produce systematically lower values
than the conventional equipment used in pulmonary
function laboratories, this is only a problem in the
higher range of FEV1 and FVC values.
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As spirometry is only one of the many tasks
demanding attention in the general practice setting, it
is to be expected that practices will find it hard to
fulfil the strict quality criteria that apply to
laboratories. As a consequence, results of surgery-
based spirometry should be handled differently to
values obtained in pulmonary function laboratories.
Spirometric indices obtained in a general practice
generally turn out to be lower, but rarely higher.
The problem of false positive diagnoses that might
result from this is particularly relevant for general
screening of subjects, much less so in selective
screening of high-risk populations (i.e. smokers) or
subjects with airway symptoms. In the case of low
values or doubt about the reliability of a surgery-based
spirometric test, GPs should seek confirmation by
referring the patient to an experienced spirometry
service.
In the light of the available evidence one could argue
whether surgery-based spirometry is the best solution.
There are several other good choices: 
Pulmonary function laboratories may provide open
access spirometry service directly to GPs or local
nurse-run asthma clinics. Mobile community-based
spirometry services or primary care group (PCG)-
commissioned spirometry services could be initiated.2
Possible advantages and disadvantages of these 
alternatives are listed in Table 2.
It is obvious that GPs who consider implementing
spirometry in their practice will have to invest 
sufficient time to develop expertise. A short training
programme alone is not sufficient to acquire the 
specific knowledge, skills and insight necessary to
judge quality and interpret results of spirometry 
adequately. This may result in false negative and 
positive diagnoses as well as misclassification of the
severity of lung function impairment.
The health-economic implications of widespread
spirometry in primary care are not clear from the 
li erature. The results of the Canadian study37reviewed
ar  difficult to extrapolate to other countries, since
declaration of spirometric tests by GPs is not possible
in other countries.
As a result of intensified use of spirometry as a
screening tool in primary care, more patients will b
treated for respiratory diseases, which will generate
additional expenses. An increase in the number of
X-rays requested and referrals to secondary care is
also conceivable.38 On the other hand, better focused
care can save the costs of inappropriate treatment and
is likely to improve health-status of patients with
obstructive lung disease. Studies evaluating both costs
and benefits are needed to establish the effectiveness
of w despread use of spirometry in primary care.
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Validity of spirometric testing in a general practice
population of patients with chronic obstructive pulmonary
disease (COPD)
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Objective: To investigate the validity of spirometric tests performed in general practice.
Method: A repeated within subject comparison of spirometric tests with a ‘‘gold standard’’ (spirometric
tests performed in a pulmonary function laboratory) was performed in 388 subjects with chronic
obstructive pulmonary disease (COPD) from 61 general practices and four laboratories. General
practitioners and practice assistants undertook a spirometry training programme. Within subject
differences in forced expiratory volume in 1 second and forced vital capacity (DFEV1 and DFVC) between
laboratory and general practice tests were measured (practice minus laboratory value). The proportion of
tests with FEV1 reproducibility ,5% or ,200 ml served as a quality marker.
Results: Mean DFEV1 was 0.069 l (95% CI 0.054 to 0.084) and DFVC 0.081 l (95% CI 0.053 to 0.109) in
the first year evaluation, indicating consistently higher values for general practice measurements. Second
year results were similar. Laboratory and general practice FEV1 values differed by up to 0.5 l, FVC values
by up to 1.0 l. The proportion of non-reproducible tests was 16% for laboratory tests and 18% for general
practice tests (p = 0.302) in the first year, and 18% for both in the second year evaluation (p = 1.000).
Conclusions: Relevant spirometric indices measured by trained general practice staff were marginally but
statistically significantly higher than those measured in pulmonary function laboratories. Because of the
limited agreement between laboratory and general practice values, use of these measurements
interchangeably should probably be avoided. With sufficient training of practice staff the current practice
of performing spirometric tests in the primary care setting seems justifiable.
I
n recent years the use of spirometric tests has rapidly
increased in primary health care. Practice guidelines assign
a central role to spirometry in the management of patients
with chronic obstructive pulmonary disease (COPD).1 2 As
most of these patients are detected and treated in primary
care, these guidelines are particularly relevant for general
practice.3 4 There is some evidence that application of
spirometric testing in general practice may reduce the
number of undetected cases with chronic respiratory mor-
bidity5 as well as diagnostic misclassification,6–8 which may
lead to overall improved respiratory health.7
The validity (or ‘‘reliability’’) of spirometric tests is a
prerequisite for their use as an instrument for diagnosis,
monitoring, and management of respiratory disease.9 Despite
their widespread use, little is known about the validity of
spirometric tests in the primary care setting. It has been
reported that at least one third of tests performed in general
practice do not meet the quality criteria which apply to
pulmonary function laboratories.10 Training of practitioners
and nurses seems to enhance the quality of testing only
temporarily.10 Four studies have shown that spirometric
indices obtained in general practices may be considerably
lower than those obtained in laboratories, suggesting
insufficient test validity in general practice.11–14 However,
none of these reports has been peer reviewed and apparent
methodological shortcomings justify further studies of
this topic. The main objective of the current study was to
assess the extent to which the results of spirometric tests
performed in general practice correspond with the results of
the same tests performed in a certified pulmonary function
laboratory.
METHODS
Study design and participants
The study was a repeated cross sectional within subject
comparison of spirometric testing in pulmonary function
laboratories and general practices. Four pulmonary function
laboratories (two in universities, two in general hospitals)
and 61 general practices comprising 149 general practitioners
(GPs) and 185 practice assistants were involved. (In Dutch
general practice the practice assistant is a paramedical
professional who has been trained for administrative and
patient care related activities.) A priori, we considered the
laboratory spirometric tests as ‘‘gold standard’’15 measure-
ments.
GPs selected subjects who met the following inclusion
criteria: age 30–75 years; current or ex-smoker; diagnosis of
COPD as assigned by a GP; meeting the clinical definition of
COPD (‘‘increased cough, sputum and dyspnoea on most
days for a minimum of 3 months a year for at least the
previous 2 years’’);16 post-bronchodilator forced expiratory
volume in 1 second (FEV1) 40–90% of the predicted value
and/or post-bronchodilator FEV1/FVC (forced vital capacity)
,88% of the predicted value for men and ,89% for women.
Subjects with severe co-morbidity and/or a history of asthma,
allergic rhinitis, or atopic rash were excluded.
The study was approved by the medical ethics committee of
the University Medical Centre Nijmegen and all subjects gave
written informed consent.
Spirometry training programme
A spirometry training programme for GPs and practice
assistants was developed and pretested before the study.
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Training consisted of two 2.5 hour sessions separated by an
interval of 1 month. The content of the training sessions is
available online on the Thorax website (www.thorax.jnl.com/
supplemental). The training programme specifically focused
on elements that need improvement in general practice
spirometric tests.10 17
Spirometric testing
Data collection took place from December 1998 to January
2001. General practices and laboratories were all equipped
with the same electronic spirometer (Microloop II; Micro
Medical Ltd, Rochester, UK) and spirometry software
(Spirare; Diagnostica Ltd, Oslo, Norway). Durability of the
Microloop turbine flow sensor has proved to be acceptable.18
The spirometry software displays real time flow-volume
curves, patient instructions, and a time indicator to monitor
duration of expiratory and inspiratory flow but does not
contain ‘‘built in’’ quality assurance prompts.4
In each study subject a pair of spirometric tests was
performed. The first test always took place in one of the
laboratories, the second in the subject’s general practice.
Subjects with an interval of .30 days between the two tests
were excluded from the analysis. In case of a recent
exacerbation the measurement schedule was postponed until
at least 6 weeks after clinical recovery. The test sequence was
repeated one year later in the same subjects.
During laboratory and general practice visits subjects
performed a full (pre-bronchodilator and post-bronchodila-
tor) spirometric test. Subjects were instructed to abstain from
short acting bronchodilators for 8 hours and long acting
bronchodilators for 12 hours before testing. Post-bronchodi-
lator tests were performed 15 minutes after administration of
400 mg aerosolised salbutamol by spacer. For each test at least
three acceptable forced expiratory manoeuvres were
required.9 The spirometric indices (including FEV1 and
FVC) of the manoeuvre with the highest sum of FEV1+FVC
were stored and used for analysis. Spirometers were checked
for errors in readings by a research nurse every 3 months
using a 3 litre syringe and ‘‘biological control’’—that is, a
manoeuvre performed by the research nurse herself. In cases
with a deviation of >3% in the volume reading or a divergent
outcome of the biological control manoeuvre the spirometer
was replaced.
Outcomes and statistical analyses
The primary outcomes were the within subject differences
between laboratory and general practice spirometric tests in
terms of FEV1 and FVC (DFEV1 and DFVC, respectively).
Crude mean DFEV1 and DFVC were calculated by subtracting
a subject’s laboratory value from the general practice value.
Mean values for the primary outcomes with 95% confidence
intervals (95% CIs) were calculated and difference versus
mean plots and accompanying limits of agreement produced
to express the variability between laboratory and general
practice measurements.19 5% trimmed means (arithmetic
mean without the largest 5% and the smallest 5% of
observations) were also calculated to rule out the impact of
outliers. Adjusted mean estimates were calculated to control
for potential bias in the primary outcomes due to differential
timing of laboratory and general practice tests. This was done
by defining three subgroups based on the circadian (‘‘diur-
nal’’) variation of lung function20: (1) a potential advantage
of >50 ml due to time of measurement favouring the
laboratory test; (2) a potential advantage >50 ml favouring
the general practice test; and (3) no potential advantage for
either test. (The 50 ml cut off reflects approximately half the
maximum variation of FEV1 throughout the day.) The
potential advantage in ml for groups 1 and 2 compared with
group 3 was estimated using a one way analysis of variance
(ANOVA) model. In groups 1 and 2 the actual measured
values of FEV1 and FVC were corrected for the estimated
values from the ANOVA model. We consider the crude
estimates to be the main results.
Differences in the primary outcomes between laboratories
were analysed using ANOVA, and associations between
primary outcomes and the number of days elapsed between
laboratory and general practice spirometric tests were
analysed using Pearson correlation.
The proportion of tests with a reproducibility of ,5% and
,200 ml (test variance) between the two highest FEV1
values from the three accepted forced manoeuvres was
considered as a marker of the quality of the spirometric
tests.9 10 Differences in the proportion of non-reproducible
tests in laboratories and general practices were analysed
using McNemar’s test. The Statistical Analysis System (SAS,
Version 6.12 for UNIX) was used for analysis.
RESULTS
Characteristics of general practices
Of the 61 general practices involved, 21 (34%) were single
handed practices, 35 (58%) were two handed or group
practices, and five (8%) were multidisciplinary health care
centres. Forty practices (65%) already possessed a spirometer
before the study was initiated. Descriptive characteristics of
the general practices are shown in table 1. Attendance rates
in the spirometric training programme were 57% for GPs and
78% for practice assistants. In two practices GPs performed
the spirometric tests, while in the remaining 59 practices the
practice assistants undertook the testing.
Study subjects and primary outcomes
Matched pairs of laboratory and general practice spirometric
tests were available for 388 subjects in the first year and 332
Table 1 Baseline characteristics of general practices and
study subjects
General practices (n = 61)
No of GPs 2.5 (1.4)
GPs’ professional experience (years) 14.3 (8.2)
No of practice assistants 3.1 (1.4)
Practice assistants’ professional experience (years) 10.7 (7.4)
Practice population size (no of patients per GP) 1862 (771)
Time since introduction of spirometry (years) 4.3 (2.9)
No of spirometers present 1.8 (1.2)
Study subjects (n = 388)
Male/female 266/122
Age (years) 59.6 (9.7)
Current smokers, n (%) 228 (59)
Cumulative cigarette smoke exposure (pack years) 28 (17)
Use of inhaled corticosteroids, n (%) 58 (15)
Use of bronchodilator, n (%) 285 (73)
FEV1*
Pre-bronchodilator (l) 1.80 (0.66)
% predicted 60.3 (18.2)
Post-bronchodilator (l) 2.00 (0.66)
% predicted 66.7 (17.4)
FVC*
Pre-bronchodilator (l) 2.91 (0.92)
% predicted 78.2 (18.7)
Post-bronchodilator (l) 3.21 (0.94)
% predicted 85.9 (18.0)
FEV1/FVC*
Pre-bronchodilator (%) 61.9 (11.7)
% predicted 80.5 (14.8)
Post-bronchodilator (%) 62.6 (11.6)
% predicted 81.3 (14.8)
Reversibility of FEV1 (%) 6.8 (6.2)
Values are mean (SD) unless stated otherwise.
*Based on first year spirometric tests performed in the pulmonary function
laboratories.
Post-bronchodilator FEV1 % predicted minus pre-bronchodilator FEV1 %
predicted.
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subjects in the second year evaluation (table 1). The mean
(SD) number of days between laboratory and general practice
tests was 7.2 (7.8) for the first year evaluation and 11.2 (8.1)
for the second year evaluation. There was no significant
correlation between the number of days between measure-
ments and the primary outcomes (DFEV1: r = 0.11; DFVC:
r = 0.13). In 24% of the spirometric test pairs the laboratory
test was favoured by the circadian variation, in 21% of the
tests the general practice test was favoured, and in 55%
neither test was favoured.
Adjusted estimates of the primary outcomes were consis-
tently (but only marginally) higher than crude estimates
(table 2). First year and second year mean DFEV1 and DFVC
values were all higher for the general practice measurements.
These findings were consistent for each of the laboratories
involved (table 3). The scatter of the DFEV1 and DFVC values
did not vary in a systematic way over the range of
measurements (fig 1 and 2). The interval between the limits
of agreements was wide in both study years for DFEV1 as well
as for DFVC, which indicates considerable discrepancies
between the two measurements.
Quality of spirometric test performance
Because of occasional imperfections in the data transfer
between the spirometer and spirometric software, informa-
tion on the number of forced manoeuvres performed and
FEV1 reproducibility was missing for 12 (,1%) laboratory
and 89 (3%) general practice tests. Within the set of tests
with complete information there were no tests with fewer
than two forced manoeuvres in either the laboratories or
practices. Table 4 shows that the proportion of non-
reproducible tests—that is, FEV1 reproducibility >5% or
.200 ml—in the first year evaluation was 16% for the
laboratories and 18% for the general practices (p = 0.302).
The corresponding figures for the second year were 18% and
18%, respectively (p = 1.000). The proportion of non-repro-
ducible tests in the general practices ranged from 4% in the
best to 35% in the worst performing practice for the pooled
first and second year data. For the four pulmonary function
laboratories the corresponding range was 13–20%.
DISCUSSION
The results of the current study indicate that, on average, the
validity and quality of spirometric tests in Dutch general
practices is satisfactory in comparison with the ‘‘gold
standard’’ procedure, a spirometric test performed in a
pulmonary function laboratory. We observed mean differ-
ences in the primary outcomes consistently in favour of
general practice spirometric testing in the first as well as the
second year evaluation. The overall proportion of non-
reproducible spirometric tests was similar for laboratories
and general practices. However, the agreement between
laboratory and general practice measurements seems limited.
This means that using laboratory and general practice
Table 2 Mean (95% CI) and trimmed mean for crude and adjusted estimates of the primary outcomes
First year (n = 388) Second year (n = 335)
Crude estimate Adjusted* estimate Crude estimate Adjusted* estimate
Mean
Trimmed
mean Mean
Trimmed
mean Mean
Trimmed
mean Mean Trimmed mean
DFEV1 (l)
Pre-bronchodilator 0.079 0.077 0.085 0.083 0.065 0.061 0.072 0.068
(0.057 to 0.101) (0.063 to 0.107) (0.044 to 0.087) (0.051 to 0.094)
Post-bronchodilator 0.058 0.060 0.065 0.067 0.050 0.044 0.057 0.051
(0.039 to 0.078) (0.045 to 0.085) (0.029 to 0.071) (0.036 to 0.079)
Pooled` 0.069 0.069 0.076 0.075 0.058 0.053 0.065 0.060
(0.054 to 0.084) (0.061 to 0.091) (0.043 to 0.073) (0.050 to 0.080)
DFVC (l)
Pre-bronchodilator 0.103 0.102 0.104 0.104 0.091 0.073 0.096 0.078
(0.062 to 0.143) (0.064 to 0.144) (0.049 to 0.133) (0.054 to 0.138)
Post-bronchodilator 0.056 0.062 0.061 0.068 0.068 0.053 0.074 0.059
(0.017 to 0.095) (0.022 to 0.100) (0.028 to 0.107) (0.035 to 0.113)
Pooled` 0.081 0.083 0.084 0.086 0.079 0.063 0.085 0.069
(0.053 to 0.109) (0.056 to 0.112) (0.051 to 0.108) (0.056 to 0.114)
A minus sign indicates higher mean laboratory values, absence of a minus sign indicates higher general practice values.
*Adjusted for the influence of differential timing between measurements performed in pulmonary function laboratory and general practice.
Arithmetic mean calculated with exclusion of the largest 5% and the smallest 5% of the values.
`Combined results of pre-bronchodilator and post-bronchodilator values.
Table 3 Mean (SD) crude estimates of the primary outcomes by pulmonary function
laboratory
Laboratory 1
(n = 218)
Laboratory 2
(n = 131)
Laboratory 3/4
(n = 39) p value`
First year
DFEV1*(l) 0.078 (0.20) 0.053 (0.21) 0.078 (0.22) 0.286
DFVC*(l) 0.079 (0.36) 0.095 (0.44) 0.046 (0.39) 0.636
Second year
DFEV1*(l) 0.082 (0.21) 0.016 (0.19) 0.036 (0.13) ,0.001
DFVC*(l) 0.086 (0.36) 0.095 (0.42) 20.016 (0.25) 0.115
A minus sign indicates higher mean laboratory values, absence of a minus sign indicates higher general practice
values.
*Combined results of pre-bronchodilator and post-bronchodilator values
Because of the small number of study subjects (n = 7) the results of laboratory 4 have been added to the results of
laboratory 3, the laboratory with the next smallest number of subjects.
`ANOVA test for difference between laboratories.
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measurements interchangeably should probably be avoided
in practice.
Strengths and limitations of the study
We aimed to compare, as strictly as possible, the spirometric
performance of general practice and laboratory staffs.
Performance depends on a number of factors related to the
executor of the test—quality of subject instruction, intensity
of coaching during forced manoeuvres, critical assessment of
acceptability of separate manoeuvres, and test reproducibil-
ity.21 As we wished to minimise any potential bias in the
comparison, we chose to equip practices and laboratories
with the same type of spirometer and to check spirometer
readings at the same 3 monthly intervals at both locations.
Although portable turbine spirometers like the one used in
our study cannot easily be calibrated on the spot and are not
commonly used in laboratories, we believe that ruling out the
‘‘equipment factor’’ makes the comparison fairer, as turbine
spirometers may produce FEV1 and FVC values which diverge
from the advanced equipment normally used in labora-
tories.22
From a methodological point of view, randomisation of the
order in which laboratory and general practice tests took
place would have been the preferred approach. However,
because most of our study subjects (67%) were participating
in an ongoing randomised controlled clinical trial,23 the order
of the tests was dictated by the trial protocol. We cannot
therefore rule out the possibility of a systematic ‘‘one sided’’
bias in favour of either general practice or laboratory
spirometric testing due to natural variability in lung function.
Sources of short term intra-individual variability such as
airway reactivity21 and diurnal variation in lung function20
may have influenced our findings. Although we used a rather
approximate method to adjust for the latter variable, this
factor did not seem to bias the results significantly. We
consider it implausible that other intra-individual factors
may have systematically put the laboratory tests at a
disadvantage.
Although we cannot rule out a possible ‘‘learning effect’’ in
study subjects due to repetition of spirometric testing within
a short time span,24 we believe that the order of tests alone
cannot fully explain our results. Three arguments support
this view: (1) Most subjects had been diagnosed as having
COPD several years earlier, which makes it quite likely that
most of them already had a ‘‘history’’ of spirometric testing
before entering the study, especially since most practices had
been using spirometric tests for some time. (2) All subjects
performed a full spirometric test in their general practice
several weeks before the first visit to the laboratory to assess
study eligibility. In other words, they could not be entirely
‘‘naive’’ with regard to spirometric testing before the tests for
the actual evaluation study were performed. (3) The
differences in favour of general practice spirometric testing
persisted after a year of regular monitoring of lung function.
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Figure 1 Difference in forced expiratory volume in 1 second (FEV1)
against mean plots for (A) the first year (n = 730) and (B) the second year
(n = 656) evaluation. Pre-bronchodilator and post-bronchodilator values
are pooled. The dashed horizontal lines indicate the limits of agreement.19
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Figure 2 Difference in forced vital capacity (FVC) against mean plots
for (A) the first year (n = 730) and (B) the second year (n = 656)
evaluation. Pre-bronchodilator and post-bronchodilator values are
pooled. The dashed horizontal lines indicate the limits of agreement.19
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Individual learning curves in study subjects should have
levelled off by that time.24 Another explanation for the
observed higher general practice values may be the perfor-
mance level of the laboratory technicians. It has previously
been recognised that significant variation may exist between
laboratories.25 This could mean that, at least in some cases,
we actually used a ‘‘gilded standard’’ instead of a pure ‘‘gold
standard’’.
In spirometry a widely used criterion for unacceptable
performance is fewer than two acceptable manoeuvres.9
Unfortunately we were not able to perform a full evaluation
of all acceptability markers—that is, adequacy of the start of
the forced expiration, duration of the expiration, abrupt
ending or cough during the manoeuvre9—because the Spirare
spirometry software used only stores one ‘‘best’’ manoeuvre.
A study performed in primary care practices in New Zealand
looked into quality assurance data and found that only a
third of spirometric tests performed by trained practitioners
and nurses fulfilled the minimum quality criterion of two or
more acceptable manoeuvres.10 Although in the current study
we could not evaluate all separate manoeuvres, we have
previously observed that manoeuvres performed by a sample
of trained practice assistants are mostly judged to be
acceptable by experienced lung function technicians.26 Apart
from the relatively small proportion of tests with missing
data, we can be sure that at least two manoeuvres were
obtained in all other spirometric tests. Reproducibility of
FEV1 cannot be calculated on the basis of a single FEV1 value.
Comparison with previous studies
Our findings contradict previous reports on the validity of
general practice spirometric testing.11–14 These studies con-
sistently reported lower mean FEV1 and FVC values for
general practice spirometric tests with differences of 70–
280 ml for FEV1
11 14 and 360 ml for FVC.11 The presence or
absence of factors responsible for short term intra-individual
lung function variability, as discussed above, may explain the
discrepancy between the studies, as may the diverging study
populations involved (asthmatics,11 subjects with respiratory
symptoms,13 adult patients with limited airflow,14 those with
severe COPD,12 and a heterogeneous group of patients with
COPD in our study).
There are several reasons why we believe that our study
reflects the actual validity of general practice spirometric
testing. Firstly, our training programme was probably more
elaborate than those in other studies because we specifically
emphasised elements of test performance which are now
known often to be insufficient in general practice.10 17 This
tailored programme may have prepared practice assistants
and GPs better for their task. Also, as far as can be extracted
from the published reports, other studies did not use
spirometers which display flow-volume curves. We have
previously reported that real time feedback of information
from flow-volume curves may lead to improved performance
in spirometric testing.26 A final alternative explanation may
be that in our study, unlike in some of the earlier studies,11 14
most of the spirometric tests were performed by practice
assistants instead of practitioners. As practice assistants will
generally have more time available, they might take more
time to attain a satisfactory test result. In our view, similar
results could be achieved in other countries or healthcare
settings as long as training of the professionals who perform
the spirometric tests is of sufficient quality and intensity.
Conclusions
We conclude that spirometric indices relevant for the
management of COPD obtained in trained general practices
were marginally but statistically significant higher than those
measured in certified pulmonary function laboratories. The
quality of spirometric tests in laboratories and general
practices in terms of test reproducibility seemed equivalent.
However, as the agreement between spirometric tests
performed in the laboratory and in general practice was
limited, using these measurements interchangeably should
probably be avoided in practice. The results of this study seem
to support the already widespread practice of performing
spirometric tests in primary care settings. Further encourage-
ment of primary care physicians to implement spirometric
tests therefore seems justifiable, providing the training of
practice staff is sufficient.
The content of the training sessions is available
online on the Thorax website at www.thoraxjnl.com/
supplemental.
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Supplement. Contents of the training sessions for general practitoners and practice assistants 
  
General practitioners* 
 
  
Practice assistants 
 
 
First training session 
 
 
Time 
  
Time 
 • General aspects of COPD and asthma (e.g., 
pathophysiology, epidemiology) 
30’  • General aspects of COPD and asthma  
(e.g., basic pathophysiology, treatment) 
30’
• Indications for spirometry in general practice 15’  • Basics of respiratory physiology, spirometric indices, 
flow/volume-curve 
20’
• Physiology of the respiratory system, spirometric 
indices, flow/volume-curve 
40’  • Basic aspects of spirometry test performance 
(measurement technique)†, ‡ 
30’
• Basic aspects of spirometry test performance 
(measurement technique)† 
20’  • Demonstration of Microloop spirometer and 
Spirare software 
15’
• Demonstration of Microloop spirometer and 
Spirare software 
15’  • Practising pre-bronchodilator spirometry in small 
groups 
55’
• Practising pre-bronchodilator spirometry in small 
groups 
30’  
+ 
 
+
 
Second training session 
 
150’   150’
• Summary of first session 30’  • Summary of first session 25’
• Interpretation of spirometric indices and flow-
volume curves  
40’  • Sharing experiences and problems encountered with 
spirometry in practice 
15’
• Review of clinical case examples 60’  • Basic aspects of spirometry test performance 
(measurement technique)†,$  
20’
• Implementation and organisation of spirometry 20’  • Aspects of inhalation technique, instruction on use of 
Volumatic spacer and salbutamol pMDI, incl. 
practising 
30’
  
+ 
• Practising pre- and post-bronchodilator spirometry in 
small groups 
60’ 
   +
  150’   150’
 
*  Instructors in GP course: pulmonologist, pulmonary physiologist, general practitioner, lung function technician; instructors 
in practice assistant course: pulmonary physiologist, general practitioner, lung function technician 
†  Special attention for errors commonly made during spirometry in general practice1;2 and markers of  acceptability and 
reproducibility of maneuvers3 
‡  A videotape with examples of both good and bad subject instruction and execution of spirometry tests was used 
$  Special attention for judging the flow-volume curve with respect to acceptability of maneuvers  
pMDI = pressurized Metered Dose Inhaler 
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Abstract 
 
Objective - To assess the effect of periodic educational outreach visits by lung function 
technicians on the validity of general practice spirometry. 
Methods – 1-yr prospective study involving 4 pulmonary function laboratories, 45 outreach 
visit group (‘intervention’, n=262 subjects with COPD) and 16 reference group (n=126 
subjects) general practices. The same baseline spirometry training was offered to both groups 
of practices. Subsequently, intervention group practices were periodically visited by lung 
function technicians, who focussed on optimization of spirometric test performance. 
Outcomes were the within subject differences in forced expiratory volume in 1 second 
(∆FEV1) and forced vital capacity (∆FVC) between laboratory and general practice tests 
(practice minus laboratory value). 
Results – Intervention and reference group practices differed in number and age of practice 
assistants and GPs’ attendance at the baseline spirometry workshops. In the first year 
evaluation the mean ∆FEV1 and ∆FVC favored the general practice tests (i.e., were >0) in 
both groups. A year later ∆FEV1 was higher in intervention group compared to reference 
group subjects (0.068 L [95%CI 0.048; 0.088] versus 0.035 L [0.013; 0.058]). ∆FVC was also 
higher in intervention (0.126 L [0.088; 0.163]) compared to reference group subjects (-0.021 
L [–0.060; 0.017]). 
Conclusion – Although initially the validity of spirometric tests was sufficient in intervention 
as well as reference group practices, periodic educational outreach visits by lung function 
technicians seemed to prevent regression of test validity over time, especially in terms of FVC 
values. Less labor-intensive options to maintain spirometric test validity in general practice 
may be more attractive. 
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Introduction 
Spirometry provides important indices to assess the severity and reversibility of airflow 
obstruction. Therefore, spirometry is assigned an important role in diagnosing and monitoring 
of patients with chronic respiratory diseases(1). In developed countries, convenient electronic 
spirometers have rapidly disseminated in primary care during the past few years. Advantages 
of using spirometry in primary care settings are, among others, early detection of, and 
improved differentiation between chronic obstructive pulmonary disease (COPD), asthma, 
and other chronic respiratory conditions(2). Moreover, primary care spirometry provides the 
opportunity to monitor disease progression as well as effects of smoking cessation 
interventions and bronchodilator and anti-inflammatory treatment. 
Regardless of the setting, validity of tests is a prerequisite for using spirometry. Several 
professional organizations have emphasized the importance of training and assign a central 
role to education before implementing spirometry in practice(3-5). A randomised controlled 
study showed that general practitioners (GPs) and practice nurses who had participated in a 
spirometry training program achieved better test results compared with GPs and nurses who 
had not been trained, although the training effect appeared to be transient(6). In 
epidemiological studies and clinical trials the institution of site visits and technician 
performance monitoring have been shown to improve quality of tests and maintenance of high 
quality grades thereafter(7;8). For primary care settings, however, such research data are non-
existing. 
In healthcare research, several other interventions to improve the quality of primary care have 
been investigated: performance-linked feedback (e.g., reminders), learning through social 
influence (e.g., peer review groups), and management support (e.g., rules or obligations)(9). 
Outreach visits by consultants who meet with healthcare providers in their own practice 
setting to provide oriented information and ‘on the spot’ feedback seem to be effective(9;10). 
It has been reported that this approach may optimize drug prescription routines(11-13), 
enhance smoking cessation interventions(14) and other preventive activities in general 
practice (i.e., screening for cardiovascular disease(15) and cervical cancer(16)). The objective 
of the current study was to assess the effect of periodic educational outreach visits by lung 
function technicians as an addition to a baseline spirometry training program with regard to 
the long-term validity of spirometric testing as performed in Dutch general practices. 
 
 
Methods 
Study design and participants 
We report a subgroup analysis of a 1-year prospectively controlled spirometry evaluation 
study which has previously been reported in full(17). Patients with COPD served as study 
subjects. GPs recruited subjects who met the following inclusion criteria: age 30–75 years; 
45
current or ex-smoker; diagnosis of COPD as assigned by a GP; meeting the clinical definition 
of COPD (‘‘increased cough, sputum and dyspnoea on most days for a minimum of 3 months 
a year for at least the previous 2 years’’)(18); post-bronchodilator forced expiratory volume in 
1 second (FEV1) 40–90% of the predicted value and/or post-bronchodilator FEV1/FVC 
(forced vital capacity), 88% of the predicted value for men and 89% for women. Subjects 
with severe co-morbidity and/or a history of asthma, allergic rhinitis, or atopic rash were 
excluded. The study was approved by the medical ethics review board of the University 
Medical Centre Nijmegen and all study subjects gave written informed consent. 
 
Intervention and reference group practices 
Forty-five (45) general practices comprising 262 study subjects served as intervention group 
(‘outreach visit’) practices. These practices all participated in a clinical trial in which 
spirometry was used to measure annual lung function decline(19). Another 16 practices 
comprising 126 study subjects were specifically recruited to serve as a reference group. 
A postgraduate spirometry training program was developed and offered to all GPs and 
practice assistants of the intervention as well as the reference group practices. In Dutch 
general practice, practice assistants are paramedical professionals who have been trained for 
administrative and patient care related activities. Spirometry training consisted of two 2.5 h 
sessions scheduled with an interval of one month. Training for practice assistants specifically 
focussed on elements of spirometry performance that need improvement in general 
practice(6;20). (Details on the contents of the training program can be found at 
www.thoraxjnl.com/supplemental.) All practices received a written protocol describing 
spirometry test procedures, which was based on existing guidelines(3). 
After the baseline spirometry training program the intervention group practices were 
periodically visited by one of the three lung function technicians involved in the study in 
order to optimize spirometry test performance. Lung function technicians are professionals 
who have completed a three year higher vocational training and are engaged in performing 
self-employed lung function tests. The frequency of visits depended not only on the needs and 
wishes of the practice assistants, but was also determined at the discretion of the technicians. 
On average, the practices were visited once every 3 to 4 months. Several methods were used 
by the technicians to maintain or improve spirometric test quality (figure 1). Practice 
assistants and GPs were encouraged to contact the visiting technician whenever they 
experienced difficulties, or with questions regarding spirometry. Apart from the same baseline 
spirometry program as in the intervention group, no subsequent quality-promoting activities 
aiming at spirometry were offered to the reference group practices. 
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Figure 1. Methods used by lung function technicians to optimize the quality of spirometric 
test performance during the outreach visits in general practices 
 
  
A. Make an inventory of, and discuss problems encountered, and answer questions regarding the 
execution of spirometric tests with practice assistants and GPs 
B.  Judging of F/V-curves already present in the practice database: 
• Selection of maneuvre (highest sum of FEV1 and FVC) 
• Reproducibility (difference between two highest FEV1 values <5%) 
• Relevant aspects of selected maneuvre (PEF, exhalation ≥6”, etc.) 
C.  Real time supervision of the execution of a spirometric test: 
Preparation 
• Correct demographic data are entered (e.g., height) 
• Correct administration of bronchodilator in post-BD tests 
Execution 
• Adequate body position 
• Correct positioning of mouthpiece 
• Encouragement to attain maximum effort 
• Number of maneuvres performed in a test (min. 3, max. 8) 
plus the points mentioned at B 
 
a derived from the criteria of the American Thoracic Society for performance of maneuver, acceptability and 
reproducibility of spirometric tests9 with special attention for errors commonly made during spirometry in 
general practice10;26 
 
 
Data collection, equipment and spirometric testing 
Data collection took place from December 1998 through January 2001. Each study subject 
performed a pair of spirometry tests at baseline and after one year. The first test always took 
place in one of the four certified pulmonary laboratories involved, the second test in the 
subjects’ general practice. 
In the intervention group practices the inclusion of study subjects started before the first 
outreach visit had taken place, but lasted until weeks after this first visit in most practices. The 
investigators encouraged the spirometric tests in general practices to be performed by practice 
assistants. A priori, we considered the tests performed in the pulmonary function laboratories 
as “gold standard” measurements(21). 
General practices and laboratories were all equipped with an electronic turbine spirometer 
(Microloop II®, Micro Medical Ltd, Rochester, Kent, UK) and compatible spirometry 
software (Spirare® for DOS, Diagnostica Ltd, Oslo, Norway). Spirare® software displays real-
time flow-volume and volume-time curves, a reminder message for patient instruction and a 
time indicator to monitor duration of expiratory and inspiratory flow, but does not provide 
built-in quality assurance prompts(22). During the intermediary year subjects returned to their 
general practice for a spirometry test every three months. When the time interval between the 
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‘paired’ laboratory and general practice tests exceeded 30 days, subjects were excluded from 
the analysis. In case of an acute exacerbation within two months before the laboratory 
measurement, the whole measurement schedule was postponed until at least six weeks after 
clinical recovery. 
During each visit to the laboratory or general practice, subjects performed a full (pre-
bronchodilator and post-bronchodilator) spirometric test. Subjects were instructed not to use 
short-acting bronchodilators 8 h, or long-acting bronchodilators 12 h prior to testing. Post-
bronchodilator tests were performed 15 minutes after administration of 400 micrograms 
aerosolized salbutamol by spacer. For each test at least three acceptable forced blows were 
required(3;4). Spirometric indices, flow-volume, and volume-time curves of the manoeuvre 
with the highest sum of FEV1 and FVC were stored and used for analysis. In the intervention 
and reference group practices as well as in the laboratories the spirometers were checked for 
errors in volume readings every three months using a 3 litre calibration syringe(3;4). In case 
of a ≥3% deviation of the volume reading, the spirometer was replaced. 
Baseline data of general practices and practice staffs were collected by questionnaires that 
comprised questions within the following domains: practice characteristics and professional 
experience; practice organisation and infrastructure; existing quality enhancing activities; 
application and appreciation of spirometry. Using the questionnaire data a general practice 
delegation index was calculated for each practice assistant: a validated index that expresses 
the autonomy of practice assistants with regard to five patient care related activities: removing 
stitches; performing vena punctures; checking patients with hypertension; freezing warts; and 
removing ear wax(23). 
 
Outcomes and statistical analysis 
In order to analyze differences in baseline characteristics between intervention and reference 
practices, p-values were calculated using appropriate univariate statistical tests. Mean values 
of the primary outcomes for both groups and accompanying t test based ninety five percent 
confidence intervals (95% CIs) were calculated. Within and between group differences were 
analyzed using paired and unpaired t tests, respectively. 
Primary outcomes were the within-subject differences between the laboratory and general 
practice spirometric tests (laboratory minus general practice value) in terms of FEV1 and 
FVC, further referred to as ∆FEV1 and ∆FVC, respectively. The higher the ∆FEV1 or ∆FVC 
the better the general practice spirometric test had been performed relative to the laboratory 
test. The proportion of tests with a reproducibility (‘test variance’) of <5% and <200 ml 
between the two highest FEV1 values from the three accepted forced manoeuvres was 
considered as a quality marker of the spirometric tests(3;6). Differences in the proportion of 
non-reproducible tests in laboratories and general practices were analysed using McNemar’s 
test. SPSS 9.0 for Windows® was used for the analyses. 
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Results 
 
Baseline characteristics 
Descriptive characteristics of the general practices, GPs, practice assistants, and study 
subjects are given in table 1. Several practice and professional characteristics differed 
statistically significant between the intervention and reference group practices: number of 
practice assistants employed; proportion of GPs ever having attended spirometry training; 
proportion of GPs taking part in the spirometry refresher training at the start of the study; age 
of practice assistants. Study subjects from the reference group practices were more often 
female and tended to have somewhat lower lung function values. 
Of the 61 general practices involved, spirometry was performed by practice assistants in 58 
(96%) practices and by GPs in 3 (4%) practices. In the year following the baseline spirometry 
training program 41% of the intervention group and 39% of the reference group GPs attended 
additional external spirometry training courses (p=0.768). Corresponding figures among the 
practice assistants were 48% for the intervention group and 31% for the reference group, 
respectively (p=0.061). 
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Table 1. Characteristics of general practices, general practitioners, practice assistants, and 
study subjects. Figures are means (SD) unless stated otherwise 
 Intervention 
group 
Reference 
group 
p value 
General practices*    
   N 45 16  
   Type of practice (%) 
 Single handed 
 Two handed 
 Group 
 Multidisciplinary healthcare centres 
 
14 (30) 
10 (23) 
16 (35) 
5 (12) 
 
7 (44) 
5 (31) 
4 (25) 
0 (0) 
 
 
 
 
0.342 
   Number of GPs 2.8 (1.5) 2.1 (1.0) 0.091 
   Number of practice assistants 3.4 (1.6) 2.6 (1.0) 0.041 
   Time since introduction of spirometry, years  4.7 (3.1) 3.9 (2.5) 0.384 
General practitioners     
   N 109 31  
   Age, years 44.4 (6.9) 46.2 (6.9) 0.196 
   Professional experience, years 14.1 (8.2) 15.0 (8.6) 0.675 
   Number of patients per GP 1860 (773) 1849 (758) 0.941 
   Working hours per week 39.8 (14.1) 38.9 (14.4) 0.778 
   Attended spirometry training (%) 73 (67) 27 (87) 0.033 
Practice assistants    
   N 132 41  
   Age, years 34.3 (9.0) 38.7 (9.6) 0.011 
   Professional experience, years 10.6 (7.2) 11.4 (8.0) 0.570 
   Working hours per week 26.1 (10.8) 22.5 (9.7) 0.069 
   Attended spirometry training (%) 67 (50.8) 25 (61.0) 0.252 
   Number of spirometric tests per month (median, IQR) 3 (0-8) 2 (0-6) 0.483 
   High delegation index# (%) 121 (91) 28 (89) 0.715 
Study subjects&    
   N 262 126  
   Age, years 59.2 (9.7) 60.6 (9.7) 0.152 
   Male/female 193/69 73/53 0.002 
FEV1    
   Pre-bronchodilator (l) 1.85 (0.68) 1.69 (0.60) 0.025 
   % predicted 60.3 (17.9) 60.1 (18.7) 0.913 
   Post-bronchodilator (l) 2.08 (0.67) 1.84 (0.60) 0.001 
   % predicted 67.3 (16.4) 65.4 (18.8) 0.312 
FVC    
   Pre-bronchodilator (l) 3.02 (0.96) 2.67 (0.76) <0.001 
   % predicted 78.9 (19.0) 76.4 (17.9) 0.217 
   Post-bronchodilator (l) 3.40 (0.98) 2.86 (0.75) <0.001 
   % predicted 88.0 (17.9) 81.9 (17.4) 0.002 
FEV1/FVC    
   Post-bronchodilator (%)  61.9 (12.3) 63.8 (10.2) 0.078 
 
* data on characteristics of practices, general practitioners and practice assistants were missing for 2 intervention group 
practices 
# score of ≥3 patient care related activities defined as high delegation index 
& lung function indices measured in pulmonary function laboratories at first year evaluation 
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; IQR = inter quartile range; BD = bronchodilator 
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Validity and quality of spirometric tests 
In the first year evaluation the mean ∆FVC was higher for the intervention group subjects 
compared to the reference group subjects (p<0.001), whereas the mean ∆FEV1 was not 
(p=0.126, table 2). In the second year evaluation, approximately a year after the outreach 
visits had been first implemented, the mean ∆FEV1 and ∆FVC were higher in the intervention 
group compared to the reference group (p=0.049 and p<0.001, respectively). Compared to the 
first year evaluation, the mean ∆FVC had slightly improved in the intervention group whereas 
in the reference group this outcome had turned to a negative value (i.e., general practice FVC 
values were now, on average, lower than laboratory FVC values). The changes in ∆FEV1 and 
∆FVC from the first to the second year were not statistically significant different between the 
two study groups (table 2). 
 
Table 2. Mean (95% CI) values of primary outcomes* in the intervention and reference group 
study subjects for the first and second year evaluation 
  
Intervention group 
 
 
Reference group 
 
 
p value of between 
group difference 
    
First year evaluation   
 
 
 
   N 
 
262 126  
   ∆FEV1 (l)& 0.078 
(0.059; 0.097)  
0.053 
(0.029; 0.077) 
  0.126 
   ∆FVC (l)& 
 
0.119 
(0.083; 0.155) 
0.008 
(-0.037; 0.052) 
<0.001 
    
Second year evaluation 
  
   
   N 
 
230 105  
   ∆FEV1 (l)& 
 
0.068 
(0.048; 0.088) 
0.035 
(0.013; 0.058) 
  0.049 
   ∆FVC (l)& 0.126 
(0.088; 0.163) 
-0.021 
(-0.060; 0.017) 
<0.001 
   
Difference between first and second year# 
 
  
   N 
 
230 105  
   ∆FEV1 (l)$ 0 
(-0.027; 0.027) 
-0.012 
(-0.046; 0.022) 
  0.598 
   ∆FVC (l)$ 
 
0.015 
(-0.038; 0.068) 
-0.040 
(-0.098; 0.019) 
  0.173 
 
* combined results of pre-bronchodilator and post-bronchodilator values 
& a minus sign indicates higher mean laboratory values, absence of a minus sign indicates higher general practice 
values 
# difference of matched primary outcomes in the second year minus the value in the first year 
$ a minus sign indicates a higher primary outcome in the first year compared to the second year evaluation 
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There were no tests with less than two forced maneuvres in the laboratories or the general 
practices in either the intervention group or the reference group subjects. The proportion of 
reproducible tests in the intervention group was 82.9% for the first year and 81.1% for the 
second year evaluation (p=0.452). Corresponding figures for the reference group were 80.5% 
versus 81.3% (p=0.927). 
 
 
Discussion 
The results of this study suggest that a structure of educational outreach visits by lung 
function technicians on top of a basic spirometry training program has added value in 
maintaining the validity of spirometric testing in general practice. In the first year evaluation, 
the primary outcomes (i.e., ∆FEV1, ∆FVC) were already statistically significant higher in the 
intervention group compared to the reference group practices. Because the two groups were 
rather comparable with regard to the practice and professional characteristics and because all 
practices received the same baseline intervention (i.e., the spirometry training program) we 
explain this first year difference in favor of the intervention group from the fact that in most 
intervention group practices the inclusion of study subjects went on until well after the first 
outreach visit had taken place. Nonetheless, the effect in the intervention group still existed a 
year later, whereas in the reference group the already lower initial outcome values had further 
regressed. 
As we anticipated beforehand based on the studies by Eaton et al.(6) and den Otter et al.(20), 
the reference group showed the most pronounced regression in the ∆FVC, whereas the ∆FEV1 
hardly declined after the first year evaluation. This is an important observation, because too 
low FVC values caused by inadequate testing are likely to cause higher FEV1/FVC ratios. As 
this ratio is a crucial index in the diagnosis of COPD(1;24), false-negative diagnoses may be 
the undesirable consequence of inadequate spirometric tests in general practice(25). Periodic 
outreach visits by lung function technicians seem to prevent this from happening. 
 
Strengths and limitations of the study 
A particular strength of the current study was the fact that we had the opportunity to 
implement the same baseline spirometry training program and could standardize other factors 
that may influence the long-term validity of spirometric testing in the intervention as well as 
in the reference group practices. For instance, the frequency of monitoring of study subjects 
was set on once every three months for both groups of practices; all practices were equipped 
with the same type of spirometer and spirometry software; and the spirometers were checked 
every three months for errors at all locations. Thus, we were able to create identical conditions 
which, in our view, minimizes the possibility of systematic bias in favor of one of the study 
groups. 
 
 52
 
From a methodological point of view random allocation of practices to the intervention and 
reference group conditions would have been the preferred approach. However, intervention 
group practices had to commit themselves to participate in a three year randomised controlled 
clinical trial and -by protocol- received maximal supervision of spirometric test performance. 
In contrast, reference group practices were specifically recruited to serve as controls for the 
comparison reported in this paper. Although the two groups of practices did not seem to differ 
on most baseline characteristics, we may have recruited particularly motivated reference 
group practices. The observed higher attendance rates at the baseline spirometry training 
(table 1) agrees with this presumption. This could mean that in real life, where general 
practice staffs may prepare less intensively before taking up spirometry in their practice, the 
regression of the primary outcomes might be larger. Thus, we may have underestimated the 
actual effect of outreach visits on the long-term validity of spirometric testing in the current 
study. 
 
Effectiveness of educational outreach visits in general practice 
To our knowledge, no previous studies have been performed to evaluate the effect of 
educational outreach visits on the validity of spirometric testing in general practice. Although 
at baseline ∆FVC was significantly different between the intervention and reference group 
subjects, the changes following the year in which the intervention took place were -as 
expected- in favor of the intervention group. There are several arguments that support the 
plausibility of this finding. Firstly, it is well established that outreach visits in which experts 
provide face to face education tailored to the unique attributes and needs of the professionals 
involved are an effective multifaceted method to improve quality of care(10). In the current 
study the outreach visits also involved interventions like feedback and audit, and emphasis 
was put on the improvement of skills necessary to conduct spirometry adequately. Secondly, 
our observations are consistent with the study performed by Eaton et al.(6), in which a 
significant training effect on the quality of spirometric tests performed in general practice was 
observed. In our study the effects of the baseline spirometry training also appeared to have 
diminished in the reference group in the second year evaluation, which points to the 
ineffectiveness of a one-off training intervention in the long term(6). Thirdly, the results of 
the current study seem to confirm observations from studies conducted in other research 
domains, in which educational outreach visits have been shown effective in improving 
various elements of healthcare provision in primary care(10). 
In this paper we did not include an evaluation of the costs of the outreach visits made by the 
lung function technicians. Because site visits by these professionals with higher vocational 
training are rather expensive, other options for maintaining spirometric test quality in general 
practice should be considered. Build-in quality prompts in spirometry software and equipment 
which can guide the operator to the best attainable test result may be a cheap and realistic 
option(8). Periodic feedback based on spirometric tests that are send to a local lung function 
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laboratory for appreciation might be another option. The actual impact of these alternative 
options on the validity of general practice spirometry should be further investigated. 
We conclude that the overall performance with regard to spirometric testing in Dutch general 
practices was quite acceptable compared with the performance of lung function laboratories, 
even without additional quality assurance measures. Nonetheless, periodic educational 
outreach visits by lung function technicians may contribute to maintaining -or even further 
improving- the validity of spirometric tests in general practice. Because of the labor-intensive 
nature of the educational outreach visits, other options to maintain spirometric test validity in 
general practice might be more attractive. 
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Feedback information from flow volume 
curves to the practice assistant improves 
spirometry test quality in general practice 
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INTRODUCTION
The use of spirometry is rapidly increasing within 
primary health care in many developed countries.
International practice guidelines on lung function 
measurement stress the importance of standardisation
of measurement conditions during spirometry.1,2These
guidelines underline the value flow volume (F/V)
curves may have in optimising spirometry test quality.
Most modern spirometers display real-time F/V or 
volume-time curves during forced breathing 
manoeuvres. However, apart from one single 
observational study3 we could find no evidence for the
assumption that providing technicians with feedback
information from F/V curves contributes to the overall
quality of forced breathing manoeuvres including
spirometry testing. 
If information from the F/V curve does indeed 
optimise quality of spirometry, ample attention on how
to judge curves is appropriate for primary care 
professionals, since sufficient test quality is not always
guaranteed there.4
The objective of the study reported in this paper was
to investigate the added value of information obtained
from viewing F/V curves on the quality of spirometric
tests performed by sufficiently trained practice 
assistants. The study focused on the performance of
the practice assistant. In Dutch general practice this is
the paramedical discipline that has been trained for
administrative and patient care related activities.
METHODS
Design
The study was designed as a randomised controlled
single session crossover study. In order to assess the
feedback value of F/V curves during spirometry 
performance by practice assistants, two measurement
conditions were created, one with and one without
feedback information to the practice assistant. Of each
study subject a pair of F/V curves – consisting of the
‘best’ manoeuvre of both conditions - was judged by
two experienced lung function technicians with special
Feedback information from flow volume curves to the practice
assistant improves spirometry test quality in general practice
T Schermer, J Hartman, C Lauwers, H Folgering, A Jacobs, B Bottema, C van Weel
ABSTRACT
Objective:To investigate whether the use of 
feedback information provided by viewing flow
volume (F/V) curves during spirometry performed
by practice assistants improves spirometry test
quality.
Methods:Randomised controlled single session
crossover study. Eight practice assistants performed
spirometry in healthy subjects (n=47). Two 
measurement conditions were applied, one allowing
viewing of F/V curves during the tests 
(‘unblinded’) the other not (‘blinded’). Outcomes
were differences in FEV1, FVC, FEV1/FVC ratio,
PEF, FEV1 repeatability and number of 
manoeuvres per test. Two lung function technicians
indicated their preference for either the blinded o
unblinded F/V curve.
Results:Higher PEF values were observed for the
unblinded condition (0.43 L/s, 95% CI 0.08, 0.77).
The other outcomes showed no differences. One
lung function technician judged that in 62%
(p=0.012) of the pairs the F/V curve from the
unblinded condition was better, the other technician
judged so in 51% (p=0.349).
Conclusion: This study in healthy subjects showe
that the use of information from F/V curves leads
to a modest quality improvement of spirometric
tests performed by practice assistants and can 
therefore be recommended for use in general 
practice.
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attention on quality criteria for F/V curves.1 The 
technicians indicated whether they preferred one curve
over the other, or if both curves were of equal quality
being unaware of the condition in which each curve
was obtained (blinded or unblinded).
Before they performed any spirometric tests in study
subjects, the practice assistants received a short, 
standardised oral reminder on how to perform 
spirometry and how to assess the ‘quality’ of forced
breathing manoeuvres by judging the F/V curve
(table 1).
Measurements
All spirometric tests were performed using one single
turbine spirometer (Microloop II®, Micro Medical Ltd,
Rochester, UK) connected to a laptop computer on
which Spirare® spirometry software (Version 2.11,
Diagnostica, Oslo, Norway) was installed. Volume
readings of the spirometer were checked with a 3-L
calibration syringe after each subject had completed
the measurements.
A full spirometry test consisted of at least three forced
breathing manoeuvres. After completing a full test the
practice assistant saved the F/V curve and matching
indices of the - in her opinion - ‘best’ manoeuvre.
Thus, a pair of single ‘best’ F/V curves was obtained
for each study subject, one from the blinded and one
from the unblinded measurement condition. 
The two measurement conditions were created as 
follows: Blinded condition: The computer screen was
covered to hide the F/V curves. Only a table showing
relevant spirometric indices (FEV1, VC, PEF) and
the percentage FEV1 repeatability between the various
performances in one full test was displayed on the
screen. Unblinded condition: spirometric indices as
well as F/V curves were visible throughout 
measurements. The order in which blinded and
unblinded measurement conditions were applied was
randomised for each subject. A time interval of at least
5 minutes was kept between consecutive series of
manoeuvres. In neither measurement condition the test
subjects could look on the computer screen.
Prior to the measurements, the practice assistant
instructed each test subject according to the 
standardised instructions (table 1). Each subject 
performed one single forced expiration and inspiration
to practice the manoeuvre.
Practice assistants and test subjects
Eight female practice assistants from 4 general prac-
tices in the eastern part of The Netherlands 
participated. All assistants had attended a two-session
spirometry training course 6 to 12 month earlier and
all regularly performed spirometry within their 
practice setting.
T st subjects were recruited from the general 
practitioners’ waiting room. Eligible subjects had to
meet the following criteria: age 25 – 80 years, no
medical history of respiratory diseases, no use of 
airway medication and no previous spirometry tests.
Outcomes
Differences between blinded and unblinded conditions
in FEV1 (Forced Expiratory Volume in One Second),
FVC (Forced Vital Capacity), FEV1/F C ratio, PEF
(Peak Expiratory Flow), FEV1 repeatability and the
number of manoeuvres per full spirometry test served
I. Initial Subject Instruction
l ‘Sit upright’
l ‘Breathe in as deep as you can’
l ‘Put your teeth on the mouthpiece and close your lips around it’
l ‘Breathe out forcefully’
l ‘Keep breathing out until you can not go on anymore’
l ‘Breathe in forcefully’
II. General Points of Attention
l Observe the subject during the manoeuvre 
l Encourage the subject during the manoeuvre
l Assess the flow volume curve after the whole manoeuvre has been completed#
III. Quality Criteria for Assessing Flow volume Curves$
l Steep initial inclination of the expiratory curve#
l Sharp peak of the expiratory curve (PEF)#
l Smooth continuation of the expiratory curve (e.g. no cough, abrupt termination)#
l Total inhaled volume should equal the total exhaled volume (FVC)#
l Three acceptable manoeuvres are necessary for a reproducible spirometry test#
IV. FEV1repeatability between the two best manoeuvres     <      5% or          < 200 ml
$ since Spirare® does not display back extrapolated volume, FVC repeatability, time to PEF or rise time to PEF these indices
could not be used by the practice assistants to eject manoeuvres, although international guidelines recommend their use. 2
# applicable for unblinded measurement condition only
Table 1. Reminder for practice assistants on how to perform and judge single forced breathing manoeuvres and overall spirometry test
quality. (Items are derived from the recommendations of the European Respiratory Society1 and the American Thoracic Society2) 
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as outcomes. FEV1 repeatability is the relative 
difference between the two highest FEV1 values from
three manoeuvres.1 A spirometry test was considered
adequate when FEV1 repeatability was less than 5% or
200 ml. The rating of the two lung function techni-
cians regarding the quality of blinded and the unblind-
ed measurements was also considered as an outcome.
Statistics
A power calculation showed that 46 subjects were
needed to detect a difference of 3% in FEV1
repeatability. The intra-cluster correlation introduced
by the fact that each practice assistant contributed
measurements from several (5 to 7) subjects was
accounted for in this calculation. Predicted FEV1 and
FVC values were calculated using ERS reference
equations1. Student-t and Wilcoxon tests for matched
pairs were used to analyse differences between
unblinded and blinded conditions, Student-t est for
independent samples to analyse carry-over and 
order-effects between consecutive test series. 
Bland-Altman plots5 were generated to graphically
express relative differences in outcomes between 
conditions.
Distribution of the lung function technicians’ 
judgements of the pairs of F/V curves was analysed
for technician A and B separately by sign-test.
Cohen’s kappa was calculated to determine the degre
of mutual agreement between the technicians. This 
statistic takes the difference between the proportion of
cases agreed between two observers and the 
proportion expected by chance and standardises this
by 1 minus the proportion expected by chance. In 
biological systems a value of 0.40 to 0.60 is generally
considered as moderate agreement. Alpha was set on
0.05 and 95% Confidence Intervals (95% CI) were
calculated if applicable. SPSS for Windows (Release
9.0.1, 24 February 1999) was used for data analysis.
RESULTS
Test subjects and practice assistants: 
Descriptive characteristics of the test subjects – all
Caucasian - are shown in Table2. A though we aimed
to include equal numbers of males and females, this
turned out to be difficult because more females than
males visited their GP on the chosen study days. Mean
age of the practice assistants was 34.7 (SD 8.0) years,
mean experience with spirometry 4 years (range 
0.5-8).
Differences between measurement conditions:
Mean PEF was 0.43 L/s or 6.1% higher (95% CI 0.08,
0.77) when practice assistants used the F/V curves as
visual feedback. No statistical significant differences
were observed for the FVC, FEV1, FVC/FEV1 or
FEV1 repeatability (Table3). While blinded for the
F/V curve, practice assistants used an average of 3.8
manoeuvres, 4.0 manoeuvres when unblinded
(p=0.375).
The relationship between the average value of each
subject and the difference between blinded and
unblinded measurements is shown in Bland-Altman
plots for the FVC and PEF (Figure 1a and 1b). Both
plots show two outliers but no clear systematic 
deviations. Excluding the two outliers (n=45) resulted
in a reduction of the mean PEF difference to 0.22 L/s
(95% CI 0.02, 0.43). No carry-over effects in favour
of the second measurement condition were observed.
Judgement of lung function technicians:
Lung function technician A judged F/V curves from
unblinded conditions superior to blinded curves in 24
(51%) pairs and inferior in 17 (36%) pairs. Technician
B judged 29 (62%) of the unblinded curves as 
s p rior, 12 (26%) as inferior compared to the blinded
curves. For the remaining 6 pairs, the technicians
could not decide in favour of either curve. The 
distribution of the judgements (“unblinded 
measurement preferred above blinded” versus “blinded
measurement preferred above unblinded”) was 
statistically significant (p=0.013) for technician B, not
for technician A. Agreement between lung function
technicians was acceptable (Kappa=0.44).
Sex (M/F) 18/29  
Smoking status (current/ex-/never smokers) 16/18/13 
Age (years)  49 (13)  
FEV1 (L)
# 3.14 (0.80)     
as % predicted normal#$ 101.3 % (17.4%)   
FVC (L)# 3.95 (0.90)     
as % predicted normal#$ 107.0 % (15.4%)  
FEV1/FVC (%)# 78.8 (7.3)  
FEV1 = forced expiratory volume in one second in litres; FVC = forced vital 
capacity in litres.
# Averaged value of blinded and unblinded measurements
$  Reference equations of the European Respiratory Society (ERS) were used 1
Table 2. Descriptive characteristics of the 47 test subjects. Figures are means 
(Sd) unless stated otherwise.
Unblinded Blinded Difference 95% CI*
condition  condition
PEF (L/s) 7.06 (2.17) 6.63 (2.12) 0.43 (1.18)  0.08, 0.77
FEV1 (L) 3.15 (0.91) 3.12 (0.92) 0.03 (0.14) -0.01, 0.07
FVC (L) 3.97 (1.08) 3.94 (1.07) 0.03 (0.18) -0.03, 0.08 
FEV1/FVC% 78.90 (7.10) 78.70 (7.90) 0.29 (3.76) -0.80, 1.40
Repeatability# (%) 1.76 (1.49)$ 2.34 (3.05)& -0.59 (2.87) -1.43, 0.25  
* 95% CI = 95% confidence interval
# difference between the highest two FEV1 values from three acceptable 
manoeuvres
$ including 1 measurement with FEV1 repeatability >5% (5.2%)
& including 4 measurements with FEV1 repeatability >5% (5.9, 6.1, 9.0 and 18.2%, 
respectively)
Table 3. Comparison of outcomes (Mean (SD)) for unblinded (F/V curve visible)
measurement condition versus blinded (F/V curve invisibled) measurement
condition.
 
 
 60
 
DISCUSSION
The objective of this study was to investigate the value
of feedback information obtained from F/V curves on
the quality of spirometry performed by trained practice
assistants. International guidelines recommend the use
of F/V curves to improve test quality, but this is not
firmly supported by empirical data. We only found one
study addressing this issue: Banks et al3 investigated
changes in lung function indices after the spirometer
of an occupational health service had been replaced by
equipment that automatically gave feedback on test
quality by assessing the F/V curve. The authors
observed an increased number of tests fulfilling ATS
acceptability criteria as well as increased FVC and
PEF values. FEV1 values did not change after 
implementation of the advanced spirometry system.
Our finding that PEF values increased and FEV1
values remained unaltered when trained practice 
assistants used F/V curves is in line with these 
findings. Because we did not observe increased FVC
values, the two studies are contradictory with regard to
the effect of feedback on this outcome. One explanation
for this inconsistency may be the fact that in Banks’
study nurses with ample experience performed the
spirometry tests, whereas in our study less seasoned
practice assistants were engaged. Indeed, previous
work from our department showed that practice 
assistants are particularly uncritical in stimulating 
subjects to exhale maximally6, which will inevitably
result in lower FVCs. A recent study by Eaton et al.4
confirms that most spirometry failures seen in general
practice are end-of-test related. Although F/V curves
typically provide information to critically assess FVC
adequacy, our data suggest that practice assistants do
not utilise this information optimally. 
However, it is important to realise that we used
healthy individuals (test subjects) as study subjects.
Patients suffering from chronic airway disease (espe-
cially COPD) may need more time to reach their FVC
plateau, enabling practice assistants to profit more
from the information the F/V curve provide
In conclusion, in this study among healthy subjects
feedback information to the practice assistants from
F/V curves led to a modest quality improvement of
spirometric tests and can therefore be recommended
for use in general practice. In spirometry training 
programs, special attention should be given on how to
critically assess F/V curves. Finally, if a GP
considers purchasing a spirometer, the device chosen
should preferably display a real-time F/V curve. 
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Summary Background: Spirometry is increasingly implemented in general practice,
while the ability of general practitioners (GPs) to interpret flow–volume curves (FV
curves) has been questioned. Furthermore, the role of spirometry in the GPs
decision-making process has barely been studied.
Aim: To compare the achievements of trained GPs in spirometric diagnosis with an
expert consensus panel (1) and to assess the influence of spirometry on the GPs
decision-making (2).
Method: Twelve cases including a wide range of FV curves were interpreted by
39 GPs as well as the expert panel. Diagnostic test characteristics were calculated
using multi-level analysis and summarised by diagnostic odds ratios (DOR).
Differences in decision-making indicators were expressed as odds ratios and 95%
confidence intervals.
Results: Normal FV curves (DOR 65.0) and obstructive FV curves (DOR 48.9)
were reasonably well diagnosed, while rare and mixed pathological patterns
achieved considerably lower scores (DOR 3.8). Intermediate scores were obtained in
the recognition of incorrect test manoeuvres (DOR 24.4). Spirometry influenced the
GPs decision-making in reducing the number of alternative diagnoses (OR 0.266
[0.200, 0.353]), but also increased referral rates (7.26 [4.71, 11.2]) and the use of
diagnostic prednisolone courses (4.55 [3.12, 6.64]) substantially.
Conclusion: Trained GPs were able to differentiate between normal and
obstructive disease patterns, while FV curves suggestive of rare and mixed
pathology were often missed. Spirometry seems to influence the decision-making
process of the GP; whether this represents an initial or a more sustained effect
remains to be evaluated in studies of daily primary care practice.
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Introduction
In general practice, medical history taking and
physical examination are the most important
instruments to establish diagnosis and initiate
treat ment. Diag nostic tools origi nating from sec -
ondar y care settings such as electroca rdiogra phy1,2
and spirom etry 3 –5 are increasingl y used in primary
care and the resul ts are bein g interpr ete d by
genera l practitio ners (GPs ). Acce ss to spirom etry
in primary care has increased rapidly in the past
years, survey s rangin g from 21% 6 (1998) to 77%
(2001) in the UK.7 By contrast, spirometer utilisa-
tion is hampered by insufficient training: less than
half are used to diagnose COPD.7 Several national
and international guidelines consider formal spiro-
metri c testing essenti al to establish a diagnos is of
COPD ,4,8,9 w hile educa tion in its use has been
identified as a major goal for primary care
phys icians. 4,10,11
However, the value of spirometry in differentiat-
ing between specific respiratory disease patterns
still needs to be assessed in general practice. Most
authors focus on the quality of spirometry test
per formance ,5,12,13 while studie s investiga ting the
interpretative skills of physicians report rather
disap pointing resul ts, bot h in primary 5 and sec ond-
ary care 14,15 sett ing.
A number of studies in COPD and asthma suggest
that spirometry could reduce both under- and
overdi agno sis of obs tructive airway disea se in
genera l pr actice, 16 –18 w hich mig ht influenc e dis-
ease management. Adjustment of treatment after
spirom etry has been re ported in 4–25% of patients
wit h mostly asthma tic compla ints. 19,20 How ever,
the direct influence of spirometry on the decision-
making process of GPs has not been assessed.
Therefore, the aim of the current study was to
determine the achievements of GPs in differentiat-
ing between various chronic respiratory diseases
when spirometry is provided as a supplementary
diagnostic tool. In addition, we investigated the
impact of the flow–volume curve on the GPs
decision-making process.
Methods
Participants and spirometry training
GPs with an interest in spirometry were recruited
from the general practice networks of the Nijme-
gen and Maastricht Universities in the Netherlands.
Most of these GPs already used spirometry in daily
practice, had received previous training and were
motivated to assess their skills. Additionally, GPs
involved in the vocational training in the Nijmegen
and Maastricht regions were invited by postal
mailing to participate in the study.
Participating GPs received a standardised post-
graduate spirometry training course (two three-
hours sessions with an interval of one month), and
could bring their newly acquired spirometric knowl-
edge and skills into practice for a period of six to
nine months before the study started. The spiro-
metry course was based on a format widely used in
the Netherlands. During the first session the focus
was mainly on the pathogenesis and clinical
characteristics of asthma, COPD and other chronic
respiratory diseases; theoretical concepts of lung
function testing; execution of spirometry tests; and
practical guidelines and strategies for spirometry
interpretation. The second session was mainly used
to discuss actual case descriptions submitted by
either the participants or course leaders. Training
was provided by a pulmonologist and an experi-
enced lung function technician. Interactive educa-
tion and feedback on the spot were emphasized
throughout the course.
Standardised case descriptions
A set of 12 standardised case descriptions was
constructed, based on actual patients from two
general practices from our academic networks. The
cases were designed in cooperation with a pulmo-
nologist and a GP with ample experience in the
field of chronic respiratory diseases. The case set
included a range of typical flow–volume curves
suggesting mild obstruction (n ¼ 1); moderate
obstruction (n ¼ 1); severe obstruction (n ¼ 2);
rare pattern of restriction (n ¼ 1); fixed upper
airways obstruction (n ¼ 1); mixed pattern of both
obstruction and restriction (n ¼ 1); incorrect test
manoeuvres (n ¼ 2); and normal curves (n ¼ 3).
The participating GPs worked through two sets of
six cases each, which were assessed in random
order within a period of one year. Randomisation
codes were prepared by a fellow-researcher who
was not involved in the study and stored in sealed
envelopes until use. Data were collected in the
period July 1999 through April 2001.
A research assistant visited the GPs in their
practice. For each case, a concise medical history
and results of the physical examination were
presented to the GP first. Subsequently, absolute
and predicted postbronchodilator spirometry test
results (including FEV1, FEV1/FVC and flow–volume
curves) were provided. After having assessed a
case, GPs had to select one spirometric diagnosis
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from a preformulated list. An example of the case
struct ure is depicted in Fi g. 1 .
Before the study, the 12 paper cases had been
judged by an independent expert panel consisting
of two pulmonologists, a pulmonary physiologist
and a GP with specific expertise in the pulmonary
field. The panel reached consensus on the spiro-
metric and clinical diagnoses of the paper cases
during a panel discussion meeting, while no cases
were excluded. The panel meeting was audiotaped
and independently scored by two of the authors (NC
and TS) in order to establish the panels’ final
diagnosis andFwhen applicableFalternative diag-
noses for each case. There was 100% agreement
between the two observers with respect to the
panels’ final and alternative diagnoses. The panel
consensus diagnoses served as ‘the gold standard’
in the subsequent evaluation of the GPs’ diagnostic
achievements.
Outcome measures
To assess the diagnostic achievements of GPs with
regard to interpretation of spirometry, the follow-
ing four outcome categories were considered most
relevant and contrasting from a clinical point of
view: (1) bronchial obstruction (from mild to
severe); (2) rare respiratory pathology (i.e., re-
striction, fixed upper airways obstruction, mixed
pattern); (3) normal lung function; and (4) incor-
rect test manoeuvre.
In addition, the impact of spirometry on the GPs
decision-making process was assessed using four
indicators: (1) diagnostic uncertainty (size of differ-
ential diagnosis, i.e. the number of alternative
diagnoses considered by the GPs while assessing a
case); (2) probability of prescribing respiratory
medication; (3) probability of initiating a diagnostic
prednisolone course, a commonly used test (albeit
its’ value is uncertain); and (4) probability of
referral to a pulmonologist and/or cardiologist.
These process indicators of GP decision-making were
assessed before and after the results of spirometry
were shown to the GPs (Fig. 1).
Statistical analyses
First, the agreement between the GPs’ interpreta-
tions and the expert panels ‘gold standard’
diagnoses was investigated univariately using the
SPSSs software package (Version 9.0 for Windows).
Subsequently, multi-level linear and logistic model-
ling was used to account for the intra-cluster
correlation induced by the fact that each GP
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Figure 1 Schematic representation of case structure ‘mild to moderate COPD’.
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assessed more than one case. SASs software
(Release 6.12 for Windows) was used for these
multi-level analyses.
The following diagnostic test characteristics
were calculated for each outcome measure:21
positive and negative predictive values (further
referred to as PPV and NPV, respectively), positive
and negative likelihood ratios (LRþ and LR,
respectively) and the diagnostic odds ratio (DOR).
PPV expresses the probability of disease in subjects
with a positive test result, NPV the probability of
absence of disease in subjects with a negative test
result. LRþ is the ratio of the probability of a
positive test in subjects with disease and the
probability of a positive test in subjects without
disease. Conversely, LR is the ratio of the
probability of a negative test in subjects with
disease and the probability of a negative test in
subjects without disease. A diagnostic test is better
the more LR differs from 1, that is, greater than 1
for LRþ and lower than 1 for LR. Finally, the DOR
summarises the overall discrimination of a diag-
nostic test with a dichotomous outcome. In fact, it
is the ratio of LRþ and LR. Therefore, a
dia gnostic test is use less if DOR ¼ 1. 21
After the four indicators of decision-making were
dichotomised (1 vs.41 diagnosis; 0 vs. 1 diagnostic
prednisolone course; 0 vs. 1 or more referrals; 0 vs.
1 or more prescriptions), the before–after spiro-
metry measurements were compared using multi-
level logistic regression analysis and expressed as
odds ratios with 95% confidence intervals (95% CI).
Results
General practitioners
Thirty-nine (39) GPs participated in the study. Three
GPs dropped out during the study, one because of
early retirement, the others due to loss of interest.
These three GPs completed one set of six cases,
instead of both sets. Ta b l e 1 shows that the study
population consisted predominantly of middle-aged
male doctors who had been using spirometry in their
daily practice for a mean of 4.3 (SD 3.7) years,
having received 4.2 (SD 4.9) hours of spirometry
training in the year preceding the experiment.
Diagnostic achievements by GPs
Alto gether, the GPs asse ssed 444 cases . Table 2
shows the agreement between GP judgements and
expert panel for each of the diagnostic outcome
categories. Concordance with the expert panel
regarding obstruction was present in 91.3% [95% CI
86.8, 95.8] of cases, followed by normal spirometry
obtaining 77.9% [95% CI 70.2, 85.6] correct
answers, while incorrect manoeuvres reached a
score of 64.9% [95% CI 54.0, 75.8], and rare
pathological curves were recognised in 41.3% [95%
CI 32.1, 50.5] of cases.
Table 3 shows that norm al and obstruc tive cur ves
were characterised by high DORs: 65.0 and 48.9,
respectively. By contrast, rare pathological curves
obtained a low DOR of 3.8. Scoring of an incorrect
test manoeuvre generated an intermediate DOR of
24.4. The negative predictive values (probability of
righteously ruling out disease) varied between 0.93
and 0.96, except for rare pathology, which reached
0.82. Positive predictive values (probability of
righteously labelling disease) however, revealed a
range of values between 0.87 (normal curves) and
0.49 (rare pathology).
Indicators of GPs decision-making
Before spirometry, GPs considered an average of
2.05 diagnoses per case, with a maximum of eight,
while after spirometry this was reduced to a mean
of 1.35, with a maximu m of six. Table 4 quan tifies
this significant reduction of diagnostic uncertainty:
41 diagnosis is considered in 59.6% [55.1, 64.1] of
cases before spirometry, while after spirometry41
diagnosis is considered in 31.2% [26.9, 35.5] of
cases (OR 0.266 [0.200, 0.353]. Conversely, spiro-
metry significantly increases the number of diag-
nostic prednisolon courses and the referral rate,
while the proportion of cases where medication is
prescribed increases, but not significantly. The
probability of diagnostic prednisolon testing rises
three-fold, from 8.0% [5.5, 10.5] to 27.6% [23.5,
31.7] per case (OR 4.55 [3.12, 6.64]) as a result of
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Table 1 Characteristics of participating general
practitioners (n ¼ 36a).
Male/female 33/3
Age, years 48 (5.1)
Patients enlisted per GP, number 2086 (712)
Surgery hours per week, hours 43.6 (12.7)
Use of spirometer in daily patient
care, yes/no
35/1
Duration of spirometry utilisation,
years
4.3 (3.7)
Spirometry training in previous year,
hours
4.2 (4.9)
Values are means (standard deviation) unless stated
otherwise.
aData missing on 3 GPs who dropped out during the study.
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Table 3 Predictive values, likelihood ratios and diagnostic odds ratios for general practitioners diagnoses.
PPV NPV LRþ LR DOR
Normal spirometry 0.87 0.93 15.16 0.23 65.0
Obstructive disease 0.75 0.96 5.18 0.11 48.9
Incorrect manoeuvre 0.68 0.93 9.23 0.38 24.4
Rare pathology 0.49 0.82 2.66 0.70 3.8
PPV: positive predictive value; NPV: negative predictive value; LRþ : positive likelihood ratio; LR: negative likelihood ratio;
DOR: diagnostic odds ratio.
Table 4 Impact of flow–volume curve on indicators of the decision-making process in general practitioners.
Process indicators Before F=V-curve After F=V-curve OR (95% CI)
Diagnostic uncertaintya 59.6% (55.1, 64.1) 31.2% (26.9, 35.5) 0.266 (0.200,.353)
Prednisolon course 8.0% (5.5, 10.5) 27.6% (23.5, 31.7) 4.55 (3.12, 6.64)
Referral rate 6.0% (3.8, 8.2) 31.7% (27.4, 36.0) 7.26 (4.71, 11.2)
Medication prescription 36.5% (32.0, 41.0) 39.4% (34.9, 43.9) 1.14 (0.87, 1.50)
Numbers are percentages with 95% confidence intervals.
aProportion of 41 diagnoses in the differential diagnosis.
Table 2 Agreement between expert panel and GP judgement for the presence (or absence) of obstructive
disease (A), rare pathology (B), normal spirometry (C), and incorrect manoeuvre (D).
Expert panel judgement
(A)
Obstruction No obstructiona
GP judgement Obstruction 136 (31) 52 (12) 188 (42)
No obstructiona 13 (3) 243 (55) 256 (58)
149 (34) 295 (66) 444 (100)
(B)
Rare pathology No rare pathologyb
GP judgement Rare pathology 45 (10) 52 (12) 97 (22)
No rare pathologyb 64 (14) 283 (64) 347 (78)
109 (25) 335 (75) 444 (100)
(C)
Normal spirometry Not normal spirometryc
GP judgement Normal Spirometry 88 (20) 17 (4) 105 (24)
Not normal spirometryc 25 (6) 314 (71) 339 (76)
113 (25) 331 (75) 444 (100)
(D)
Incorrect Manoeuvre Not incorrect manoeuvred
GP judgement Incorrect Manoeuvre 48 (11) 26 (6) 74 (17)
Not incorrect manoeuvred 26 (6) 344 (77) 370 (83)
74 (17) 370 (83) 444 (100)
Percentages of total number of cases within parenthesis.
aEither rare pathology, normal spirometry, or incorrect manoeuvre.
bEither obstruction, normal spirometry, or incorrect manoeuvre
cEither obstruction, rare pathology, or incorrect manoeuvre.
dEither obstruction, rare pathology, or normal spirometry.
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spirometry. The probability of referral changes
from 6.0% [3.8, 8.2] to 31.7% [27.4, 36.0] as a
result of spirometry (OR 7.26 [4.71, 11.2]).
Discussion
The present study demonstrates for the first time
the reasonable diagnostic achievements of trained
GPs with regard to commonly encountered spiro-
metric patterns. Curves of obstructive airways
disease as well as the physiological can be con-
sidered the more prevalent conditions, as opposed
to patterns suggestive of restriction or fixed upper
airways obstruction, which GPs can be expected to
be less familiar with. On the whole, the positive
predictive values are lower than the negative
predictive values. This reflects the fact that in
primary care it remains more difficult to label a
disease than to exclude it, due to the lower a priori
probability. The relatively low positive predictive
value of an incorrect test manoeuvre illustrates the
need to emphasise the importance of quality
assessment of the flow–volume curve, which should
precede interpretation. The low diagnostic achieve-
ments in the less prevalent categories points out the
paradoxical necessity of recognising patterns one
does not understand. Another explanation might be
that dynamic spirometry is of limited use in
differentiating between normal and restrictive dis-
ease, thus contributing to the low diagnostic yield.
These elements should receive considerable atten-
tion in future spirometry courses, professional
supervision or automated supportive software.
The significant influence of the flow–volume
curve on the trained GPs’ decision-making is
expressed in a reduction of the number of alter-
native diagnoses but an increase in referral rates
and diagnostic prednisolone courses. Thus, the
flow–volume curve seems to support establishing
a diagnosis in patients with respiratory morbidity,
but probably leads to an increased use of additional
diagnostic procedures or specialist care, at least
initially. This could partially reflect the relatively
high prevalence of pathology in this specific case-
set, warranting further work-up. Another explana-
tion could be that the number of options was
limited; for example, an option to repeat spirome-
try to verify correctness of the manoeuvre was
missing, possibly leading to increased prednisolone
testing or referral instead. The current design does
not allow us to deduct if this initial increase would
be sustained in time, nor does it predict the exact
effect size in daily practice.
Spirometers are increasingly available but seem
underu sed, 7 while doct ors hav e been observed to
overestimate their actual interpretative skills in
spirom etry,22 as well as in ECGs. 23 Th is unde rlines
that training is a prerequisite for meaningful
implementation of advanced diagnostic tools in
primary care. Both quality assessment and pattern
recognition have been part of our standardised
spirometry training course, which took place 6–9
months preceding the measurements, allowing the
primary care physicians to integrate skills in daily
practice. The format and duration of the training
were directly derived from a common postgraduate
spirometry course, which has been attended by
large numbers of Dutch primary care physicians in
the past few years.
The results of the present study reflect the ability
of trained GPs to diagnose this specific case-set.
Therefore, we do not pretend to reflect actual
prevalences of the disease patterns within the
constitution of the cases. By analysing spirometric
patterns separately this over-representation is cor-
rected for. Consequently, the multi-level analysis was
performed to account for intra-cluster correlation
within the GPs. However, it remains to be investi-
gated what the results will be in a real-life setting,
with actual patients and less or even untrained GPs.
The case-set structure allowed us to compare the
level of pattern recognition quite precisely with an
expert panel, which was confronted with the
identical set of cases. Moreover, the expert panel
scored cases preceding the study, independent of the
results of the primary care physicians, thereby
eliminating a potential bias which might have been
overlooked in previous studies. 5,14,15
In this study we demonstrated that the novel
method of combining standardised case material
with techniques of multi-level analysis may be useful
to evaluate complex diagnostic tools, like spirome-
try. We conclude that trained GPs were able to
differentiate between normal and obstructive dis-
ease patterns, while FV curves suggestive of rare
and mixed pathology were often missed. Spirometry
seems to influence the decision-making process of
the GP by reducing diagnostic uncertainty but
increasing use of additional diagnostics and referral
to specialist care. Whether this represents an initial
or a more sustained effect remains to be evaluated
in studies of daily primary care practice.
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Spirometry in primary care: is it good enough to face demands like
World COPD Day?
T. Schermer, T. Eaton, R. Pauwels, C. van Weel
On November 19th this year, World Chronic Obstructive
Pulmonary Disease (COPD) Day 2003, people worldwide
will be encouraged to review their respiratory health status
and consult a doctor in case of certain symptoms [1].
Spirometry would be regarded as an integral component
of this consultation. Additionally, asymptomatic smokers
>40 yrs will be advised to have their lung function checked
[1]. Thus, a likely and desirable outcome of World COPD
Day could be a considerable and perhaps dramatic increase
in demand for spirometry. This is a potentially daunting
prospect with important implications in terms of the availa-
bility and utilisation of healthcare resources. It is therefore
not only timely but essential to re ect on the current status
of spirometry in primary care.
Thus far, a New Zealand study which was reported in
1999 presents the only, but extremely welcome, randomised
prospective evaluation of the implementation of spirometry in
primary care practice formally assessing both the impact of
training and quality assurance [2]. The results of this study
should be placed in the context of the growing prevalence of
COPD which presents an increasing burden on healthcare
resources globally [3]. An essential requirement would seem to
be the development of high quality spirometry by family
physicians on a large scale. The implications are sobering.
Family physicians already diagnose 5–10 new cases annually
[4], a  gure expected to increase in the coming decades. This
 gure, albeit dramatic, still underestimates the true challenge
of COPD. The burden of the disease in the community is
much higher and for a substantial number of patients COPD
remains undiagnosed and consequently untreated [5]. Cigar-
ette smoking remains the leading cause of COPD and despite
heightened public awareness and smoking cessation initia-
tives, a signi cant impact on global COPD numbers is not
expected in the short or medium term. World COPD Day
aims to promote public awareness of COPD. It is to be hoped
that early diagnosis of COPD will facilitate the prevention of
further damage to the airways and lungs, predominantly by
focusing on smoking cessation.
Interface between primary and secondary care
A crucial initial success of the Global Initiative for
Obstructive Lung Disease (GOLD) has been the establish-
ment of a working relationship with primary care, with the
involvement of the World Organization of Family Doctors
(WONCA) [6] and the International Primary Care Respira-
tory Group (IPCRG) [7]. Early next year the  rst global
primary care guidelines for COPD, based on GOLD, will be
published: the International Primary Care Airways Guide-
lines (IPAG) project [8], developed in cooperation with the
World Health Organization (WHO). The introduction of
these guidelines will substantially coordinate diagnosis and
treatment of COPD in primary care. Although a welcome
and valuable initiative, the guidelines do not by themselves
address the critically important issue of ensuring that family
physicians and other primary care professionals have ready
access, not just to spirometry but to quality spirometry.
Spirometry quality assurance
The impact of World COPD Day is expected to be
considerably diminished if spirometry is not widely available
and accessible. However, more importantly, poorly per-
formed spirometry may lead to "misdiagnosis" with conse-
quent misdirection of precious healthcare resources and
giving rise to unnecessary patient concern. The pivotal role
of family physicians dictates that ideally spirometry should
be directly available in "every" practice. However, spirometry
on this scale does present considerable logistic challenges.
Resource and training constraints have for a long time
hampered the large-scale introduction of spirometry to
primary care. Research and development projects have
emphasised rigorous training and performance standards as
essential prerequisites of a successful spirometry programme
[2, 9]. Furthermore, longer term "maintenance of standards"
is crucial. It is salutary that even under the strict conditions of
the Lung Health Study it was observed that the performance
of certi ed technicians with regard to spirometry fell over
time [9]. In primary care, spirometry is often, wrongly,
regarded as a noninvasive simple screening test. However, it is
apparent that careful consideration needs to be given to a
number of aspects including selection and maintenance of
equipment, optimal performance of the test by both patient
and operator, adherence to standard criteria for acceptability
and repeatability, appropriate selection of normal predicted
values, and careful and informed interpretation of the results
[10]. The newer generation electronic spirometers facilitate the
adoption of acceptability and reproducibility criteria in
primary care, but this should not engender complacency.
While well-established criteria for acceptability and repro-
ducibility have been widely disseminated, it is by no means
certain that these are adhered to in clinical practice. The
aforementioned New Zealand study of spirometry by family
physicians highlights some of these issues and possible solu-
tions [2]. Although a signi cant training effect was demon-
strated, the quality of the spirometry performed by family
physicians did not generally satisfy full American Thoracic
Society (ATS) criteria for acceptability and reproducibility
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[11]. However, the ATS guidelines allow for the use of data
from unacceptable or nonreproducible manoeuvres at the
discretion of the interpreter. Since most of the failures seen in
primary care spirometry appear to be end-of-test related [2,
12] the forced expiratory volume in one second (FEV1) may
still be valid for screening purposes. Formal laboratory-based
diagnostic lung function testing could subsequently con rm
abnormal screening  ndings and identify the inevitable false-
positive cases. There is little doubt that poorly performed
spirometry leads to increased inappropriate referral to chest
physicians, particularly when end-of-test criteria are not
met [2]. This serves only to further reinforce the importance
of adequate training and quality assurance for successful
spirometry in primary care.
Organising spirometry in primary care
The British Thoracic Society guidelines for COPD [13]
acknowledge that healthcare planners may need to consider
options for the provision of primary care spirometry other
than having the appropriate equipment on-site. Alternatives
could include utilising primary care diagnostic services or
hospital-based laboratories, although there may be certain
disadvantages, including barriers to access (table 1) [10].
Furthermore, relevant spirometric indices measured by
trained family physicians or their staff may be marginally
higher compared with pulmonary function laboratories [14].
In view of the limited agreement between laboratory and
primary care practice FEV1 and forced vital capacity values,
these measurements should not be used interchangeably [14].
The bottom line is that with suf cient training of family
physicians and their staff, the current practice of performing
spirometry in primary care seems justi able. However the
experience serves as a valuable insight into the clinical reality
of performing spirometry on a larger scale in primary care
practice. It is envisaged that the optimal method of ensuring
quality spirometry will entail a close partnership between
primary healthcare providers and specialised respiratory care.
This integrated approach with specialist respiratory services is
to be recommended, but it is unrealistic to expect this to
become the state of the art universally overnight. The true
challenge is to build the required infrastructure, in terms
of equipment resource and adequate training and expertise.
Although the magnitude of this challenge should not be
underestimated, the published evidence [2, 14] points the way
to widespread implementation of spirometry in primary care.
The community of respiratory health professionals is at
the start of a journey; the goals being to address the global
burden of COPD as outlined by GOLD. Spirometry by
family physicians, with due consideration to quality assur-
ance, is quintessential to this process.
Conclusions
Spirometry, in conjunction with a commitment to smoking
cessation initiatives, has the exciting potential to impact
signi cantly on global health. Given the partnership with
primary care that the Global Initiative for Obstructive Lung
Disease (GOLD) has established, and capitalising on the
experience of family physicians the priority now is the
development of accessible primary care spirometry around
the world, working in close cooperation with specialised
respiratory facilities to facilitate quality assurance. World
Chronic Obstructive Pulmonary Disease Day is a valuable
and important initiative and will serve to mobilise global
action on chronic obstructive pulmonary disease. However its
Table 1. – Advantages and disadvantages of different alternatives for organising spirometry in primary care
Where spirometry performed Advantages Disadvantages
General practice surgery Least barriers to access Reliability of measurements less certain
No extra healthcare costs Extra workload for family practices
Least travelling distance for patients Family practice has to build up expertise
Minimises number of patient
visits ("one-stop shop")
Changes in practice organisation (often) necessary
Results of spirometry integrated
into  rst consultation
Enables FPs to acquire expertise
Nurse-run asthma/COPD clinic Good reliability of measurements Extra healthcare costs
Few access limitations (Considerable) travelling distance for patients
No extra workload for family practices Timely feedback of spirometry
results to family practice crucial
No high demands on spirometry
expertise in family practices
PCG-commissioned Good reliability of measurements Extra healthcare costs
spirometry service Few access limitations (Considerable) travelling distance for patients
No extra workload for family practices Timely feedback of spirometry
results to family practice crucial
No high demands on spirometry
expertise in family practice
Centralisation of interpretation
of spirometry
Hospital-based pulmonary Optimum reliability of measurements Possible access limitations#
function laboratory No extra workload for family practices Limited capacity next to regular tasks
No high demands on expertise Extra healthcare costs
in family practice (Considerable) travelling distance for patients
Facilitates consultation of specialist
respiratory services#
Timely feedback of test results
to family practice crucial
COPD: chronic obstructive pulmonary disease; PCC: primary care group; FP: family practitioner. #: depending on local cooperation with secondary
care chest physicians. Table modi ed from [10].
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true potential will only be achieved by ensuring that quality
spirometry is widely available in primary care. This is a vital
prerequisite to the success of both World Chronic Obstructive
Pulmonary Disease Day and the larger Global Initiative
for Obstructive Lung Disease (GOLD) strategic plan. Never
before have all parties involved been better positioned to
contribute towards this collective goal.
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A B S T R A C T
Background: The burden of asthma and chronic obstructive
pulmonary disease (COPD) on national healthcare systems
is expected to increase substantially in future years. Referral
guidelines for general practitioners (GPs) and pulmonologists
may lead to more efficient use of healthcare facilities. We
explored the prevailing views of pulmonologists regarding
referral and once-only consultation in asthma and COPD, and
compared these views with recently published transmural
referral guidelines for GPs and pulmonologists.
Methods: Cross-sectional multiple case study. Twenty-nine
Dutch pulmonologists working at non-university hospitals
or specialised chest clinics participated in group discussion
sessions. 
Results: The outcome of the discussions and recently
published referral guidelines for GPs and pulmonologists
showed considerable similarity, but also some marked
discrepancies. During the discussions, the main points of
disagreement among the pulmonologists were: 1) should
GPs or pulmonologists add long-acting 2-agonists to
asthma treatment regimens; 2) should the current cut-off
point ‘predicted FEV1 <50%’ for referral of COPD patients
be increased to 60 or 70%; and 3) should an annual
exacerbation rate of two episodes a year be used as an
undifferentiated referral criterion for COPD patients? For
asthma, proposed back-referral (i.e. from pulmonologist to
GP) criteria rested on: required dose of inhaled steroids,
persistent need for long-acting 2-agonists, duration of
clinical stability and persistence of airway obstruction.
Back-referral criteria for COPD rested on age, blood-gas
abnormalities and ventilatory limitations. Primary care
monitoring facilities and ‘shared-care’ constructions were
considered to be facilitating conditions for back-referral. 
Conclusions: This explorative study provided insights into
how pulmonologists visualise a rational referral policy for
patients with asthma or COPD. These insights can be
taken into consideration in future revisions of referral
and back-referral guidelines for GPs and pulmonologists. 
I N T R O D U C T I O N
Over the next few years, it is expected that a sharp increase
will occur in the incidence and prevalence of asthma and
chronic obstructive pulmonary disease (COPD) in many
Western countries.1-4 Consequently, patients with these
chronic pulmonary diseases will make steadily increasing
demands on healthcare services. General practitioners
(GPs) and pulmonologists will soon become aware of
this, owing to the increasing time investment in these
categories of patients. One of the major challenges for the
near future is to achieve efficient use of available care
facilities for asthma and COPD patients. Adequate referral
policies from the GP to pulmonologist and back-referral
to the GP form an inextricable part of this challenge.
Although the theme ‘referral in asthma and COPD’ has
been receiving increasing attention in the literature over
the past few years and various guidelines have been put
forward that contain concrete referral criteria,5-9 no research
has been performed into the effectiveness of (alternative)
referral policies for the two diseases. Nevertheless it is
Referral and consultation in asthma and COPD:
an exploration of pulmonologists’ views
T. Schermer, F. Smeenk, C. van Weel
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reasonable to assume that if GPs follow an efficient referral
policy, then superfluous specialist care will be prevented,
while patients who do require specialist care will receive it
all the sooner. If, at the same time, pulmonologists endeavour
to refer patients back to their GPs as soon as they consider
it medically justified, then optimal use will be made of
their valuable time. Guidelines that dictate when referral
is indicated contribute to more effective care. However,
incorrect guidelines or recommendations that are poorly
linked with daily practice can have an unfavourable effect.10
Therefore, the Dutch professional organisations of GPs and
pulmonologists recently developed two transmural ‘agree-
ments’, in which concrete recommendations are made
about referral and back-referral of patients with asthma and
COPD.11,12 As there is very little evidence-based information
on which to base concrete referral criteria, these agreements
(developed in the light of empirical findings and expert
consensus) are the highest attainable at the present time.
In the development of guidelines, it is of decisive importance
to have intimate knowledge of daily practice; experts are
often inclined to make too little allowance for this. In
addition, it is important to be able to anticipate how new
guidelines will be accepted by the workforce.13
A series of postgraduate courses enabled us to study the
views of pulmonologists, regarding referral, back-referral
and once-only consultation in asthma and COPD. The
aim of the study was to make an inventory of prevailing
views within this professional group and to compare these
views to the expert consensus recently reached in the
national transmural agreements for asthma and COPD.11,12
M E T H O D S
Between March 1999 and April 2000, four group discussion
sessions were held with pulmonologists working at non-
university hospitals or specialised chest clinics in four
different regions of the Netherlands, to make an inventory
of prevailing views on ‘referral’ and ‘back-referral’ of patients
with asthma or COPD. Pulmonologists acting as regional
contact persons were approached to evaluate the level of
interest in postgraduate courses in this field. Participants
in the four discussion groups were representatives from
partnerships in the regions concerned. A total of 29 pul-
monologists from 18 partnerships (approximately 10% of all
registered pulmonologists active in the Netherlands) took
part. In each discussion group one GP with a special interest
in asthma and COPD was present to explain the guidelines
issued by the Dutch College of General Practitioners
(NHG),7-9 and the utility and applicability of these guidelines
in daily practice. Prior to each discussion session, the
pulmonologists were asked to fill in a short questionnaire
on personal characteristics, their own criteria for back-
referral of asthma and COPD patients, and local working
agreements with GPs.
To ensure that a number of previously determined issues
would be dealt with during the course of the discussions,
two standardised cases were developed: one for asthma
(see table 1) and one for COPD. Step by step, a specific
part of the initial case description was modified using a
standard set of overhead sheets. In this semi-structured
manner, two of the authors (F. Smeenk and C. van Weel)
were able to bring various issues under discussion that
play a role in referral and back-referral in asthma and COPD.
Criteria from the general practice guidelines were incor-
porated into the discussions. The asthma case was always
discussed first, followed by the COPD case. This approach
was tested and modified in a pilot discussion session held
with pulmonologists working in the Nijmegen region.
With the pulmonologists’ consent, the discussions were
recorded on audiotape. After the recordings had been
typed out, two of the authors (T. Schermer and F. Smeenk)
independently extracted conclusions from the discus-
sions and classified them per theme. The themes for
Table 1
Asthma case used to structure group discussion sessions 
INITIAL CASE DESCRIPTION
A 24-year-old non-smoking female cashier with a history of 
childhood asthma and atopic rash consults a GP. Renewed onset 
of respiratory symptoms (intermittent dyspnoea attacks, max. 
once a week) at age 20. Adequate symptom relief on salbutamol 
on an as-needed basis. 
Should a GP refer this patient to a pulmonologist?
FIRST MODIFICATION
Additional diagnostic information is available: FEV1 2.56 l (73% of 
predicted value), FEV1 reversibility after salbutamol 20% of 
predicted value, allergic response to house dust mite and pollen. 
Should a GP refer this patient to a pulmonologist?
SECOND MODIFICATION
Frequency of respiratory symptoms increases from once a week to 
daily and symptoms are more severe. Salbutamol is needed every day. 
Should a GP refer this patient to a pulmonologist?
THIRD MODIFICATION
Respiratory symptoms and salbutamol use are less frequent (once 
a week) with addition of budesonide 400 g twice a day. Tapering 
off the budesonide dose is unsuccessful. 
Should a GP refer this patient to a pulmonologist?
SUBSEQUENT MODIFICATIONS COVER THE FOLLOWING ISSUES
Persistent or deteriorating airway obstruction
(High) dose of inhaled corticosteroids
Addition of a long-acting 2-agonist
Rapid deterioration of asthma condition
Frequent asthma exacerbations
Current smoking
Food allergy
Occupational exposure
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asthma were medication and treatment targets, titration
of the dose of inhaled corticosteroids, diagnosis and
monitoring, and asthma exacerbations. The themes for
COPD were lung function, exacerbations, treatment options,
and diagnosis. Spirometry in general practice was considered
as a separate theme. The results section describes the content
of the discussions held in one or more of the sessions.
The most important conclusions about referral and once-only
consultation are summarised in tables. Explicit mention
is made of all divergent views that became apparent during
the discussion sessions. For the sake of simplicity, ‘he’
(read: he or she) is used in the text to refer to GPs, pul-
monologists and patients.
R E S U L T S
Characteristics of the pulmonologists
All 29 pulmonologists were working at non-university
hospitals or specialised chest clinics (28 men, one woman;
mean age 46 ± 5.2 years; mean time since specialist
qualification 14 ± 6.7 years). All indicated that they were
familiar with the asthma and COPD guidelines issued by
the Dutch College of General Practitioners. The pulmon-
ologists estimated that on average, formal back-referral to
general practice occurred in 51% (range 15 to 82%) of
their asthma and COPD patients. Table 2 presents the
criteria used for back-referral, subdivided into ‘global’ and
‘specific’ criteria. Existing arrangements with GPs regarding
the reason for referral and consultation were once-only
consultation to determine diagnosis (38%), assistance
with spirometry interpretation (20%), shared-care (20%)
and local protocol for referral/back-referral (7%).
Issues on referral and consultation in asthma
Medication and treatment targets
Referral by GP to pulmonologist: In the case of intermittent
or mild asthma with (reversible) airway obstruction, GPs
have sufficient means at their disposal to initiate treatment.
If the treatment does not lead directly to visible improvement,
a GP should not be too hasty in referring the patient to a
pulmonologist: a minimum evaluation period of six months
was recommended. If the a priori set treatment targets
(table 3) are not reached within this period, then the GP can
Table 2
Global and specific criteria used by participating pulmonologists (n=29) to refer asthma and COPD patients back 
to general practice care 
ASTHMA COPD
GLOBAL CRITERIA SPECIFIC CRITERIA GLOBAL CRITERIA SPECIFIC CRITERIA
Stable asthma condition PC20 >8 mg/ml Stable COPD condition FEV1 >60% of predicted 
(13, 45%) (4, 7%) (13, 45%) value and clinically stable (2, 7%)
Lung function parameters Stable lung function Lung function parameters FEV1/VC >50% of 
(7, 25%) >1 year (4, 7%) (7, 25%) predicted value (2, 7%)
Well-regulated medication Competence of GP 
use (4, 14%) in question (2, 7%)
Competence of the 
GP in question (2, 7%)
Figures in brackets represent the number and proportion of participants that indicated the particular criterion, respectively.
Table 3
Treatment targets and indications for (once-only) consultation with a pulmonologist in adult patients with asthma,
according to the national guidelines of the Dutch College of General Practitioners8
TREATMENT TARGETS IN PATIENTS
No, or only minor asthma symptoms, acceptable night’s rest, (nearly) normal daily activities
As few interventions as possible, minimal or no side effects of asthma medication
Prevention or timely treatment of asthma exacerbations
Achieving and preserving optimal lung function
INDICATIONS FOR (ONCE-ONLY) CONSULTATION WITH A PULMONOLOGIST
Persistent use of high-dose inhaled steroids without being able to taper off; treatment targets cannot be achieved on this regimen
Continuous use of high-dose inhaled steroids or moderately high dose of inhaled steroids combined with a long-acting 2-agonist
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increase the dose of inhaled steroids or add a long-acting
2-agonist. If no progress is made during the new evaluation
period with this combination therapy, then referral to the
pulmonologist is indicated. The phase in which lung
medication is initiated depends on the degree to which the
GP decides to extend the medication himself. In one of the
discussion groups, the prevailing view was that (partial)
substitution of an inhaled steroid for a long-acting 2-agonist
should be performed by the pulmonologist, not by the GP.
In any case, before deciding to administer long-acting
medication, the GP should first reconsider his diagnosis of
asthma. If after repeating the anamnesis and supplementary
peak flow measurements there is still doubt about the
accuracy of the diagnosis, then a once-only diagnostic
consultation with the pulmonologist can be requested.
Tapering off the dose of inhaled steroids
Referral by GP to pulmonologist: The maintenance dose
of inhaled steroids is in itself a factor that should play a
role in the GP’s decision as to whether or not to refer the
patient. Upper dose limits of 800 to 1000 g of budesonide
or beclomethasone, or 500 g of fluticasone a day, as
recommended in the current Dutch GP guidelines, were
considered to be acceptable referral criteria by the pul-
monologists. At higher doses, the risk of systemic side
effects can form an indication for referral.
Several of the pulmonologists had the impression that GPs
are often reluctant to administer long-term maintenance
treatment with inhaled steroids; they seem to have the
tendency to prematurely taper off the dose. Once again, the
factor time should play a role. If a GP decides to taper off
a moderately high maintenance dose (800 to 1000 g a
day) in a stable asthma patient, but is unable to do so over
a period of two years, then the risk of long-term side effects
can form an indication for referral. Most pulmonologists
were of the opinion that if the GP is certain of the diagnosis
and has excluded all possible trigger factors, he can first
add a long-acting 2-agonist and then subsequently try to
taper off the dose. If it still proves impossible to reduce
the dose of steroids, then a once-only consultation with
the pulmonologist can be requested to check whether any
trigger factors have been missed. Several of the discussions
revealed that owing to the fact that referral information
from the GP does not always offer sufficient footing, it might
not be possible to gain an adequate overview during a
once-only consultation.
Back-referral from pulmonologist to GP: During consultation
with an asthma patient, the pulmonologist provides further
confirmation of the diagnosis and treatment, and establishes
the minimum required maintenance dose of medication.
On the basis of the histamine threshold, he evaluates
whether the inhaled steroid dose can be tapered off. In
the majority of cases, it is possible to refer the patient back
to the GP with clear treatment instructions and recommen-
dations for frequency-of-monitoring visits. Adaptation of
a medication regime by the pulmonologist should always
include a period of intensive spirometry or peak flow
measurements which, in principle, the GP can undertake.
When a patient in the care of a pulmonologist has become
clinically stable on an 800 to 1000 g daily dose of inhaled
steroids, he can normally be referred back to his GP. 
Even at higher doses, back-referral does not need to be a
problem if the patient has been stable for some time. In
only one of the discussion groups was the term ‘stable’
further specified as: normal lung function and very few
respiratory symptoms, while the steroid dose is clearly
based on the minimum required dose. The main reasons
mentioned by the pulmonologists for not referring asthma
patients back to the GP are given in table 4. If a patient is
using an inhaled steroid dose of more than 800 to 1000 g
a day (with or without addition of a long-acting 2-agonist)
the pulmonologist can decide to monitor the patient himself.
However, cooperation with the GP in the form of a shared-
care construction is also possible, although structured
communication between the pulmonologist and GP is
essential in this situation.
Diagnosis and monitoring
Referral by GP to pulmonologist: In the majority of cases,
the GP can make the diagnosis of asthma himself using
peak flow measurements. Spirometry in patients with
suspected asthma only has additional value when previously
conducted peak flow measurements have shown that the
patient has reversible airway obstruction or day-night
variability. In asthma patients who have very few respiratory
symptoms but show persistent airway obstruction, despite
adequate treatment with inhaled steroids, there seems to
be an indication for referral. Stipulations for referral are
that the obstruction must in principle be fully reversible
and there must be an obvious discrepancy between lung
function and respiratory symptoms. Relatively young
patients with persistent airway obstruction that does not
subside after a ‘diagnostic’ course of oral steroids should
be referred to the pulmonologist for further testing. Other
reasons mentioned for referral are given in table 4.
Back-referral by pulmonologist to GP: The discussions
showed that pulmonologists do not tend to refer patients
back to general practice on the basis of hard evidence alone.
The feeling that the pulmonary condition is stable plays a
more important role. When the pulmonologist refers the
patient back, he expects the patient to be monitored by
his GP in accordance with the current asthma guidelines
for GPs. It therefore depends on the GP in question
whether the pulmonologist refers the patient back or not,
especially in patients whose monitoring is of an urgent
nature.
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Asthma exacerbations
Referral by GP to pulmonologist: If an asthma patient is
undergoing optimal monitoring by the GP but suffers three
or more exacerbations a year that require prednisolone,
then referral to a pulmonologist is indicated. In cases
with a clear explanation for the recurrent exacerbations,
referral does not seem to be so worthwhile. If the GP is
unable to identify the triggering factor in a patient with
recurrent exacerbations, then referral is indicated. Two of the
discussion sessions revealed that some of the pulmonologists
felt that particularly patients with persistent symptoms
were referred to them relatively quickly, whereas patients
who needed several courses of prednisolone a year but
expressed very few respiratory symptoms were not
referred until the prednisolone became less effective.
Several pulmonologists suggested that GPs are sometimes
too premature with administering courses of prednisolone,
without first attempting to identify the underlying cause
of the exacerbation. If there is no relevant improvement or
persistent deterioration occurs while a patient is receiving
optimally regulated maintenance treatment, then the GP
should not wait too long before referring the patient to a
pulmonologist.
Table 4
Summary of statements concerning referral and once-only consultation in asthma, derived from four discussion sessions
with non-university pulmonologists (n=29)
DESCRIPTION OF STATEMENT NO. MEETINGS IN PRO/CON*
WHICH ITEM CAME UP$
Situations in which GPs should consider (once-only) consultation with a pulmonologist
Consider referral if: Attempts to taper off a high dose of inhaled steroids (>800-1000 g 4 (4/0)
budesonide or beclomethasone, >500 g fluticasone) are unsuccessful 
after two years
(Partial) substitution of inhaled steroids by a long-acting 2-agonist 4 (1/3)
is considered
Poor medication compliance, ill-advised lifestyle or other patient-centred 4 (4/0)
causes for recurrent exacerbations despite sufficient attention from the GP
Persistent asthma symptoms coinciding with normal lung function, 3 (3/0)
despite otherwise adequate treatment with inhaled steroids
≥3 asthma exacerbations a year, each requiring treatment with oral 3 (3/0)
prednisolone, without an identified trigger for the high exacerbation rate
No clinical improvement is observed six months after adjustment of 2 (2/0)
the asthma medication regime
Consider once-only Persistent diagnostic uncertainty, even after repeating medical history 4 (4/0)
consultation if: taking, elimination of all possible trigger factors and additional peak 
flow monitoring
Doubt about the feasibility of tapering off inhaled steroids 4 (4/0)
Persistent airway obstruction after a diagnostic prednisolone course at 3 (3/0)
relatively young age
Drastic allergen avoidance measures are inevitable 2 (2/0)
Situations in which pulmonologists should consider back-referral to a GP
Consider referring A patient has been clinically stable# for 1.5 to 2 years on a low to 3 3/0
back if: moderately high dose of inhaled steroids (≤800-1000 g 
budesonide/beclomethasone, ≤500 g fluticasone)
A patient has been clinically stable# for 1.5 to 2 years on a high dose of 3 3/0
inhaled steroids (>800-1000 g budesonide/beclomethasone, >500 g 
fluticasone), with or without a long-acting 2-agonist, provided that 
the GP supervises the monitoring schedule, or a solid shared-care 
construction is available
None of the following are applicable: 1 1/0
Persistent necessity for the combination high-dose inhaled steroid 
+ long-acting 2-agonist 
Persistent airway obstruction
Asthma-related hospital admission <1.5 to 2 years ago
Statements are ranked by the number of meetings in which each particular issue was discussed. $ Minimum 1, maximum 4; * PRO=prevailing view during session
in favour of statement; CON=prevailing view during session against statement; # in one session specified as ‘normal lung function, few respiratory symptoms
and inhaled steroids adjusted to the lowest possible effective dose’.
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Although the current GP guidelines recommend that an
asthma patient should be referred to a pulmonologist in
the case of two or more exacerbations a year, it seems to
be difficult – if not impossible – in practice to establish a
general absolute cut-off point. The specific circumstances
of the patient and the existence of a possible explanation
for a high exacerbation rate are strong determinants. In
addition, the degree to which the asthma patient himself
is responsible for ‘aggravating’ his asthma can play a role
in the GP’s decision whether or not to refer the patient.
Back-referral by pulmonologist to GP: If a patient has recently
suffered an acute severe asthma attack, it is advisable for him
to remain under the care of the pulmonologist for a fairly
long time. An evaluation period of 18 to 24 months was
mentioned as a rule of thumb in several of the discussion
groups, irrespective of whether the patient has become
clinically stable on a maintenance dose of inhaled steroids.
After the evaluation period the pulmonologist can consider
referring the patient back to the GP. If he decides to refer
the patient back, he should preferably give the most concrete
possible advice about the further management policy.
Conclusions regarding referral and consultation in asthma
are summarised in table 4.
Issues on referral and consultation in COPD
Lung function, exacerbations and treatment options
Referral by GP to pulmonologist: In all discussion groups
the pulmonologists made it clear that when making a
referral decision, GPs should not only take the Dutch GP
guidelines (table 5) into consideration, but also the respiratory
symptoms and possible discrepancies between these
symptoms and clinical presentation. In the GP guidelines,
the lung function criteria for referral are an FEV1 <50%
of the predicted value and/or an FEV1 <1.5 litres. An
important point of discussion in relation to these criteria
was that a COPD patient who has not (yet) dropped under
these cut-off levels will develop problems at some stage,
which will persist for the rest of his life. If the GP does not
establish any relevant baseline values for lung function,
then the pulmonologist should be given the opportunity
to do that for him.
The pulmonologists held the view that COPD patients with
moderate to severe airway obstruction, but a discrepancy
between respiratory symptoms and clinical presentation,
should always be referred. Although there is evidence in
the literature that the prognosis deteriorates when lung
function falls below the above-mentioned FEV1 cut-off levels,
it is not clear whether earlier referral has any additional
value. However, owing to the fact that, depending on the
specific circumstances, multiple problems can be expected
in patients with moderate to severe airway obstruction in
a relatively early stage of the disease, earlier referral is
desirable, for instance at FEV1 <60% of the predicted
value. In any case, GPs must be encouraged not to wait
until the FEV1 has fallen below 50% before they refer a
COPD patient. A possible disadvantage of lowering the
referral limit is the considerable increase in burden on
specialist care. Furthermore, the pulmonologists agreed
that GPs should not base their referral decision only on
FEV1 values. FEV1 alone is not sufficient to characterise a
COPD patient, although in practice, this is all the GPs have
to go on. Discussions on the role of exacerbations revealed
that in the case of frequent exacerbations (i.e. two or
more exacerbations a year), there are two arguments in
favour of referral by the GP: evaluation of the causal factors
and the risk of side effects from frequent prednisolone
courses.
Bronchial hyperresponsiveness in COPD patients not only
forms a prognostic factor, it can also be used to identify the
(relatively small) group of COPD patients that also have
Table 5
Treatment targets and indications in patients with COPD for (once-only) consultation with a pulmonologist, according
to the national guidelines of the Dutch College of General Practitioners9
TREATMENT TARGETS IN PATIENTS WITH COPD
Short term: reduce respiratory symptoms, improve exercise tolerance, improve lung function and prevent exacerbations
Long term: decelerate progressive lung function decline and postpone or prevent complications and disability
INDICATIONS FOR CONSULATION WITH A PULMONOLOGIST
Severe COPD (FEV1 <50% of predicted value or <1.5 l) despite optimal treatment
Persistent uncertainty about whether COPD is complicated by chronic heart failure
COPD at a relatively young age (<50 years)
Severe progressive FEV1 decline (>100 ml/year) despite treatment with inhaled steroids
Frequent exacerbations despite treatment with N-acetylcysteine
Possible indication for oxygen treatment, maintenance treatment with antibiotics or theophylline, pulmonary rehabilitation
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features of asthma. With changing insights into the role
of inhaled steroids in COPD it remains to be seen whether
in the future, GPs should also consider the degree of
bronchial hyperresponsiveness in their decision to prescribe
inhaled steroids. As pulmonologists are better able to
distinguish between subgroups than the GP, some
patients might not receive maximum benefit from the
existing treatment options during the years that are lost
prior to referral. In two of the sessions, discussion arose
about whether pulmonologists have more means at their
disposal than GPs to help COPD patients quit smoking.
Perhaps pulmonologists in their capacity as medical
specialists have greater authority in the patient’s view, but
in principle, the GP should be able to achieve the same
results.
Back-referral by pulmonologist to GP: Pulmonologists
should include the factor (advanced) age in their decision
about whether or not to refer COPD patients back to general
practice. Otherwise there is the risk that the outpatient clinic
will ‘fill up’ with elderly COPD patients. If these elderly
patients can manage on their regular maintenance treatment
supplemented with a course of prednisolone now and
again, then the pulmonologist has little more to offer
than the GP. However, it is better for patients with gas
transfer abnormalities to remain under the care of the
pulmonologist, although a shared-care construction can
also be considered, in which the GP monitors the patient
and specially trained COPD nurses provide assistance.
If the pulmonologist refers a patient on oral theophylline
back to his GP, then it is important that he realises that
the GP guidelines do not contain any recommendations
about this treatment. Therefore his advice should include
clear instructions. If the pulmonologist has tried in vain
to stop the theophylline, this should also be mentioned
explicitly in the back-referral letter.
Diagnosis
Referral by GP to pulmonologist: Although the GP himself
can refer a patient for supplementary tests (e.g. chest X-ray),
referral to a pulmonologist might be worthwhile to exclude
malignancy or to ‘map’ the patient’s status on the basis of
carbon monoxide diffusion capacity, blood gasses, respiratory
mechanics and ergometry. In every COPD patient with
moderately severe airway obstruction (FEV1 50 to 70% of
the predicted value) the GP should consider referral for a
once-only (diagnostic) consultation. The pulmonologist
can map the patient’s lung function more extensively and
evaluate unfavourable prognostic factors. When they refer
a patient just for spirometry and the accompanying inter-
pretation of the pulmonologist, GPs also expect to receive
concrete information about the diagnosis and advice about
treatment. As the pulmonologist only sees the spirometry
test results and not the patient himself, this is not an ideal
situation. Within the discussion groups the participants
clearly expressed preference for ‘evaluation mapping’ by
the pulmonologist in such circumstances, in which he
personally sees the patient (at least) once.
Back-referral by pulmonologist to GP: A COPD patient
cannot be referred back to the GP on the basis of lung
function criteria alone. It is important for the pulmonologist
to gain insight into the impact of COPD on the patient’s
daily functioning so that he can give the GP more detailed
advice about treatment. In the case of moderately to
severely disturbed diffusion capacity, continuation of regular
monitoring by the pulmonologist takes preference over
referral back to the GP. Although the spirometry and
ventilatory parameters might be borderline normal, these
patients are approaching the level of permanent invalidity.
In patients with ventilatory limitations, hypoxaemia and/or
hypercapnia on exertion, it is preferable for the pulmon-
ologist to continue seeing the patient for checkups. If the
patient is subjectively and objectively stable and the pul-
monologist considers it possible to transfer the checkups to
the GP, then he can refer the patient back. The
pulmonologist can, for example, advise the GP to refer
the patient to a lung function laboratory for periodical
supplementary testing.
Conclusions regarding referral and consultation in COPD
are summarised in table 6, see page 78.
D I S C U S S I O N
The results of this explorative study sketch a useful profile
of the views of Dutch pulmonologists regarding the wide-
sweeping theme: referral and consultation in asthma and
COPD. Although previous research has shown that question-
naires can be used to make such inventories,14,15 it has also
become clear that they are unable to map nuances. The
present qualitative study design offered the opportunity to
explore the major issues and discussion points surrounding
this complex theme in fairly great detail. However, it is
possible that the selection of regions influenced the findings:
our survey did not include all the separate regions of the
Netherlands. If regionally determined variations exist in
referral and back-referral policies and views, then this
may have affected the direction of the results. In addition,
the discussions, despite uniform structuring by means of
the standardised case descriptions on an overhead sheet,
were kept fairly open. It is therefore possible that not all
prevailing views were expressed, as certain topics received
less attention.
One of the most important findings in this study was
that broadly speaking, Dutch pulmonologists approved
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the contents of the GP guidelines7-9 and the transmural
agreements published by their own, and the GPs’ pro-
fessional organisations.11,12 However, they clearly had their
own professional views about referral by GPs and subsequent
back-referral. Another important conclusion is that it is
reasonably easy to formulate univocal referral criteria for
asthma; the literature and empiricism offer sufficient
points of application for this. In contrast, this task is much
more complex for COPD. According to the pulmonologists,
there are so many individual, patient-related factors that
can play a role in the GP’s decision to refer a patient with
COPD that it is very difficult to devise strict criteria. On the
one hand, this situation is inconsistent with the referral
limit of an FEV1 <50% of the predicted value or <1.5 litre
currently recommended,9,12 because this cut-off point still
leads to many discussions between GPs and pulmonologists.
On the other hand, it is not clear whether the pulmonologists
justifiably expressed concern that GPs wait until the FEV1 has
deteriorated to the recommended cut-off point. A possible
solution was the proposal to refer all COPD patients with
an FEV1 of 50 to 70% of the predicted value (‘moderate
obstruction’) to a pulmonologist for once-only evaluation
mapping of diffusion capacity, blood gasses, etc. This policy
is in line with the position held by Dutch pulmonologists
regarding detection of the group of COPD patients with
moderate to severe bronchial hyperresponsiveness. In
this way, pulmonologists can evaluate the presence of an
asthma component in the cause of airway obstruction and
the indication for inhaled steroid treatment.
Comparison with published Dutch transmural agreements
Nine months after the last discussion session was held, the
Dutch professional organisations of GPs and pulmonologists
published their joint transmural agreements for asthma
and COPD,11,12 which include detailed recommendations
on referral and back-referral for GPs as well as pulmon-
ologists. In many respects, the contents of the transmural
agreements are in line with the existing asthma and
COPD guidelines for GPs.7-9 The outcomes of our discussion
sessions and the transmural agreements showed considerable
Table 6
Summary of statements concerning referral and once-only consultation in COPD, derived from four discussion sessions
with non-university pulmonologists (n=29)
DESCRIPTION OF STATEMENT NO. MEETINGS IN PRO/CON*
WHICH ITEM CAME UP$
Situations in which GPs should consider (once-only) consultation with a pulmonologist
Consider referral if: FEV1 <50% of predicted value or FEV1 <1.5 l 4 3/1
&
FEV1 value ≥50% of predicted value or FEV1 ≥1.5 l, but persistent 4 4/0
respiratory symptoms or a discrepancy between symptoms and the 
clinical profile
≥2 exacerbations a year, in order to evaluate causal factors and assess the 3 1/2#
risk of side effects due to frequent prescription of prednisolone courses
Consider once-only FEV1 is 50 to 70% of predicted value, in order to enable the 3 3/0
consultation if: pulmonologist to map relevant baseline parameters (e.g. TLCO, 
blood gasses)
The GP anticipates that the probability of successful smoking cessation 2 2/0
may be higher when supervised by a pulmonologist
Determine whether treatment with inhaled steroids is appropriate, 2 2/0
based on measurement of bronchial hyperresponsiveness
Situations in which pulmonologists should consider back-referral to a GP 
Consider referring None of the following are applicable: 2 2/0
back if: Presence of moderate to severe gas transfer abnormalities 
(except when a high-quality shared-care construction is guaranteed)
Presence of ventilatory limitations
Presence of hypoxaemia and/or hypercapnia
An elderly patient is managing sufficiently well on the established 1 1/0
maintenance treatment and an occasional oral prednisolone course
Statements are ranked by the number of meetings in which each particular issue was discussed. $ Minimum 1, maximum 4; * PRO=prevailing view during 
session in favour of statement; CON=prevailing view during session against statement; # in two sessions, the participants were in doubt whether it is appropriate
to assert one cut-off point concerning annual exacerbation rate in all patients with COPD; & in one session a cut-off point of 60% of the predicted FEV1 value
was proposed; TLCO = diffusing capacity for carbon monoxide.
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similarity, but also some marked discrepancies. For asthma,
the most notable discrepancies were:
- the issue of tapering off inhaled steroids does not come
up at all in the agreement,11 whereas it was a major
issue in all discussion sessions;
- GPs should wait longer (i.e. six instead of three months)11
after adjustment of an asthma medication regime
before concluding that no clinical improvement has
been achieved;
- GPs should first try to identify underlying triggers for
(recurrent) asthma exacerbations before referring a
patient to a pulmonologist;
- GPs should refer an asthma patient for once-only
consultation in case drastic allergen avoidance measures
are planned;
- pulmonologists should take longer (i.e. 18 to 24 months
instead of 3 to 12 months)11 before referring clinically
stable asthma patients back to their GP, regardless of
the maintenance dose of inhaled steroids. 
The transmural COPD agreement12 comprises more (and
far more detailed) recommendations regarding referral
and back-referral compared with the pulmonologists’ views
expressed during the discussion sessions. As indicated
above, some notable additions were suggested: referral
of patients with a predicted FEV1 of 50 to 70% for once-
only (diagnostic) consultation to map relevant baseline
characteristics; once-only consultation of a pulmonologist
to evaluate the indication for inhaled steroid treatment on
the basis of bronchial hyperresponsiveness.
Referral and efficiency of care
Although there is only one indication in the literature that
a structured referral policy can result in more efficient
asthma care,16 we do not know which set of referral criteria
leads to the most efficient care for asthma patients. No
studies have been performed on COPD in this area.
Therefore for the time being, guidelines for referral and
consultation in asthma and COPD can be based solely on
common sense and consensus. It is particularly for this
reason that the findings in this study may offer useful
leads for authors who are formulating or revising referral
guidelines. The fact that the pulmonologists from the study
regions could apparently hold different views about who
should be responsible for substituting inhaled steroids
for a long-acting 2-agonist can in practice form a barrier
against accepting asthma guidelines. Most pulmonologists
agreed that an 800-1000 g dose of inhaled steroids was
a useful referral criterion, which provides support for the
current GP guidelines and transmural agreement. The
additional referral criteria for GPs proposed in the discussions
about asthma (see table 4) can be taken into consideration
when devising or revising guidelines. It is possible that clear
formulation of the reason for referral and clear presentation
of the question – something that was often missing according
to our study participants – would contribute to more efficient
care. In the literature, it is stated that in at least 15% of all
referrals, the nature of the problem remains obscure.17
GPs’ diagnostic uncertainty and the value of spirometry 
In one of the discussion groups it was stated that when
asthma is suspected, spirometry only has supplementary
value if the GP finds reversible airway obstruction or 
day-night variability using peak flow measurements.
Because airway obstruction – or its reversibility – can be
detected more effectively with spirometry than with peak
flow measurements, this is doubtful. As a steadily increasing
number of GPs are setting up their own spirometry facilities,
the value of peak flow measurements is decreasing.
However, negative findings on supplementary tests (i.e.
normal peak flow, absent peak flow variability, normal
spirometry), while the GP nevertheless has clinical suspicions
of asthma, can form a relevant referral indication. In such
a case, supplementary tests by the pulmonologist have
clear additional value: if the histamine threshold is normal,
then clinical asthma is almost certainly excluded and the
GP can continue his search within the differential diagnosis.
During the discussions, the pulmonologists laid great emp-
hasis on the ‘degree of certainty’ about the diagnosis asthma.
Recent studies have also shown that this should be an impor-
tant point of attention for GPs. For instance, Marklund et al.
found that GPs’ diagnoses of asthma could not be confirmed
by an allergologist in 34% of the patients.18 In addition, 7%
of the patients were found to have a combined diagnosis
of asthma and COPD, which the GP had not recognised.
Primary care research by Pinnock et al. showed that spiro-
metric re-evaluation of COPD patients led to a different
(spirometric) diagnosis in 35% of the cases.19
Back-referral to general practice and ‘shared-care’
The suggestion made to stimulate pulmonologists to
refer asthma patients back to general practice once their
lung function has normalised, they have few respiratory
symptoms and inhaled steroids have been reduced to the
lowest possible maintenance dose is of particular interest.
This also applies to the exclusion criteria mentioned in
the discussions, an asthma-related hospital admission
less than two years previously and the persistent need for
combined treatment with high-dose inhaled steroids and
a long-acting 2-agonist. The support that seems to exist
among pulmonologists for cooperation with GPs in the
form of shared-care is an extra reason to stimulate such
constructions for the group of more complex asthma and
COPD patients. However, the term ‘more complex’ should
be clearly defined, because research has shown that
shared-care in a large group of asthma patients as a whole
did not prove to be more effective than full specialist treat-
ment, even though the financial cost was considerably lower.20
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In the discussion about when pulmonologists should refer
COPD patients back to general practice, it was concluded
that guidelines can only offer a certain amount of footing,
because the pulmonologist’s own ‘feeling’ must continue
to play a major role. Although it is difficult to lay down
hard criteria, the view that patients with moderately to
severely disturbed diffusion capacity, ventilatory limitations,
hypoxaemia and/or hypercapnia on exertion should remain
under the care of the pulmonologist, is relevant within
this framework.
Communication and mutual expectations by GPs and
pulmonologists
Research into referral and consultation in patients with
chronic respiratory diseases has received little attention in
the literature. Recently, Li et al. performed a survey in the
USA on 37 GPs to gather information on the prevailing
customs, preferences and expectations when referring
asthma patients.15 Although the GPs who participated
were not at all representative for the ‘average’ GP (all the
respondents had affiliations with the university that
conducted the survey), a striking finding in the study was
that the majority of referrals to pulmonologists were written
at the patient’s own request. A satisfied patient and clear,
applicable recommendations from the pulmonologist
appeared to be the prevailing expectations of the GPs.
Research in Canada by Langley et al. showed that the
geographic distance to specialist care and the relationship
between GP and specialist were important factors in the
GP’s decision whether or not to refer a patient.21 The study
concerned not only asthma and COPD patients, but referrals
by GPs in general. The view expressed in the current study
that pulmonologists should give clear advice about the
treatment policy when referring patients back to the GP
is in line with the findings in other studies. Williams et al.
reported that pulmonologists and GPs in the USA are of
the opinion that the information supplied when a patient
is referred is too often inadequate or unclear.22
Primary care research has shown that GPs follow referral
guidelines for asthma and COPD only to a limited extent.
Jans et al. reported that the guidelines for referral to the
pulmonologist were followed by the GP in only 17% of the
cases with an indication.23 Doubt about the value of referral
in individual cases was the most important reason for this.
Studies have also shown that referral behaviour of GPs can
be influenced positively, although it is not yet clear which
intervention method is the most effective.24
C O N C L U S I O N
This explorative study provided insight into how non-
academic pulmonologists visualise a rational referral policy
for asthma and COPD patients. Although the outcome of
the discussions and the recently published GP guidelines
and transmural agreements showed considerable similarity,
we also observed some marked discrepancies. To achieve
optimal integration of published referral guidelines into
daily practice the insights of this study should be taken
into consideration during future revisions of referral
guidelines for patients with asthma or COPD.
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Background: A study was undertaken to determine the effectiveness of asthma self-management in
general practice.
Methods: Nineteen general practices were randomly allocated to usual care (UC) or self-management
(SM). Asthma patients were included after confirmation of the GP diagnosis. Follow up was 2 years.
Patients kept diary cards and visited the lung function laboratory every 6 months. Outcomes were
number of successfully treated weeks, limited activity days, asthma specific quality of life, forced
expiratory volume in 1 second (FEV1), FEV1 reversibility, concentration of histamine provoking a fall in
FEV1 of 20% or more (PC20 histamine), and amount of inhaled steroids.
Results: A total of 214 patients were included in the study (104 UC/110 SM; one third of the total
asthma population in general practice); 62% were female. The mean percentage of successfully treated
weeks per patient in the UC group was 72% (74/103 weeks) compared with 78% (81/105 weeks) in
the SM group (p=0.003). The mean number of limited activity days was 1.2 (95% CI 0.5 to 1.9) in the
SM group and 3.9 (95% CI 2.5 to 5.4) in the UC group. The estimated increase in asthma quality of
life score was 0.10 points per visit in the UC group and 0.21 points per visit in the SM group
(p=0.055). FEV1, FEV1 reversibility, and PC20 histamine did not change. There was a saving of 217
puffs of inhaled steroid per patient in favour of the SM group (p<0.05).
Conclusion: Self-management lowers the burden of illness as perceived by patients with asthma and
is at least as effective as the treatment usually provided in Dutch primary care. Self-management is a
safe basis for intermittent treatment with inhaled corticosteroids.
Asthma is a chronic inflammatory pulmonary diseasewhich has a significant socioeconomic impact onpatients and their families.1 The finding that airway
inflammation is the key underlying process in asthma has led
to recommendations that inhaled corticosteroids should be
introduced early in the management of the disease.2–5 Despite
these guidelines and increasing knowledge, asthma morbidity
is still considerable. Poor compliance with prescribed inhaled
treatment is an important cause of uncontrolled disease.6–10
Poor control of asthma is associated with an impaired quality
of life11 12 and is calculated to be responsible for three quarters
of the total costs of asthma.1 It is therefore likely that improv-
ing compliance with treatment will lead to improvements in
asthma control and quality of life. Low compliance results in
underuse of medication, but asthma is also characterised by
overuse, particularly of inhaled medication. Overuse of
inhaled steroids may increase the number of unwanted side
effects without additional benefits. There are indications that
inhaled steroids can be tapered off or stopped during certain
periods,13 or at least reduced to the minimal effective daily
dose that provides adequate control of the disease.14 Optimis-
ing treatment for the individual patient may balance benefits
and risks and lead to a more efficient and cost effective treat-
ment.
Patients with mild asthma treated by their general
practitioner (GP) may be suitable for intermittent
treatment,15 providing adequate control of their asthma is
maintained. Implementing guided self-management takes a
considerable effort16 and studies on effectiveness and use in
general practice are needed. Most published studies have
shown self-management to be effective in patients with more
severe asthma or those with frequent exacerbations,17 and it is
unknown whether guided self-management may also be
effective in patients with milder asthma. Loss of asthma con-
trol occurs less frequently and there is lower impact on quality
of life,18 leaving limited room for improvement. The aim of this
study was to determine if guided self-management can
provide a safe treatment strategy for asthmatic patients in
general practice.
METHODS
Practices
General practices were recruited from two pools; the first were
in and around the city of Eindhoven and the second were
practices from our department’s academic research network.
Recruitment was stopped when a sufficient number of
participating practices was reached. Practices rather than
individual patients were randomised to prevent contamina-
tion. To prevent management bias, stratified cluster random-
isation was performed based on the type of practice (one GP,
two GPs, group practice), the number of identified asthmatics
(above or below the median number (14) of identified
patients), and use of computerised prescriptions (yes, no).
Selection of patients
GPs identified all asthma patients aged between 16 and 60
years using problem list coding (ICPC), prescription data from
practice records, the annual influenza vaccination campaign
list, and prescription data provided by the local pharmacist.
Identified patients received an invitation letter from their GP
to participate in the study. Patients willing to participate were
invited for assessment in a lung function laboratory. Inclusion
and exclusion criteria are summarised in box 1. Inclusion cri-
teria were measured for all patients without exclusion criteria.
Patients with a pre-bronchodilator forced expiratory volume
in 1 second (FEV1) of <80% predicted were treated with
800 µg budesonide twice daily during a 6 week run in period
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to obtain optimal asthma control at baseline and to enable
proper assessment of the personal best peak flow of patients in
the self-management group.
Self-management programme
The self-management (SM) programme started with four
individual training visits of 30, 20, and 2 × 10 minutes, respec-
tively, at the GP’s surgery during a period of 3 months. These
visits consisted of tailored education19 and instructions on how
to use a personalised written self-treatment plan. Patients
weekly recorded morning and evening peak flow values and
the presence of asthma symptoms. Three alarm symptoms
were defined: waking at night because of asthma (yellow
zone), use of bronchodilator >4 times a day (red zone), and
increased dyspnoea without exertion (purple zone). In the
presence of alarm symptoms or a fall in peak flow values
below 80%, 60%, or 40% of the personal best value, patients
were instructed to start daily measurements of peak flow and
symptoms. Self-treatment instructions for budesonide and
oral steroids (30 mg prednisolone per day for 1 week) are
summarised in box 2. After the training visits biannual control
visits were recommended over a follow up period of 21
months. At each control visit (10 minutes) GPs checked the
patients’ performance of the self-treatment instructions. It
was left to the initiative of the GP and patient if and when
these control visits took place. Training in the inhalation tech-
nique and peak flow measurement was repeated at each visit.
Usual care
In the usual care (UC) group GPs were instructed to treat all
asthma patients as usual; for most GPs this is according to the
guidelines of the Dutch College of Family physicians20 21 which
recommend follow up visits (10 minutes) every 3–6 months.
These national guidelines are largely comparable to most
international guidelines but do not include self-management
so far. At the start of the programme, one visit to the GP’s sur-
gery was scheduled to instruct patients on the use and dosage
of their inhaled steroids (budesonide 200 µg Turbuhaler).
Study medication
The aim of the self-treatment plan was individual optimisa-
tion of treatment with inhaled corticosteroids. To study the
effects on the amount of inhaled steroids used, all study
patients were treated with budesonide 200 µg/dose dry
powder inhaler (Turbuhaler). In the UC group the daily dosage
was determined by the patients’ GPs according to the national
guidelines for treatment of asthma.20 21 Both groups received
regular inhalation instructions.
Outcome measures
The main outcome measures of the study were asthma
control, asthma specific quality of life, and lost activity days.
Asthma control was defined using the following parameters:
• percentage of successfully treated weeks;
• changes in post-bronchodilator FEV1 (800 µg salbutamol
once daily through spacer);
• changes in reversibility of FEV1 as percentage of the
predicted value; and
• changes in concentration of histamine provoking a fall in
FEV1 of 20% or more (PC20 histamine).
Patients visited the lung function laboratory every 6months
over a period of 2 years. Diary cards were collected and
checked for errors. At each visit post-bronchodilator FEV1,
reversibility, and asthma specific quality of life weremeasured.
PC20 histamine
22 was measured at baseline and after 2 years.
Assessors were not blinded to study group allocation.
A successfully treated week was defined as a week in which
acceptable asthma control in terms of perceived dyspnoea was
maintained. Patients in both groups weekly recorded dys-
pnoea on a modified Borg scale ranging from 0 (no dyspnoea)
to 10 (maximally severe dyspnoea).23 The median dyspnoea
score of all individual recordings was considered as the cut off
point between successfully and unsuccessfully treated weeks.
Weeks with a dyspnoea score equal to or below this cut off
point were counted as successful. Successfully treated weeks
were calculated if patients had recorded at least 52 weeks. To
correct for differences in the number of recorded weeks, suc-
cessfully treated weeks were standardised to the percentage of
recorded weeks. An example of this procedure is summarised
graphically for one patient in fig 1. In addition to the dyspnoea
scores, patients weekly recorded the number of days during
the previous week with limited activities due to asthma.
Asthma specific quality of life was measured using the
Asthma Quality of Life Questionnaire (AQLQ) developed by
Juniper et al.11 12 An individual increase of 0.5 points on the
Box 1 Inclusion and exclusion criteria
Exclusion criteria
• Smoking history of 15 or more pack years
• Serious diseases other than asthma with a low survival rate
• Exacerbations during the month before the start of the study
• Other diseases which influence bronchial symptoms and/or
lung function such as heart failure, sarcoidosis
• Inability to inhale medication correctly or to measure and
record peak flow adequately and unlikely that this can be
taught
Inclusion criteria
• Treated for asthma by the GP and
• Age 16–60 years and
• FEV1 >40% of predicted value and >55% of predicted
value 15 minutes after inhalation of 800 µg salbutamol or
6 weeks after inhalation of 800 µg budesonide twice daily
and
• FEV1 reversibility (after bronchodilation with 800 µg
salbutamol metered dose inhaler or 8 weeks treatment with
800 µg budesonide twice daily) of at least 10% of the pre-
dicted value or PC20 histamine of 8 mg/ml.
Box 2 Summary of self-treatment plan
Step-up instructions
• Peak flow deteriorates <80%, peak expiratory flow rate
(PEFR) >60% of personal best value (PBV) for 2 out of 3
consecutive days:
• double budesonide dosage;
• in case of insufficient response within 3 weeks. again
double budesonide dosage.
• Peak flow deteriorates <60%, PEFR >40% of PBV for 2 out
of 3 consecutive days:
• increase budesonide dosage to 800 µg twice daily;
• in case of insufficient response within 2 days, start course
of oral prednisolone
– and contact your GP.
• Peak flow deteriorates <40% of PBV:
• if sufficient response to bronchodilator, start course of
oral prednisolone;
• Otherwise, immediately contact your GP.
Step-down instructions
• Peak flow improves to >40%, PEFR <60% of PBV:
• continue the current budesonide dosage until PEFR is
>80% of PBV.
• Peak flow improves to >60%, PEFR <80% PBV:
• continue the current budesonide dosage until PEFR is
>80% of PBV.
• Peak flow improves to >80% of PBV:
• halve budesonide dosage when PEFR >80% for a
period of 6 weeks.
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overall score or one of the domain scores was considered a
minimal clinically relevant improvement (MCRI).
Secondary outcome measures were the number of puffs of
budesonide, number of dose equivalents of short acting bron-
chodilators, number of short courses of oral prednisolone and
antibiotics, and number of GP diagnosed exacerbations. The
number of puffs of budesonide used was counted at each
laboratory visit by subtracting the number of remaining dos-
ages in each Turbuhaler inhaler issued from the total number
of dosages prescribed over the previous period. The amount of
short acting bronchodilators was based on the weekly record-
ings of patients. Based on presumed differences in deposition
between metered dose inhalers and dry powder inhalers, dry
powder inhaler dosages were halved to obtain dose
equivalents.24 25 Short acting bronchodilators were thus con-
verted to equipotent doses of either salbutamol or ipratropium
metered dose inhalers in µg/day. Exacerbations were recorded
by GPs at each scheduled and unscheduled visit. GPs recorded
an exacerbation if two of the following three criteria were
present: increased asthma symptoms, fall in peak flow below
80% of predicted value, and increased use of bronchodilators.
Short courses of prednisolone and antibiotics prescribed were
recorded as other indicators of exacerbations.
Power calculation
The power calculation for determining the trial size was based
on the AQLQ, with a change of 0.5 points between groups
being considered clinically relevant. Based on multilevel
analysis, we assumed an average inclusion of 10 patients per
practice and an interclass correlation of 0.02. With an
observed standard deviation of 0.9, a power of 90% and an α of
0.05 (two sided), 17 practices with a total number of 170
patients were needed.After taking into account a drop out rate
of 20%, it was calculated that 213 patients were needed.
Analysis of data
Outcome parameters were evaluated on an intention to treat
basis and by repeated measurement techniques.26 A random
coefficient linear model (multilevel) with an autoregressive
error structure was performed on post-bronchodilator FEV1
and AQLQ scores. Reversibility of FEV1 (% predicted value)
was analysed in a similar non-linear model. Baseline values,
age, sex, and smoking were entered as possible confounders.
All analyses were performed using the PROC MIXED
procedures by SAS.27 Transformed PC20 values (
2log PC20) were
compared with a Student’s t test. If there was a significant dif-
ference over time in any quality of life domain, the proportions
of subjects with a relevant change over 2 years (MCID) were
compared using χ2 tests. The amounts of medication used in
both groups and the percentages of successfully treated weeks
were compared using a t test when normally distributed and a
Mann-Whitney U test when not normally distributed.
RESULTS
Of 38 practices invited to participate in the study, 19 agreed to
do so. Table 1 shows the characteristics of the participating
practices in both treatment groups. The flow chart in fig 2
summarises the number of patients. During the pretreatment
phase 15 patients dropped out of the programme and a further
five dropped out before the first follow up assessment. A total
of 193 patients (98 SM) were therefore included in the inten-
tion to treat analysis. The baseline characteristics of the
patients included in the intention to treat analysis are shown
in table 2. The treatment groups did not differ in general or
clinical characteristics at baseline apart from a higher
proportion of patients reporting a recent episode of aggravated
asthma symptoms and lower AQLQ scores in the SM group.
Fourteen patients in the SM group and 16 in the UC group did
not use bronchodilator medication during the study. At base-
line, long acting β2 agonists were used by six patients in the
SM group and by four in the UC group. During the study 12
SM and five UC patients used a long acting β2 agonist;
theophyllines were used by three patients in the SM group.
Successfully treated weeks could be calculated for 83 (85%)
and 87 (92%) subjects in the SM and UC groups, respectively.
The mean percentage of successfully treated weeks per patient
in the SM group was 78% (95% CI 75.1 to 80.6) (81/105)
recorded weeks compared with 72% (95% CI 68.8 to 74.8) (74/
103) recorded weeks in the UC group.
During follow up 79% of SM and 62% of UC patients
reported one or more limited activity days. When all patients
were included, the mean number of limited activity days was
1.9 (95% CI 0.7 to 3.2) for the SM group and 6.0 (95% CI 2.6
to 9.4) for the UC group. Closer examination identified two
distinct outliers in the UC group with 142 limited activity days
and 69 limited activity days, respectively. One of the outliers
Table 1 Characteristics of participating practices
Self-management Usual care
Type of practices
1 GP 2 (25%) 1 (9%)
2 GPs 3 (37%) 5 (46%)
>2 GPs 3 (38%) 5 (45%)
Total 8 11
No (95% CI) of asthmatics per 1000 patients 7.6 (5.6 to 9.6) 9.0 (4.9 to 13.2)
Computerised prescription
Yes/no 7/1 8/3
Figure 1 Calculation of successfully treated weeks for one patient
in the usual care group. Number of registered weeks = 104; median
dyspnoea score = 3; number of weeks with dyspnoea < median
dyspnoea score = 64; percentage of successfully treated weeks =
(64/104) × 100 = 61.5%.
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had a period of several months with frequent but short
episodes of sick leave due to asthma, the other a 3 month epi-
sode of uninterrupted sick leave. In both cases irritant
exposure in the workplace explained the high counts. Because
of the clear work related cause and the disproportionate
impact of these two outliers on the group mean, we decided to
exclude subjects above the 98th percentile from the final cal-
culations in both groups. This resulted in a mean number of
limited activity days of 1.2 (95% CI 0.5 to 1.9) for the SM
group and 3.9 (95% CI 2.5 to 5.4) for the UC group.
Figure 2 Flow chart showing study participants.
135 not willing to
participate
38 excluded at
laboratory
Withdrawn 13:
Intervention ineffective: 0
Lost to follow up: 3
Other: 10
5 dropped out
before 1st follow
up measurement
7 did not start
224 not willing to
participate
40 excluded at
laboratory
Withdrawn 9:
Intervention ineffective: 0
Lost to follow up: 2
Other: 7
1 dropped out
before 1st follow
up measurement
8 did not start
Self-management
283 identified
by GP
Usual care
368 identified
by GP
110 patients
included
104 patients
included
98 intention to
treat analysis
95 intention to
treat analysis
85 completed trial86 completed trial
Randomisation of practices:
11 usual care (24 GPs)
8 self-management (22 GPs)
Table 2 Baseline characteristics of study subjects included in the intention to treat analyses
Self-management (n=98) Usual care (n=95) p value
Age (years) 39.6 (11.2) 39.3 (12.0) 0.859
Sex (M/F) 34/64 40/56 0.394
Smoking:
Never smokers 45 (46%) 54 (56%)
Former smokers 31 (32%) 21 (22%)
Current smokers 22 (22%) 21 (22%) 0.254
Pack years* 5.8 (4.5) 5.7 (4.5) 0.881
Requiring pretreatment with budesonide† 34 (35%) 22 (23%) 0.077
% with asthma attack(s) in previous 6 months 48.5% 31.6% 0.017
FEV1 (% predicted value):
Pre-bronchodilator (BD)** 84.0 (13.1) 86.9 (14.2) 0.141
Post-bronchodilator (BD) 90.0 (12.1) 92.6 (12.9) 0.135
FEV1 reversibility (%) (median)‡ **
PostBD – preBD/predicted 5.0 (8.6) IQR 5.4 (6.8) IQR 0.930
Bronchial hyperresponsiveness
PC20 geometric mean 1.20 0.97 0.442
Initial dose of inhaled steroids 0.622
None 12 (12%) 16 (17%)
Low (<400 µg daily or equivalent) 36 (37%) 30 (32%)
Intermediate (>400 and <800 µg daily or equivalent) 34 (35%) 37 (39%)
High (>800 µg daily or equivalent) 16 (16%) 12 (12%)
Quality of life:
Activities domain 5.3 (1.03) 5.6 (0.77) 0.015
Emotions domain 5.8 (1.01) 6.2 (0.76) 0.002
Symptoms domain 5.3 (1.03) 5.6 (0.90) 0.074
Environment domain 5.3 (1.10) 5.5 (1.1) 0.165
Overall score 5.4 (0.872) 5.7 (0.771) 0.013
Figures are mean (SD) values unless stated otherwise.
FEV1=forced expiratory volume in 1 second in litres; FVC=forced vital capacity.
*Missing data (self-management 2; usual care 1); **missing data (self-management 2; usual care 2); †pretreatment consisted of 6 weeks
budesonide 800 µg twice daily; ‡difference between FEV1 before and after bronchodilator/predicted FEV1.
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As shown in fig 3, the post-bronchodilator FEV1 had an
estimated decline rate of 0.048 l/year in the SM group and
0.026 l/year in the UC group (p=0.239). There were no
between group differences in the estimated rate of decline in
FEV1 reversibility and PC20 histamine.
Changes from baseline in overall AQLQ score are summa-
rised in fig 4. Based on repeated measurements analysis, the
estimated increase in overall asthma quality of life score was
0.10 points per visit in the UC group and 0.21 points per visit
in the SM group (p=0.055). Changes in quality of life were
also estimated for each of the sub-domains (emotions, activi-
ties, symptoms, and environment). There was a significant
change between groups only in the emotions domain (0.02
points per visit in the UC group; 0.20 points per visit in the SM
group; p=0.006). To determine whether statistically signifi-
cant changes in quality of life were clinically relevant, we
compared proportions of subjects with individual changes of
at least 0.5 points. In the emotions domain 41% of patients
from the SM group had an increase of at least 0.5 points com-
pared with 23% of patients in the UC group (χ2=8.811,
p=0.012).
Mean budesonide usage was 1680 puffs per patient (95% CI
1538 to 1822) in the SM group and 1897 puffs per patient
(95% CI 1679 to 2115) in the UC group, indicating a saving of
217 puffs per patient.
With a median (IQR) dose of 97 (168) µg/day of short act-
ing β2 bronchodilators in the SM group and 69 (340) µg/day in
the UC group, there was no statistically significant difference
between the two study groups (p=0.711, Mann-Whitney U
test). In the SM group a median (IQR) dose of 12 (28) µg/day
of ipratropium was used compared with 35 (114) µg/day in
the UC group (p=0.607, Mann-Whitney U test).
Table 3 summarises the indicators of exacerbations. There
were no differences in the number of GP diagnosed exacerba-
tions and the number of antibiotics between the two groups,
but the SM group had a significantly higher number of
courses of oral prednisolone than the UC group (p=0.015,
Mann-Whitney U test).
DISCUSSION
Findings from this study indicate that asthma control
improved in the SM group in terms of a higher number of
successfully treated weeks and fewer limited activity days.
There were no major changes in lung function parameters. In
the SM group there was a slight improvement in asthma spe-
cific quality of life with a clinically relevant improvement in
the emotions domain, indicating that patients in this group
felt less worried or insecure about the influence of their
asthma on daily life. GPs did not diagnosemore exacerbations,
but the number of oral prednisolone courses was higher in the
guided SM group. The study population consisted of approxi-
mately one third of all subjects initially identified by GPs.
Determinants of willingness to participate and their implica-
tions have been discussed extensively elsewhere.15 The main
implication is that subjects with low or intermediate doses of
inhaled corticosteroids at baseline may have been relatively
over-represented in this study. Based on initial levels of pre-
and post-bronchodilator FEV1, the observed reversibility and
initial dosage of inhaled steroids, included patients appeared
to be a representative sample of patients with mild to moder-
ately severe asthma.5 18 20 28–30
Half of all invited practices participated in this study, which
does not differ from previously studied acceptance rates.16
Other practice characteristics (table 1) also suggest that
participating practices were a representative sample of Dutch
general practice, with the restriction that participants have a
positive attitude towards self-management.
There have been few randomised controlled trials to date on
the effects of guided self-management programmes in family
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Figure 3 Mean changes from baseline in post-bronchodilator FEV1
(l) with standard errors.
Figure 4 Mean changes from baseline in quality of life (overall
score) with standard errors.
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Table 3 Indicators of exacerbations (between group comparison using
Mann-Whitney U test)
Self-management Usual care
Exacerbations per patient per 2 years (p=0.678)
No (% within group) with 0 exacerbations 29 (36) 33 (41)
No (% within group) with 1 exacerbations 28 (35) 22 (28)
No (% within group) with 2 exacerbations 7 (9) 12 (15)
No (% within group) with 3 exacerbations 7 (9) 6 (8)
No (% within group) with >4 exacerbations 9 (11) 7 (9)
Oral prednisolone courses per patient per 2 years (p=0.015)
No (% within group) with 0 courses 64 (70) 80 (85)
No (% within group) with 1 course 19 (21) 11 (12)
No (% within group) with 2 courses 6 (7) 1 (1)
No (% within group) with >3 courses 2 (2) 2 (2)
Courses of antibiotics per patient per 2 years (p=0.643)
No (% within group) with 0 courses 71 (78) 71 (76)
No (% within group) with 1 course 15 (17) 15 (16)
No (% within group) with 2 courses 2 (2) 5 (5)
No (% within group) with >3 courses 3 (3) 3 (3)
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medicine. As in our study,most have shown limited reductions
in symptoms or improvements in lung function and quality of
life. Hoskins et al31 showed reductions in morbidity in terms of
hospital admission, (emergency) consultations, oral steroid
courses, and emergency nebulisations but, because of possible
selection bias, superiority of self-management plans could not
be proved. Their results suggest that improvements in clinical
and morbidity parameters are indeed less likely to occur in
patients with mild asthma. This was also concluded by Jones
et al,32 but theymay have failed to show results due to the small
number of subjects. On the other hand, neither of these stud-
ies found that self-management caused unwanted loss of
asthma control or increased morbidity. In our study we
observed a significantly higher number of patients requiring
one or more courses of oral steroids in the SM group. Based on
instructions in the self-treatment plan, patients could start an
oral course of prednisolone independently, so patients were
routinely prescribed one prednisolone course at the third edu-
cational session. As there are strong indications that GPs acci-
dentally recorded these prescriptions as true oral prednisolone
courses, over-registration may have occurred. Another expla-
nation for the higher number of prednisolone courses may be
the larger number of patients with an asthma attack in the
previous 6months and the larger number of patients requiring
pretreatment at the start of the study in the SM group. This
may indicate that asthma control in the SM groupwas initially
worse than in the UC group. This is also reflected in a lower
baseline quality of life.
During the study changes in post-bronchodilator FEV1,
FEV1 reversibility, and PC20 did not differ between the groups.
In view of these findings, the higher number of oral steroid
courses in the SM group can be attributed to a baseline differ-
ence between the groups in asthma control. In addition, the
use of oral steroids can be biased by instructions in the guided
SM programme. Subjects in the SM group were explicitly
instructed about when to take oral courses of prednisolone.
The increased number of prescriptions may therefore indicate
either overtreatment or the self-treatment instructions
worked as planned. In instances with more severe loss of
asthma control, adequate treatment was initiated without
unnecessary delay, which is consistent with the increased
number of successfully treated weeks and the lower number of
lost activity days.
The number of successfully treated weeks is an indicator of
the burden of asthma as perceived by patients. It is based on
perceived changes in dyspnoea rather than on perceived levels
of dyspnoea. Patients who constantly experience the same
high levels of dyspnoea may thus have a relatively higher
number of successfully treated weeks. Assuming that the pre-
treatment phase did result in the highest achievable level of
asthma control, constantly high symptom levels are only an
indicator of the severity of asthma experienced, not asthma
control. Subjects with increased weekly variations in perceived
dyspnoea levels will therefore have a lower number of
successfully treated weeks. Accordingly, the increased number
of successfully treated weeks in the SM group suggests less
loss of asthma control in this group. These findings are in
accordance with the lower number of limited activity days, but
are not strongly reflected in improvements in quality of life.
Although it must be kept in mind that symptoms experienced
represent a totally different concept from the impact of
asthma symptoms on quality of life, it is reasonable to
hypothesise that comparable improvements in both outcomes
can be observed. There were significant differences in
observed changes in quality of life in favour of the SM group.
The magnitude of these gains was limited, however. Quality of
life was high in both groups at baseline andmay have left little
room for improvement. The finding that observed baseline
differences in quality of life scores completely disappeared
after 24 months may indicate that quality of life had been
maximised in both groups.
During the study long acting β agonists were introduced in
updated Dutch guidelines on diagnosis and treatment of
asthma. Treatment with long acting β agonists was initiated in
a relatively higher proportion of patients in the SM group but
numbers were too small to allow for reliable statistics. It is
therefore unlikely that prescription of long acting β agonists
substantially contributed to improvements in successfully
treated weeks or quality of life in favour of the SM group.
Based on our findings, we conclude that self-management
of asthma is at least equally effective as asthma treatment
usually provided in Dutch primary care. Asthma self-
management provides a safe basis for intermittent treatment
with inhaled corticosteroids and lowers the burden of illness
as perceived by patients. Observed patient related outcomes
are those in which self-management distinguishes itself from
usual asthma care, even under conditions where room for
improvement initially seemed limited.
. . . . . . . . . . . . . . . . . . . . .
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Randomized Controlled Economic Evaluation of Asthma
Self-Management in Primary Health Care
Tjard R. Schermer, Bart P. Thoonen, Guido van den Boom, Reinier P. Akkermans, Richard P. Grol,
Hans T. Folgering, Chris van Weel, and Constant P. van Schayck
In this randomized controlled economic evaluation we compared A systematic review including 23 trials concluded that self-
guided asthma self-management with usual asthma care according management programs are able to improve health outcomes
to guidelines for Dutch family physicians. Nineteen family practices in adult asthma if they include self-monitoring and are accom-
were randomized, and 193 adults with stable asthma (98 self-man- panied with written action plans and regular medical profes-
agement, 95 usual care) were included and monitored for 2 years. sional review (8). However, the trials included in this meta-We hypothesized that introducing self-management would not com-
analysis have been conducted mainly in selected (secondarypromise asthma control and cost would be equal to or lower than
care) patients.in usual care. Patient-specific cost data were collected, preference-
When competing for scarce health care resources it is notbased utilities were assessed, and incremental cost per quality-ad-
justed life year (QALY) and successfully treated week gained was sufficient to determine the effects of asthma self-management
calculated. Self-management patients gained 0.039 QALY (95% con- programs solely in terms of health outcomes. It is also impor-
fidence interval [CI], 0.003 to 0.075) and experienced 81 (95% CI, 78 tant to analyze whether the costs of introducing self-manage-
to 84) successfully treated weeks in 2 years’ time; the corresponding ment outweigh the—potential—subsequent savings in health
figures for usual care were 0.024 (95% CI, 0.022 to 0.071) and 75
care utilization and productivity (“indirect”) costs, the latter(95% CI, 72 to 78). Total costs were C1,084 (95% CI, 938 to 1,228)
resulting from fewer days of limited activities and incapacityfor self-management and C1,097 (95% CI, 933 to 1,260) for usual
for work (9). If the savings do not outweigh the investments,care. Self-management patients consumed 1,680 (95% CI, 1,538 to
it is essential to assess whether the additional—or incremen-1,822) puffs of budesonide, usual care patients 1,897 (95% CI, 1,679
to 2,115). Mean productivity cost due to limited activity days was tal—costs of a self-management program can be justified by
C213 lower among self-management patients. When all costs were the health gains.
included, self-management was cost-effective on all outcomes. The Meanwhile, several asthma guidelines recommend self-
probability that self-management was cost-effective relative to usual management (10, 11) and health professionals and patients
care in terms of QALYs was 52%. We conclude that guided self-
with asthma themselves seem to appreciate the contemporarymanagement is a safe and efficient alternative approach compared
approach (12–14). A number of economic evaluations ofwith asthma treatment usually provided in Dutch primary care.
asthma education and self-management have been published
Keywords: asthma; economics, pharmaceutical; family practice; patient (15–27), but most authors have confined themselves to sepa-
education; randomized controlled trial rate descriptions of costs and health effects without directly
assessing their relationship by calculating summary ratios.Asthma is a chronic respiratory disease affecting people of
Essential methodological shortcomings were the absence of aall ages. In Western countries, 4 to 6% of the adult population
control group receiving an appropriate comparator treatmenthave a physician-confirmed diagnosis of bronchial asthma
and a too-short duration of follow-up. None of the published(1, 2). Compliance with prophylactic inhaled corticosteroid
economic studies included instruments to assess preference-treatment is poor in many patients with asthma, thus limiting
based utilities (e.g., quality-adjusted life years [QALYs] orits effectiveness (3, 4). Because the costs of asthma for society
are largely due to the consequences of uncontrolled disease, similar universal outcome measures) as is currently recom-
it is presumed that the cost could be significantly reduced if mended for all economic evaluations (28, 29). Moreover, only
disease control is improved (5). a part of the studies used written action plans, which seems
Using a comprehensive approach generally consisting of to be a prerequisite for a successful treatment result (8).
education and training, written action plans, and periodic This article reports a state-of-the-art economic evaluation
supervision, health professionals may try to improve knowl- of a guided self-management program for adult patients with
edge, practical skills, decision-making responsibility and, ulti- asthma treated in Dutch primary care. We compared the
mately, disease control in their patients with asthma (6, 7). self-management program with the “best” generally available
medical treatment for asthma (“usual care”) according to
asthma treatment guidelines for family physicians (30, 31).
Beforehand, we did not expect substantial differences in
health outcomes because medical care for patients with
asthma is already of a high standard in The Netherlands,
with asthma-related hospital admissions and deaths almost
becoming rare events (32). Therefore, the main objective of
this evaluation was to investigate whether a family practice-
based self-management program for adults with asthma pro-
vides an efficient treatment alternative in terms of health
care utilization and absence from work, without asthma con-
 trol being compromised.
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 METHODS
Study Design
The study was a randomized controlled parallel group multicenter clini-
cal trial. Nineteen (19) Dutch family practices (49 family physicians)
were randomly allocated to guided self-management or usual care.
Randomization was stratified on type of practice, number of patients
with asthma initially identified from the practice records, and use of a
computerized prescription system. Duration of follow-up was 2 years
per patient. Self-management and usual care were fully pursued by the
family physicians; no other health professionals were involved. The
study protocol was approved by the medical ethics committee of the
University Medical Center St. Radboud (Nijmegen, The Netherlands).
Patients gave written informed consent before study entry. The first
subject entered the study in March 1996, and the last subject completed
the study in June 1999.
Participants
The 49 family physicians involved in the study selected subjects with
asthma, aged 16–60 years, who were to be treated with inhaled steroids
according to national guidelines (30, 31). Identification of subjects was
based on the following information sources: problem list coding (Inter-
national Classification of Primary Care: R96); prescription of inhaled
steroids or bronchodilators from practice or pharmacy records; and the
Figure 1. Summary of step-up and step-down instructions for self-man-annual influenza vaccination campaign list. Subjects willing to partici-
agement patients regarding the use of budesonide. *If no budesonidepate were included if (1 ) their PC20-histamine (provocative dose of
was used at the time of deteriorating peak flow, the patient shouldhistamine causing a 20% drop in FEV1) was less than 8 mg/ml and/or
commence with the lowest dose (200 g, twice daily). Patients weretheir reversibility of FEV1 was greater than 9% of the predicted value
not allowed to double their dosage of budesonide anymore, once theafter 800 g of salbutamol was administered as an aerosol by spacer;
maximum dosage of 800 g twice daily had been reached. †Either(2 ) they had a smoking history of less than 15 pack-years; (3 ) they
morning or evening value. PBV  personal best value; PEFR  peakwere not currently treated by a chest physician; and (4 ) they were able
expiratory flow rate.to communicate in the Dutch language. Eligible patients with an initial
FEV1 of less than 80% of the predicted value were pretreated with
budesonide 800 g twice daily for 6 weeks.
symptoms (Figure 1). Detailed information about the exact contentsGuided Self-Management and Usual Care
of the education program and self-treatment guidelines have been pub-
All participants were prescribed budesonide administered by multidose lished elsewhere (33). Usual care physicians were instructed to adhere
dry powder inhaler (Pulmicort Turbuhaler, 200 200g; Astra Zeneca, to the asthma treatment guidelines issued by the Dutch College of
Zoetermeer, The Netherlands) by one of the investigators (B.T.). Parti- Family Physicians in 1992 (30) and to the revised guidelines issued in
cipants received new budesonide inhalers and handed in used inhalers 1997 (31). Usual care patients did not receive peak flow meters, nor
during half-yearly visits to the pulmonary function laboratory. The were they instructed on how to adjust their dosage of budesonide.
family physician of each patient was responsible for regulating the
Clinical Effectivenessdosage scheme at study entry. Family physicians were not restricted in
prescribing nonsteroid lung medication in either group, apart from Clinical effectiveness was evaluated on the basis of asthma control
cromoglycates and nedocromil being prohibited during the trial. Bron- parameters and quality of life. Asthma control was expressed as the
chodilators were preferably prescribed on an as-needed basis, if neces- number of successfully treated weeks in 2 years of follow-up, changes
sary at all. in postbronchodilator FEV1, changes in FEV1 reversibility as a percent-
age of predicted value, and changes in PC20-histamine (34). Asthma-Self-management patients received education and training of skills
specific quality of life was assessed with the interview-administered 32-on an individual basis from their family physician. Training consisted
question Asthma Quality of Life Questionnaire (AQLQ) (35). Thisof four visits to the practice scheduled within a period of 3 months.
instrument assesses four domains: (1 ) asthma symptoms, (2 ) limitationSubsequent control visits for the remaining follow-up period of 21
of activity, (3 ) emotional dysfunction, and (4 ) responses to environmen-months were recommended, but it was left to the initiative of the family
tal stimuli, respectively. An overall score as well as separate domainphysician and patient if and when these visits took place. Training tools
scores were calculated.consisted of (1 ) a detailed manual for the physicians describing the
educational topics to be discussed during the consecutive training ses- Economic Evaluation: Data Collection and Resource Valuation
sions and instructions on how to teach patients self-management skills
A societal perspective was adopted for the economic evaluation. Pa-(i.e., peak flow measurement, proper inhalation technique, completing
tient-specific resource use was measured in natural units if possible.the self-management diary, and application of self-treatment guide-
Resource use was valued in monetary terms by multiplying the unitslines); (2 ) checklists for patients and physicians to assess and record
consumed by the cost per unit. Three major cost categories were distin-specific information needs of patients; (3 ) two booklets of the Dutch
guished: program implementation, direct health care, and productivity
Asthma Foundation, one containing general information about asthma (indirect) costs.
and the other containing information about asthma medication; and Data regarding bronchodilators and other prescribed nonsteroid
(4 ) diaries containing self-treatment guidelines, also used for data col- asthma medication, over-the-counter medication, and limited activity
lection. Self-management patients were equipped with a portable peak days were extracted from the diary cards. A limited activity day was
flow meter (Asmaplan; Vitalograph, Buckingham, UK) and instructed defined as any day on which a patient could not perform his or her
to measure morning and evening peak expiratory flow rates once a usual (paid or unpaid) daily activities. Consumption of budesonide was
week and record the best of three attempts in their diary. Self-treatment assessed by counting the remaining puffs in the inhalers returned and
by registration on the diary cards. We considered the puff counts asguidelines were based on peak flow values and severity of respiratory
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the most reliable source of information for estimating budesonide con- of 100 patients each would receive either self-management or usual
sumption (36). Patient out-of-pocket cost on house dust mite allergen care. Consequently, the cost–effectiveness ratios of the AQLQ data
avoidance measures and smoking cessation attempts were assessed ret- should be interpreted as the incremental cost or net savings to improve
rospectively by an ad hoc questionnaire. Family physicians reported quality of life in one patient. A treatment was qualified to be “dominant”
details of asthma-related consultations, medication prescriptions, influ- when this particular treatment was both more effective and less costly
enza vaccinations, referrals, and diagnostic procedures on study report than the alternative (29). Secondary analyses were performed by calcu-
forms. Completeness of consultation data was verified after a patient lating cost–effectiveness ratios with exclusion of the productivity cost.
had completed study participation. The SAS statistical software package (release 6.12 for Windows;
The first-choice source for resource unit valuation was the sum SAS Institute, Cary, NC) was used for statistical analyses. Regarding
charged by family physicians to privately ensured patients (including the incremental cost per successfully treated week, a 95% CI was deter-
value-added tax and a mark-up for administrative expenses). Secondary mined on the basis of the Fieller theorem (43). To express uncertainty
sources were annually updated drugs and diagnostic indexes (37, 38) in the estimated incremental cost per QALY, DATA for Healthcare
and more recent recommendations regarding cost analysis (39) (all software (DATA Pro; TreeAge, Williamstown, MA) was used to gener-
issued by the Dutch College of Health Insurance), study expense ac- ate graphical representations of the cost–effectiveness plane and accom-
counts, and patient questionnaires. The human capital approach (28) panying two-dimensional 90 and 95% confidence intervals. This was
was adopted to value limited activity days. An individual hourly wage done by nonparametric bootstrapping (Monte Carlo simulation): re-
based on the gross monthly income and the number of hours of dis- sampling with replacement from the patient-level cost and QALY data
bursed work was calculated for all participants in paid employment. from the two comparator groups (1,000 random samples with size n 
The resultant average gross hourly wage (C9.53) was subsequently used 100 each). Each point in the resulting scatter plot represents the incre-
to convert all limited activity days (8-hour workday) into monetary mental cost–effectiveness ratio of one iteration of the Monte Carlo
terms, regardless of the employment status or income of individual simulation. A diagonal line intersecting the origin of the plot simplifies
participants. All resources used were valued in Dutch guilders and identification of points for which the incremental cost–effectiveness
converted to euros. For conversion to U.S. dollars, costs in euros should ratio of self-management versus usual care is less than, or equal to, an
be multiplied by a factor of 0.912, based on the 2000 Purchasing Power a priori specified societal “willingness-to-pay” limit (44) () to gain
Parities as issued by the Organisation for Economic Co-operation and one additional QALY. Arbitrarily,  was set to C22,500. A graphic
Development (www.oecd.org). Purchasing Power Parities are the rates representation (“acceptability curve”) of the probability that a particu-
of currency conversion that equalize the purchasing power of different lar intervention is cost-effective over a range of increasing values for
currencies, thus eliminating differences in price levels between coun-  was generated (45). This bayesian approach of the stochastic analysis
tries. Neither costs nor effects were discounted for time preferences. provides information relevant to health care decision making.
Cost-Effectiveness Analysis: Outcome Measures
RESULTS
We performed a “base case” cost–effectiveness analysis, as well as second-
Study Population and Clinical Effectsary cost–effectiveness analyses. With the term “base case” we refer to
an analysis in which the direct health care cost, program implementation Ninety-eight (98) self-management and 95 usual care patients
cost, and productivity cost of patients are included. Outcome for the
were included in the intention-to-treat analyses (Figure 2). Treat-base case analysis was defined in terms of QALYs. To calculate QALYs,
ment groups did not differ on general or clinical characteristicspreference-based utilities were assessed at baseline and half-yearly at
at baseline, apart from a higher proportion of patients reportingthe pulmonary function laboratory. An interval rating scale ranging
a recent episode of aggravated asthma symptoms and lowerfrom 0 to 1 was used for this purpose, 0 being equal to death and 1 being
AQLQ scores in the self-management group (Table 1). Fourteenequal to perfect health (40). Participants first marked a standardized
(hypothetical) reference health state on the rating scale and subse- self-management patients and 16 usual care patients did not
quently their own perceived health state. use bronchodilator medication during the study. Twelve self-
The number of successfully treated weeks served as the main out- management and 5 usual care patients used a long-acting 2-
come for secondary cost–effectiveness analyses (9). Successfully treated agonist, and theophyllines were used by 3 self-management pa-
weeks were defined on the basis of recorded scores for shortness of tients only. The course of the pre- and postbronchodilator FEV1breath in the diaries (modified Borg interval scale scoring: 0  no
did not differ between groups, nor did FEV1 reversibility or PC20shortness of breath; 10maximal shortness of breath) (41). Any given
(34). The mean number of successfully treated weeks in 2 years’week with a score higher than the individual’s median score over the
time was 81 (95% CI, 78 to 84) for self-management and 75total follow-up was considered an unacceptably low level of control of
(95% CI, 72 to 78) for usual care (Table 2). This correspondsasthma symptoms and therefore counted as unsuccessful. Subtracting
this figure from the individual’s total number of recorded weeks resulted with a statistically significant gain of six successfully treated
in the proportion of weeks being treated successfully, which was eventu- weeks in 2 years in favor of self-management. In the self-manage-
ally standardized to the number of successfully treated weeks per 2 ment group, 17% (95% CI, 10 to 24) more participants showed
years (104 weeks). Next to successfully treated weeks, the number of an MCID on the AQLQ Emotions Domain compared with usual
patients with a minimal clinically important difference (MCID) in qual- care. No statistically significant differences were observed for
ity of life between the baseline and final visit was studied as a secondary
the Activities, Environmental, and Symptoms Domains, or theoutcome. MCID was defined as a within-subject improvement of 0.5
total AQLQ score.unit on the overall AQLQ or domain scores (35).
Cost AnalysisStatistical Analysis
The total implementation cost of the self-management programPatients were included in the intention-to-treat analysis if they had
amounted to C189 (95% CI, C179 to C199) per patient (Table 3).been present at the first follow-up visit at the pulmonary function
laboratory after 6 months. Although distributions of resource units Time invested by family physicians and purchase of peak flow
were skewed to the right for most cost components, arithmetic means meters constituted the major part of the implementation cost
and t test-based 95% confidence intervals (95% CIs) were calculated (60 and 16%, respectively). Mean budesonide usage was 1,680
to compare self-management and usual care groups (42). Within-group puffs (95% CI, 1,538 to 1,822) or C414 for self-management and
cost differences between the first and second study year were analyzed 1,897 puffs (95% CI, 1,679 to 2,115) or C467 for usual care,by paired, between-group differences by unpaired t test. QALYs were
indicating a saving of 217 puffs or C53 per patient during thedetermined by calculating the area under the curve (time rating scale
2-year follow-up (Table 4). Converted to the level of budesonidescore) for each participant. Mean costs and effects were multiplied by
inhalers, 0.5 inhaler per year was saved by self-managementa constant of 100 to standardize for inequalities of group sizes. Because
of that, cost–effectiveness results reflect a situation in which 2 groups patients. Costs of short-acting bronchodilators were significantly
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Figure 2. Flow chart of recruitment and
dropout of study participants.
lower for self-management, but this difference was largely com- sick leave. In both cases, irritant exposure in the workplace
explained the high productivity cost. Because of the clear work-pensated by the higher cost of long-acting 2-agonists and the-
ophyllines in this same group. During the study, 30 (31%) self- related cause and the disproportionate impact of these two outli-
ers on the average productivity cost in the usual care group, wemanagement and 10 (11%) usual care patients took domestic
house dust mite avoidance measures (relative risk  1.7; 95% decided to exclude subjects above the 98th percentile of the
productivity cost distribution from the final cost calculations inCI, 1.3 to 2.2). Consequently, mean costs of domestic house
dust mite allergen avoidance measures were significantly higher both groups. This resulted in an average number of limited
activity days of 1.2 (95% CI, 0.5 to 1.9) for self-managementamong self-management patients (C193 versus C109 for usual
care, p  0.0015). Although the cost of influenza vaccinations and 3.9 (2.5 to 5.4) for usual care, corresponding to a C213
productivity cost saving for self-management (Table 4). We con-composed only a marginal proportion of the total direct cost,
there were significantly more vaccinations in the self-manage- sider the productivity cost without the outliers as the main re-
sults.ment group (Table 4): 46 (47%) self-management and 27 (28%)
usual care patients received at least one influenza vaccination The sum of direct health care and implementation costs
amounted to a difference of C199 (95% CI, 70 to 328) in favorduring follow-up (relative risk  1.5, 95% CI, 1.1 to 1.9). There
were more referrals to chest physicians among self-management of usual care (Table 5). The between-group difference in the
total cost of C13 was not statistically significant (p  0.906).than among usual care patients: 9 (4.6%) and 1 (0.6%), respec-
tively (p  0.011). No asthma-related emergency unit visits or Analyzing the cost for the first and second year separately
showed that, as expected, the major part (91%) of the programhospital admissions were reported. Mean direct health care cost
aggregated to C809 (95% CI, 683 to 934) for self-management implementation cost was spent during the first study year
(Figure 3). A significant reduction of the productivity cost fromand C798 (95% CI, 682 to 914) for usual care (Table 4).
Sixty-two percent of self-management patients and 79% of the first to the second year was observed for self-management
(p 0.036) but not for usual care (p 0.487). During the secondusual care patients reported one or more limited activity days
at some point during follow-up. The mean number of limited year the total cost per patient was C147 (p  0.0013) lower in
the self-management group.activity days was 1.9 (95% CI, 0.7 to 3.2) for self-management
and 6.0 (95% CI, 2.6 to 9.4) for usual care, corresponding with
Base Case Cost-Effectiveness Analysismean productivity costs of C144 and C462, respectively. How-
ever, closer examination of the productivity cost data identified The course of rating scale scores is given in Figure 4. The mean
two distinct outliers in the usual care group, with a productivity number of QALYs gained during the 2-year follow-up was 0.039
cost of C10,831 (142 limited activity days) and C5,263 (69 limited (95% CI, 0.003 to 0.075) for self-management and 0.024 (95%
activity days), respectively. One outlier had a period of several CI, 0.022 to 0.071) for usual care (Table 2). This would imply
months with frequent but short episodes of sick leave due to that in 100 patients with asthma, self-management is associated
with a gain of 1.5 QALYs (95% CI,1.4 to 4.4) relative to usualasthma, and the other had a 3-month episode of uninterrupted
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TABLE 1. BASELINE CHARACTERISTICS OF THE STUDY POPULATION BY TREATMENT GROUP
Self-Management Usual Care
(n  98) (n  95) p Value
General characteristics
Age, yr 39.6 (11.2) 39.3 (12.0) 0.859
Sex, male/female 34/64 40/56 0.394
Employment status
Student, % 5 4
Full-time or part-time job, % 66 66
Unemployed or retired, % 29 30 0.953
Smoking status
Never smokers 45 (46%) 55 (56%)
Former smokers 31 (32%) 21 (22%)
Current smokers 22 (22%) 21 (22%) 0.254
Pack-years number 5.8 (4.5) 5.7 (4.5) 0.881
Clinical characteristics
Duration of asthma,* yr 21.0 (16.5) 18.1 (14.3) 0.232
Subjects with asthma attack(s) in previous 6 mo 47 (48%) 30 (32%) 0.017
Allergy, number of positive skin prick tests†
0 19 (23%) 20 (26%)
1–3 37 (44%) 29 (38%)
 4 28 (33%) 27 (36%) 0.735
Lung function parameters
FEV1, post-BD % of predicted value 90.0 (12.1) 92.6 (12.9) 0.135
Median FEV1 reversibility,‡ % 5.0 (IQR 8.6) 5.4 (IQR 6.8) 0.930
PC20, geometric mean 1.20 0.97 0.442
Utilities and quality of life
Utilities
Median “Own health state” 0.80 (IQR 0.15) 0.80 (IQR 0.16) 0.668
Median “Reference health state” 0.40 (IQR 0.30) 0.40 (IQR 0.20) 0.380
Quality of life
Overall AQLQ score 5.4 (0.87) 5.7 (0.77) 0.013
AQLQ activities domain 5.3 (1.03) 5.6 (0.77) 0.015
AQLQ emotions domain 5.8 (1.01) 6.2 (0.76) 0.002
AQLQ symptoms domain 5.3 (1.03) 5.6 (0.90) 0.074
AQLQ environment domain 5.3 (1.10) 5.5 (1.1) 0.165
Definition of abbreviations: AQLQ  Asthma Quality of Life Questionnaire; BD  bronchodilator; IQR  interquartile range.
* Missing in 17 self-management and 14 usual care patients.
† Missing in 14 self-management and 19 usual care patients.
‡ Difference between FEV1% predicted before and after bronchodilator.
care. In terms of cost-effectiveness, self-management dominated ment cannot be firmly established. This is supported by the
cost–effectiveness acceptability curve (Figure 6): regardless ofusual care (Table 6). Uncertainty around the incremental cost
per QALY point estimate is depicted in Figure 5. This scatter the societal willingness to pay, the probability that self-manage-
ment is cost-effective relative to usual care is about 52% whenplot shows that the uncertainty around the cost–effectiveness
estimate is large. In other words, the dominance of self-manage- a prior probability of 50% is assumed.
TABLE 2. AVERAGE AND INCREMENTAL EFFECTS OF SELF-MANAGEMENT AND USUAL CARE
IN ADULTS WITH ASTHMA
Average Effect
Incremental* Effect
of Self-Management
in 100 Subjects
Outcome Self-Management Usual Care Treated for 2 yr
QALYs (95% CI) 0.039 (0.003, 0.075) 0.024 (0.022, 0.071) 1.5 (1.4, 4.4)
Number of successfully treated weeks (95% CI) 81 (78, 84) 75 (72, 78) 600 (230, 970)
Proportion of subjects with MCID
AQLQ total score† (95% CI) 39 (29, 48) 29 (20, 38) 10 (3, 23)
AQLQ emotions domain† (95% CI) 42 (32, 51) 25 (16, 33) 17 (10, 24)
AQLQ activities domain† (95% CI) 52 (42, 62) 39 (30, 49) 13 (1, 27)
AQLQ symptoms domain† (95% CI) 35 (26, 45) 28 (19, 37) 7 (6, 20)
AQLQ environment domain† (95% CI) 42 (32, 51) 39 (30, 49) 3 (11, 17)
Definition of abbreviations: AQLQ  Asthma Quality of Life Questionnaire; CI  confidence interval; MCID  minimal clinically
important difference; QALY  quality adjusted life year.
Results of the base case analysis are printed in boldface. Increments are standardized to 100 subjects per group treated for 2
years.
* Self-management minus usual care.
† Final AQLQ measurement was missing in two self-management and six usual care patients.
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TABLE 3. BREAKDOWN OF THE IMPLEMENTATION COST OF THE SELF-MANAGEMENT PROGRAM
FOR 98 ADULTS WITH ASTHMA TREATED FOR 2 YEARS IN EIGHT FAMILY PRACTICES
Source for Number Cost per Unit Total Cost
Component of Cost Unit Valuation Unit of Units (C) (C)
Preparation
Prestudy training and instruction
of family physicians * Hours 23 73.53 1,691
Application of self-management program
Educational and self-management aids † Set‡ 98 14.25 1,396
Peak flow meters † Meter 98 29.61 2,902
Education sessions
Family physician time * Hours 151 73.53 11,075
Patient time § Hours 151 9.53‖ 1,436
Total implementation cost: 18,500
Average implementation cost per patient (95% CI): 189 (179, 199)
* Source used for unit valuation: Guidebook for Cost Investigation (Dutch College of Health Insurance [39]).
† Source used for unit valuation: retail prices (index year 2000).
‡ Set: all materials necessary to educate and train one patient, that is, information brochures, self-management diaries, and
information feedback forms.
§ Source used for unit valuation: study-specific inquiry by questionnaire.
‖ Based on the average gross hourly wage of all employed participants.
TABLE 4. MEAN AND INCREMENTAL PROGRAM IMPLEMENTATION, DIRECT HEALTH CARE, AND PRODUCTIVITY COST
OF SELF-MANAGEMENT AND USUAL CARE PER PATIENT PER 2 YEARS
Self-Management (n  98) Usual Care (n  95)
Source for Incremental
Component of Cost Unit Valuation Units (95% CI) Cost (C) Units (95% CI) Cost (C) Cost (C)‖
Program implementation cost† a,b,c 98 189 0 0 189
Subtotal implementation cost: 189 (179, 199) 0 189
Direct health care cost
Drugs and other interventions
Budesonide, doses d 1,680 (1,538, 1,822) 414 1,897 (1,679, 2,115) 467 53
Short-acting bronchodilators, doses d 469 (347, 591) 84 796 (526, 1,066) 141 57
Long-acting bronchodilators, doses d 67 (10, 124) 51 30 (6, 66) 16 35
Theophylline, doses d 11 (5, 26) 2 0 0 2
Prednisone, courses d 0.33 (0.19, 0.46) 3 0.22 (0.08 , 0.36) 2 1
Antibiotics, courses d 0.28 (0.11, 0.44) 1 0.40 (0.19, 0.61) 2 1
Other asthma medication* b,d,e NA 2 NA 6 4
Influenza vaccinations, number d 0.72 (0.55, 0.90) 5 0.38 (0.25, 0.51) 3 2
Physiotherapy, courses a 0.03 (0, 0.07) 4 0.01 (0.01, 0.03) 1 3
Allergen avoidance measures† c NA 193 NA 109 84
Other resources
Family physician consultations, number a 2.2 (1.6, 2.8) 37 2.4 (1.9, 2.9) 40 3
Chest physician consultations, number a 0.09 (0.03, 0.15) 5 0.01 (0.01, 0.03 ) 1 4
Diagnostic procedures‡ f NA 6 NA 6 0
Emergency room visits, number — 0 0 0 0 0
Hospital admissions, number — 0 0 0 0 0
Subtotal direct cost: 809 (683, 934) 798 (682, 914) 11
Productivity cost
Limited activity days, d§ c 1.2 (0.5, 1.9) 86 3.9 (2.5, 5.4) 299 213
Subtotal productivity cost: 86 (35, 136) 299 (191, 406) 213
Total cost: 1,084 (938, 1,228) 1,097 (933, 1,260)13
* Both prescribed and over-the-counter medication.
† Purchase of house dust mite impermeable mattress covers, smooth floors, special vacuum cleaners and air cleaning equipment.
‡ Cost of various pulmonary function and allergy tests, chest X-rays, and sputum cultures.
§ Highest two patients were excluded in both groups (see text).
‖ Self-management minus usual care.
NA  not applicable.
Sources used for unit valuation: [a] guidebook for Cost Investigation (Dutch College of Health Insurance, reference [39]); [b] retail prices (index year 2000); [c] study-
specific inquiry by questionnaire; [d] sum charged by family physicians to privately insured patients, including administrative expenses; [e] Pharmacotherapeutic Compass
(Dutch College of Health Insurance, reference [37]); [f] Diagnostic Compass (Dutch College of Health Insurance, reference [38]).
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TABLE 5. AVERAGE AND INCREMENTAL COST* DURING 2 YEARS OF SELF-MANAGEMENT AND
USUAL CARE IN ADULTS WITH ASTHMA
Cost Components†
Average Total Cost (95% CI) Incremental
‡ Cost of
Direct Program Self-Management per
Health Care Implementation Productivity Self-Management Usual Care Subject Treated
   1,084 (938, 1,228) 1,097 (933, 1,260) 13 (232, 206)
  — 997 (871, 1,124) 798 (681, 914) 199 (70, 328)
 —  894 (751, 1,038) 1,096 (933, 1,260) 202 (420, 16)
 — — 809 (683, 934) 798 (681, 914) 11 (77, 99)
Definition of abbreviation: CI  Confidence interval.
Results of the base case analysis are printed in boldface. A plus sign indicates an expenditure due to the self-management
program, a minus sign indicates a saving.
* In euros.
†   cost components included in the calculations of average costs.
‡ Self-management minus usual care.
tor treatment. In summary, the results were as follows. Net savingsSecondary Cost-Effectiveness Analyses
in favor of self-management were observed in some of the directWhen productivity costs were excluded, the incremental cost per
health care cost components (i.e., use of budesonide and short-QALY of self-management relative to usual care was C13,267
acting bronchodilators) and productivity (“indirect”) cost. When(Table 6). Self-management dominated usual care with regard
all costs were included, a mean net saving of C13 in favor ofto successfully treated weeks and the proportion of patients with
self-management was observed (not statistically significant). De-an MCID in quality of life. Without the productivity cost, the
spite the investment necessary for program implementation, theincremental cost–effectiveness ratio was C33 (95% CI, 4 to 99)
total costs for the self-management group were significantlyto gain one successfully treated week due to self-management.
lower during the second year of follow-up. The base case cost–Cost–effectiveness ratios based on the cost per patient with an
effectiveness ratio pointed to self-management as a cost-effectiveMCID in quality of life preponderantly pointed to self-manage-
ment as the dominant treatment, regardless of the inclusion or treatment option: self-management dominated usual care (i.e.,
exclusion of productivity cost (Table 6). was more effective and less costly). However, the graphic evalua-
tion of uncertainty around the cost per QALY estimate showed
DISCUSSION that the observed dominance of self-management could not be
firmly established. Overall, the secondary analyses based onThis article reports the economic evaluation of a family medi-
successfully treated weeks and patients with a clinically impor-cine-based asthma self-management program, with “usual care”
tant improved quality of life pointed to self-management asaccording to Dutch asthma treatment guidelines as the compara-
the dominant treatment option. When productivity costs were
ignored, self-management was no longer dominant in the second-
ary analyses (C13,267 to gain 1 QALY and C33 to gain one
successfully treated week).
Some comments on the methodology of the study need to
be made before further discussing our findings. First, a disadvan-
tage of using rating scales to value health states (and subse-
quently estimate QALYs) is that these instruments do not take
risk avoidance and uncertainty about future health outcomes
into account. Therefore, rating scale utilities tend to produce
higher quality weights then other techniques such as time-trade-
off and standard gamble methods (46). Moreover, rating scale
scores appear not to be a true interval scale of preference for
certain health states. Unfortunately, in the current study we did
not include a standard gamble or time-tradeoff instrument. The
mean number of QALYs in both treatment groups may have
been overestimated because of this, but the incremental differ-
ence between the groups is probably valid. However, this point
should be kept in mind when comparing our QALY results with
external information from other studies.
We did not randomize individual patients with asthma, but
family practices. The reason for doing so was to avoid potential
“contamination” of the usual care group by family physicians
Figure 3. Cost analysis for the first and second year of follow-up of self-
who had to practice both usual care and self-management simul-management and usual care patients. Gray sections represent direct
taneously for different patients. Whereas in the clinical evalua-health care cost, black sections represent program implementation cost,
tion a multilevel analysis was used to address possible depen-and white sections represent productivity cost. The hatched area in the
dency in clustered observations induced by this kind ofgray section of each column represents the patient out-of-pocket cost
randomization (34), some influence on the cost data cannot befor domestic allergen avoidance measures. * Between-group difference
ruled out completely. For instance, prevailing habits and prefer-in total cost for Year 2 (unpaired t test). †Within-group difference in
productivity cost between Year 1 and Year 2 (paired t test). ences in prescribing bronchodilators by family physicians may
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Figure 4. Mean changes in rating
scale scores for self-management and
usual care groups adjusted for base-
line level. Vertical bars represent stan-
dard errors. The gray area between
the two lines represents the differ-
ence in QALYs between treatment
groups. Because not all participants
had their laboratory visits scheduled
at exactly 6, 12, 18, and 24 months,
this visual representation is an ap-
proximation of the exact sum of all
individual QALYs as reported in text
and in Table 2. Solid squares, self-
management; solid circles, usual care.
have biased the results for this cost component to an unknown guidelines to an asthma education program does yield extra
effects in terms of health outcomes (47).extent. The same argument holds for the promotion of influenza
vaccination among individuals with asthma. We have previously looked at the generalizability of our study
population (48). Evaluation of the recruitment process showedThe baseline level of quality of life scores was higher in usual
care patients, possibly leaving less room for improvement in this that patients who use a low or intermediate dosage of inhaled
steroids were more likely to participate in the study than patientsgroup. The comprehensive clinical evaluation of the data showed
that the differences in AQLQ scores existing at baseline gradu- receiving a high dosage or patients who did not use inhaled
steroids at all (although, according to our national treatmentally disappeared during the 2-year follow-up period, which may
indicate that quality of life was maximized in both groups (34). guidelines [30, 31], they should have). Moreover, patients in paid
employment were more likely to refrain from participation thanHowever, the observation that self-management patients experi-
enced significantly more successfully treated weeks implies that those not in paid employment.
Regarding the cost analysis, several points need to be ad-the self-management program also had an independent effect,
regardless of the health status differences present at baseline. dressed. The most important expenditure necessary to imple-
ment the self-management program was the time spent by familyAs a consequence of our study design, we cannot be sure
which component of the self-management program in particular physicians to educate and train their patients with asthma (C113
per patient on average). Delegation of this task to, for instance,was responsible for the observed effects and savings: the (expen-
sive) educational efforts made by the family physicians or the nurses specialized in respiratory care could reduce these costs
considerably. Assuming delegation would not diminish program(relatively inexpensive) guidelines for self-monitoring and self-
treatment. There is some evidence that addition of self-treatment effectiveness, any reduction in the implementation cost would
TABLE 6. INCREMENTAL COST–EFFECTIVENESS RATIOS FOR ASTHMA SELF-MANAGEMENT
RELATIVE TO USUAL CARE DURING 2 YEARS OF FOLLOW-UP
Productivity Cost Included Productivity Cost Excluded
(95% CI) (95% CI)
Incremental cost per QALY gained Self-management dominant*,† 13,267
Incremental cost per successfully treated week gained Self-management dominant 33 (4, 99)
Observed incremental cost for one patient to experience an MCID,
when 100 patients are treated:
AQLQ‡ total score Self-management dominant§ Self-management dominant§
AQLQ‡ Emotions Domain Self-management dominant§ Self-management dominant§
AQLQ‡ Activities Domain Self-management dominant§ Self-management dominant§
AQLQ‡ Symptoms Domain Self-management dominant§ 1
AQLQ‡ Environment Domain Self-management dominant§ 328
Definition of abbreviations: AQLQ  Asthma Quality of Life Questionnaire; MCID  minimal clinically important difference; QALY 
quality-adjusted life year; 95% CI  95% confidence interval.
Costs are in euros. Results of the base case analysis are printed in boldface.
* Dominant: treatment both more effective and less costly than the alternative treatment.
† Uncertainty in the base case cost per QALY estimate is depicted in Figure 5.
‡ Final AQLQ measurement was missing in two self-management and six usual care patients.
§ Because the cost per MCID estimates are based on group mean cost, it should be noted that uncertainty exists around the
ratio estimates (results not presented).
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Figure 5. Top: Scatter plot of 1,000 modeled incre-
mental cost per QALY estimates. The table (bottom)
shows the proportion of iterations in the respec-
tive quadrants and compartments. Observations in
compartments C1, C2, and C3 indicate cost-effective-
ness of self-management. The diagonal dashed line
represents the societal willingness to pay (C22,500
per QALY, arbitrarily chosen). Inner and outer ellipses
represent 95 and 90% confidence intervals, respec-
tively.
obviously affect cost–effectiveness ratios in favor of self-manage- the greater part by the extra out-of-pocket cost for domestic
ment. Another advantage of transferring the actual pursuance allergen avoidance measures, and, although to a much lesser
of self-management training to other professionals would be the extent, more influenza vaccinations and referrals to chest physi-
diminished impact on the (already) high workload of family cians. These favorable “side effects” of the self-management
physicians. Targeting the self-management intervention to pa- program are probably explained by the emphasis put on the
tients with a high likelihood of treatment success could also importance of healthy behavior (i.e., allergen avoidance, influ-
enhance overall efficiency, although at this time it is unknown enza vaccination, and smoking cessation) during the education
how these patients could be identified beforehand. sessions. The higher out-of-pocket cost for domestic allergen
One of the most remarkable findings in this study was that the avoidance measures in the self-management group may be due
introduction of self-management led to substitution of particular to specific contents of our educational program. “Nature, cause
cost components with other components. For instance, the fi- and prevention of allergy or allergic symptoms,” “Hyperreactiv-
nancial saving due to reduced budesonide use and fewer limited ity and personal triggers,” and “Allergen avoidance measures
activity days in the self-management group was outweighed for at home” were 3 of the 31 educational topics the family physicians
discussed with their participants. One previous study has re-
ported that asthma education may be effective in promoting
house dust mite avoidance measures in patients with moderate
to severe asthma (49). The extra attention focused on self-man-
agement patients as a consequence of the intensified doctor–
patient relationship may have influenced the higher referral rate
observed in the self-management group.
We observed significant differences in the use of asthma medi-
cation between self-management and usual care patients, espe-
cially for budesonide. This difference suggests a more efficient
use of prophylactic medication due to self-management, a finding
inconsistent with previously reported higher compliance rates
regarding the use of inhaled steroids after introducing self-man-
agement (4, 50). However, use of the term “compliance” may be
inappropriate when it comes to evaluation of self-management in
patients with asthma. After all, the essence of the approach is
to fine-tune the use of inhaled steroids to the actual need asFigure 6. Acceptability curve reflecting the probability that asthma self-
determined by self-monitoring, without a prescribed (fixed) dailymanagement is cost-effective relative to usual care given a societal
willingness-to-pay () value. dose. For this reason, we anticipated a reduced consumption of
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Summary
Background. Early treatment with inhaled corticosteroids may prevent
progression of irreversible obstruction in COPD, especially in patients with bronchial
hyperresponsiveness. We investigated the clinical effects of early introduction of
inhaled steroids in subjects showing early signs and symptoms of COPD without a prior
clinical diagnosis.
Methods. Study subjects were detected in a general population screening and
monitoring program. Those with a moderately accelerated annual FEV1 decline and
persistent respiratory symptoms were invited to participate in a 2-year randomized
controlled trial comparing fluticasone propionate DPI 250 mg b.i.d. with placebo. Pre-
and post-bronchodilator (BD) FEV1, PC20 histamine, functional status (COOP/WONCA
charts) and occurrence of exacerbations were periodically assessed. Subjects
recorded respiratory symptoms. Post-BD FEV1 decline served as the main outcome.
Multivariable repeated measurements analysis techniques were applied.
Results. 48 subjects were randomized (24 fluticasone, 24 placebo). After 3 months,
the post-BD FEV1 had increased with 125ml (SE¼ 68, P ¼ 0:075) and the pre-BD FEV1
with 174ml (SE 90, P ¼ 0:059) in the fluticasone relative to the placebo group. The
subsequent post-BD and pre-BD FEV1 decline were not beneficially modified by
fluticasone treatment. There were no statistically significant differences in
respiratory symptoms, functional status, or exacerbations favoring fluticasone.
Subgroup analysis indicated that the presence of bronchial hyperresponsiveness
modified the initial FEV1 response on fluticasone, but not the subsequent annual FEV1
decline.
Conclusion. Early initiation of inhaled steroid treatment does not seem to affect
the progressive deterioration of lung function or other respiratory health outcomes in
subjects with early signs and symptoms of COPD. In subjects at risk for, or in an early
ARTICLE IN PRESS
stage of COPD, long-term inhaled steroid treatment should not be based on a single
spirometric evaluation after 3 months.
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Introduction
Bronchial inflammation is the main cause of
bronchial hyperreactivity and symptoms in asth-
ma.1 As a consequence of inflammatory cell
infiltration, goblet cell hyperplasia, basement
membrane thickening and hyperplasia and hyper-
trophy of airway smooth muscle cells, persistent
inflammation of the bronchial wall may cause
irrevers ible loss of lung functio n. 2 Altho ugh its
pathogenesis is less well clarified in chronic
obstructive pulmonary disease (COPD), bronchial
infl ammat ion al so see ms to play a significa nt role in
this disea se. 1
Treatment of asthma is directed at the inflam-
matory process and inhaled steroids are the
corne rstone of asthma mana geme nt. 3 Althoug h in
patients with manifest COPD inhaled steroid treat-
men t may re duce bronchi al hyperr espons iveness 4
and neutroph ilic bronc hial inflamm ation, 5–7 the
benefits of maintenance treatment with inhaled
steroi ds in COP D remain controvers ial. 8 At this
time, recent studies investigating the effectiveness
of inhaled steroi ds in patie nts with manifest COPD 9 –
12 failed to dem onstrate significan t lon g-term
effects on the decline of lung function, but there
may be subgrou ps in which inh aled steroi ds are
inde ed effe ctive in terms of pre vention of lung
functi on dete rioration. 13,1 4 Given the contr overs y
of inhaled steroids in COPD, we hypothesized that
initiation of this anti-inflammatory treatment in
the earliest stages of the disease is critical for its
effi cacy in the long term. Beca use mild bronchi al
inflammation and airflow obstruction are not al-
ways accompanied by bronchial symptoms and go
largely unnoticed by patients and primary care
pract ition ers, 15 study partici pants were selecte d
from a general population screening program,
which was initiated to detect subjects previously
undi agnosed wit h COP D or ast hma, but with earl y
signs and symptoms of COPD.
Methods
Study design and recruitment of subjects
A 2-year randomized placebo-controlled double-
blind trial was performed to compare fluticasone
propionate with placebo treatment in subjects with
mild but persistent signs of early COPD detected in
the general population. Study subjects were se-
lected through the two-stage detection strategy of
the DIMCA program (‘‘Detection, Intervention and
Mo nitoring of COPD and As thma ’’ , Fig. 1), which
has been desc ribed in detail elsewhe re 16 but is
summarized here. For the first stage of the
detection strategy, in 10 Dutch general practices
a random sample of all subjects aged 18–75 years
wit hout a prior dia gnosis of COPD or asth ma was
invited for a screening visit. Screening took place in
the general practices and consisted of spirometric
assessment and a respiratory symptoms question-
naire. Subjects with chronic respiratory symptoms
and signs of persistent airflow obstruction and/or
bronchial hyperresponsiveness were included in the
second stage of the DIMCA program, a 2-year
monitoring phase. During the monitoring, lung
function (including reversibility), bronchial hyper-
responsiveness, occurrence of acute exacerbations
and respiratory symptoms were assessed every 3
months. Based on the screening and monitoring
findings, subjects were categorized into one of five
groups: (1) persistent airflow obstruction (i.e.,
FEV1o80% of the predicted value after bronchodi-
lation); (2) rapid decline in lung function (i.e.,
annual FEV1 decline480ml); (3) persistent respira-
tory signs and symptoms (i.e., annual FEV1 decline
40–80ml and bronchitis symptoms); (4) persistent
mild symptoms and reversible airflow obstruction;
(5) no abnormal respiratory signs or symptoms
during monitoring (‘‘screening false-positives’’).
Group 1–4 subjects were invited to participate in
a series of randomized placebo-controlled trials in
order to assess the efficacy of early initiated
main tenance treatment with inhaled flutic asone. 15
There was no evidence of recruitment or selection
bias during the two stages of the detection
prog ram. 16 An ext ensive des cription of reasons for
non-participation to all different parts of the DIMCA
prog ram has been publi shed elsewhe re. 17
The current paper reports on the findings in
Group 4, i.e. subjects with persistent respiratory
signs and symptoms of early COPD. Subjects were
included in the trial when, during the 2-year
monitoring, they had reported chronic cough and/
or sputum production for at least three consecutive
months and showed an annual decline in pre-
bronchodilator FEV1 of 40–80ml. Subjects were
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excluded in case of: previous diagnosis of a
pulmonary condition; presence of a co-morbid
condition with reduced life expectancy; intoler-
ance for inhaled b2 agonists; use of b-blocking
agents; inability to use inhalation devices or peak-
flow meters.
In the power calculation we assumed that the
within-subject variation of FEV1 measurement was
100ml. A minimal detectable difference in annual
FEV1 decline of 60ml due to fluticasone treatment
was assumed .18 In an interi m an alysis of the first
16 subjects who finished the 2-year monitoring
phase, the standard deviation (SD) of the mean
annual FEV1 decline w as 66 ml. 
19 Th us, wit h a ¼
0:05; 1 b ¼ 0:80 and an anticipated 10% with-
drawal rate, 18 subjects per treatment arm had to
be recruited.
The study was approved by the medical ethics
review board of the University Medical Center
Nijmegen and all trial participants gave written
informed consent.
Treatment arms and rescue medication
Subjects randomized to the active treatment group
received fluticasone propionate (Flixotides) 250mg
b.i.d. by dry powder inhalation (Rotadisks) at each
3-monthly visit to the pulmonary function labora-
tory. Subjects were instructed to return all disks
(full and empty) during the laboratory visits in order
to assess treatment compliance. Individual compli-
ance rates were determined by expressing the
number of puffs consumed (number of dosages
provided minus number of dosages returned) as a
percentage of the amount prescribed during the
trial. Treatment compliance and inhaler technique
were checked half-yearly at the pulmonary function
laboratory. When non-compliance was reported, a
subject was reminded to use the study drug twice
daily. In case of insufficient inhaler technique
additional inhalation instruction was given.
Apart from short-acting (‘‘rescue’’) bronchodila-
tors in case of acute dyspnea, subjects were not
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Figure 1 Flow chart of the initial general population cohort in the DIMCA program, 18 and the trial populations derived
from it. This paper reports on the DIMCA 4 trial.
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allowed to use other pulmonary medication. At
each quarterly visit, consumption of rescue inhala-
tions was recorded. At the start of the study, the
participating GPs were reminded of the contents of
the Dutch guidelines for management of asthma
and COPD in general practice, which included a
quit-smoking recommendation. In case of an acute
exacerbation, GPs were advised to prescribe a
10-day course of prednisolone and a broad-spec-
trum antibiotic agent.
Study outcomes and measurements
The primary outcome of the study was the annual
decli ne of the pos t-bron chodila tor FEV1. 
20 Decl ine
of pre-bronchodilator FEV1, PC20 histamine, ex-
acerbation rate, number of episodes with aggra-
vated sympt om s, and use of rescu e bronch odilators
were studied as secondary outcomes. At the start
of the trial and after 6, 12, 18 and 24 months, pre-
and post-bronchodilator FEV1 and FVC were as-
sessed by a trained lung function technician in a
certified pulmonary function laboratory using a
Microspiro HI-298 spirometer (Chest Corporation,
Jap an). 21 Bronchi al hyperr espons iveness was mea-
sured half-yearly as the concentration of histamine
provoking a 20% fall in FEV1 (PC20-histamine,
proced ure desc ribed by Cockc roft et al. 22) and
estimated by linear interpolation. Pre- and post-
bronchodilator FEV1 and FVC were also assessed in
the general practices at 3, 6, 9, 15, 18 and 21
months using hand-held turbine spirometers (Micro-
plus, SensorMedics, US). General practice assis-
tant s w ere thor oughly tra ined in perform ing
spirom etry.23 Fo llowing the cr iteria issue d by the
Ameri can Thor acic Societ y, the FEV1 from the
maneuver with the highest sum of FEV1 and FVC
out of three acceptable forced expiratory maneu-
ver s was use d for analysi s.24 In case of 4 10 %
reproducibility (i.e., difference between the high-
est FEV1 value and the mean of all three maneu-
vers) an FEV1 value was excluded from the analysis.
Post-bronchodilator FEV1 was assessed 15
0 after
administration of 800 micrograms salbutamol by
spacer. Measurements were only performed in
exacerbation-free periods and not within 8 h of
bronchodilator use.
Smoking history was assessed at the start of the
trial and expressed as the number of pick-years
smoked. Changes in smoking habit during the trial
were recorded every 3 months. A skin-prick test with
16 allergens (including pollen, house dust mite, fungi,
and pets) was performed. Subjects were considered
to be allergic when the whealsize of X1 allergen
exceeded 2/3 of the histamine control wheal.
Functional status was assessed at the quarterly
genera l practice visits using the COO P/WO NCA
charts .25 Th is instrumen t consists of six domai ns
(‘‘physical fitness’’, ‘‘feelings’’, ‘‘daily activities’’,
‘‘social activities’’, ‘‘changes in health status’’, and
‘‘general health’’) with scores ranging from 1
(‘‘very good’’) to 5 (‘‘very bad’’).
Exacerbations were recorded by the GPs using
standardized report forms. An exacerbation was
defined as at least two positive answers on the
following three items during a consultation: in-
creased cough, wheezing and/or dyspnea; change
in sputum color; use of bronchodilator rescue
med ication. 26 Consul tations with an interval o4
weeks were considered as pertaining to the same
exacerbation.
In order to detect episodes with aggravated
respiratory symptoms, subjects recorded symptom
scores for dyspnea, cough, wheezing and phlegm
for the past week (0: no complaints, 3: complaints
on all days and/or nights during the past week). An
episode was defined as either ‘‘increased cough,
wheezing and/or dyspnea’’, ‘‘change in phlegm
color’’, ‘‘increased use of rescue bronchodilators’’,
and/or ‘‘having a cold’’. When in the next week no
item was reported the episode was considered to
have terminated. Information about serious and
minor adverse events was collected.
Statistical analyses
The SAS statistical software package was used for
analysis. All subjects with at least one follow-up
measurement for the primary outcome (post-
bronchodilator FEV1) were included in an inten-
tion-to-treat analysis. The effects of fluticasone
versus placebo treatment on primary and secondary
outcomes were analyzed using repeated measure-
men ts analysis of vari ance (PROC MIXED ),27 in
which subject, treatment, and time effects are
analyzed simultaneously. Short-term responses (0–3
months) and long-term treatment effects (3–24
months) were analyzed in separate models. Base-
line PC20 and number of packyears prior to the
study were included in all models in order to adjust
for their potential confounding effects. Based on
the repeated measurements models, adjusted
estimates of the long-term effect of fluticasone
versus placebo on the decline of post-BD and pre-
BD FEV1 were calculated for the 3–24 month data.
Estimates for longitudinal changes in PC20 hista-
mine were calculated using the full 2-year follow-
up data.
A subgroup analysis was performed to investigate
bronchial hyperresponsiveness (PC20o8 versus
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X8mg=ml) as a potential effect modifier of the
short- and long-term efficacy of fluticasone treat-
ment. This was done by including interaction terms
in the repeated measurements models of the post-
and pre-bronchodilator FEV1. PC20 values were log2
transformed before analysis. Consequently,
changes in PC20 values are expressed as geometric
means and should be interpreted as doubling doses
of histamine. Between-group differences in the
occurrence of acute exacerbations and episodes
with aggravated symptoms were analyzed using
Poisson tests, differences in functional status by
Wilcoxon rank test. Between-group differences
were considered to be statistically significant when
Po0:05:
Results
Study population and drop-outs
Seventy four (74) subjects met the inclusion
crite ria (Fi g. 1 ). Of these subjects, 21 decli ned
the invitation to participate in the trial, the main
reasons being ‘‘general dislike of medication’’,
‘‘general dislike of medical testing’’, and ‘‘lack
of time’’. Five subjects were excluded by the
investigators (two used b-blockers, two moved
away, and one wanted to become pregnant). The
remaining 48 subjects were randomized to receive
either fluticasone or placebo treatment for two
years.
Demographic and clinical characteristics of par-
ticipants and non-participants did not differ (re-
sults not pre sented) . Tabl e 1 shows the basel ine
characteristics of the trial participants by treat-
ment group. Fluticasone group subjects had a
higher number of pick-years compared to placebo
group subjects (11.9 [SD 9.5] versus 5.8 [SD 8.4],
respectively, P¼ 0.02). Seven fluticasone and six
placebo-treated subjects showed baseline bron-
chial hyperresponsiveness.
Twelve subjects (25% of the trial population)
dropped out during the 2-year treatment period.
Pharyngeal irritation and aversion to using pulmon-
ary medication in the absence of respiratory
symptoms were the main reasons for drop-out.
Numbers of, and reasons for drop-out were equally
distributed over the fluticasone and placebo
groups. The overall compliance of the use of trial
medication was 72% of the prescribed dose (range
7–102%). Compliance rates were similar in both
treatment groups.
Effects on FEV1 decline and PC20
The course of the post-bronchodilator FEV1, pre-
bronchodilator FEV1, and PC20 in the treatment
gro ups is depic ted in Figs. 2 –4. Three mo nths after
randomization, the mean post-bronchodilator FEV1
was 125 (SE 68) ml higher in the fluticasone-treated
subjects compared to the placebo-treated subjects
(P ¼ 0 :075 ; Fig. 2 ). Durin g th e 2-year follow-up the
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Table 1 Baseline characteristics of the study population by treatment group.
Fluticasone propionate
(n¼ 24)
Placebo (n¼ 24)
Age (years) 46 (10) 47 (11)
Male/female 12/12 13/11
Smoker (yes/no) 12/12 8/16
Pick-years 11.9 (9.5) 5.8 (8.4)
FEV1 pre-bronchodilator (I) 3.05 (0.70) 3.17 (0.76)
as % predicted 95 (18) 98 (17)
FEV1 post-bronchodilator (I) 3.16 (0.68) 3.19 (0.79)
as % predicted 98 (15) 99 (18)
FEV1/VC pre-bronchodilator (%) 75 (10) 77 (6)
FEV1 decline during monitor stage 109 (46) 124 (66)
(ml/year)
FEV1 reversibility as % predicted 4.0 (5.1) 3.0 (4.0)
MEF50 as % predicted 65.6 (27.4) 68.5 (24.1)
PC20 histamine
a (mg/ml) 14.2 9.2
Allergy (yes/no/missing) 8/15/1 10/13/1
Symptom score 1.7 (1.5) 1.3 (1.3)
*P¼ 0.02.Values are means (SD) unless stated otherwise.
aGeometric mean.
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estimated annual decline of the post-bronchodila-
tor FEV1 was 93 (SE 30) ml for fluticasone and 14
(SE 17) ml for placebo treatment (P ¼ 0:001). For
the pre-bronchodilator FEV1 the difference be-
tween fluticasone and placebo treatment was 174
(SE 90) ml after 3 months, favoring fluticasone
treat ment (P ¼ 0: 059 ; Fig. 3 ). The an nual pre -
bronchodilator FEV1 decline was 85 (SE 32) ml for
fluticasone and 38 (SE 19) ml for placebo
treatment (P ¼ 0:078). At the end of the 2 year
treatment period the difference in post-broncho-
dilator FEV1 was 47 (SE 63) ml in favor of placebo
treatment (P ¼ 0:458), for the pre-bronchodilator
FEV1 the corresponding figure was 60 (SE 70) ml in
favor of fluticasone treatment (P ¼ 0:394). PC20
measurements did not show a significant difference
between fluticasone and placebo treatment at any
poin t in time (P ¼ 0:980 ; Fig. 4 ).
Bronchial hyperresponsiveness as well as pack-
years were confounders in the multivariable models
for both the post- and pre-bronchodilator FEV1
decline. The subgroup analysis on baseline bronchial
hyperresponsiveness showed that, compared to
placebo, fluticasone was significantly more effica-
cious in terms of the short-term (0–3 months) pre-
and post-bronchodilator FEV1 response (Ta b l e 2 ).
However, no modifying effect of bronchial hyperre-
sponsiveness in favor of fluticasone treatment on
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Figure 2 Short-term response and long-term course for the post-bronchodilator FEV1 in the fluticasone (FKF) and
placebo (–~–) groups*. Vertical bars indicate standard errors. (* For reasons of clearness, the general practice
measurements at 6 and 18 months are omitted from the figure (but not from the statistical analysis).)
Figure 3 Short-term response and long-term course for the pre-bronchodilator FEV1 in the fluticasone (FKF) and
placebo (–~–) groups*. Vertical bars indicate standard errors. (* For reasons of clearness, the general practice
measurements at 6 and 18 months are omitted from the figure (but not from the statistical analysis).)
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either the post- or pre-bronchodilator annual FEV1
decline was observed (Ta b l e 2 ).
Effects on exacerbations, respiratory
symptoms and functional status
Six exacerbations in five fluticasone-treated sub-
jects and four exacerbations in three placebo-
treated subjects were reported. In the fluticasone
group, 127 episodes of increased respiratory symp-
toms were reported by 18 subjects, whereas 57
episodes in 17 subjects were observed in the
placebo group (Po0:001). The number and severity
of reported respiratory symptoms did not differ
between the treatment groups, nor did the number
of subjects who used rescue bronchodilators during
the trial: seven subjects in the fluticasone group and
eight subjects in the placebo group, respectively.
The baseline COOP/WONCA chart scores varied
from ‘not impaired’ (1.2, SD 0.6 for social
activities) to ‘slightly impaired’ (2.4, SD 1.2) for
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Figure 4 Course of the PC20 histamine in the fluticasone (FKF) and placebo (–~–) groups. Vertical bars indicate
standard errors.
Table 2 Results of the subgroup analyses on short-term FEV1 response and subsequent annual FEV1 decline with
regard to bronchial hyperresponsiveness.
Short-term response
in ml (SE) 0–3
months
P Annual decline in
ml/year (SE) 3–24
months
P
Post-bronchodilator FEV1
BHRþ
Fluticasone þ 95 (215) 93 (64)
Placebo 200 (125) 0.124 þ 19 (37) 0.032
BHR
Fluticasone þ 56 (84) 92 (33)
Placebo 8 (48) 0.350 27 (18) 0.016
Pre-bronchodilator FEV1
BHRþ
Fluticasone þ 276 (307) 115 (82)
Placebo 401 (178) 0.022 1 (47) 0.093
BHR
Fluticasone 21 (83) 73 (30)
Placebo 14 (48) 0.918 53 (17) 0.403
FEV1: forced expiratory volume in 1 s; BHRþ : bronchial hyperresponsiveness present (PC20p8mg/ml); BHR: no bronchial
hyperresponsiveness present (PC20X8mg/ml).
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general health). The majority of subjects perceived
no changes in COOP/WONCA charts score and
differences between the fluticasone and placebo
groups were never statistically significant (data not
shown).
Adverse events
Four serious adverse events were reported during
the trial: one diagnosis of polymyalgia rheumatica
and three hospitalizations, one for severe head-
ache, one for polyposis nasi, and one for uterus
leiomyoma, none of which could be related to the
trial medication. Fourteen subjects (29% of the trial
population), equally distributed over the flutica-
sone and placebo groups, reported minor adverse
events that could be related to the use of trial
medication: dry mouth; hacking cough after in-
halation of trial medication; sore throat or phar-
yngeal irritation; vomit; hoarseness; and loss of
sense of taste. For five subjects (two fluticasone
and three placebo) minor adverse events were the
reason for dropping-out of the study.
Discussion
This study indicates that early initiation of regular
treatment with fluticasone does have an initial and
short-term effect, but does not seem to alter the
subsequent course of lung function decline in
subjects who are characterized by a moderately
accelerated FEV1 decline and persistent respiratory
symptoms. The short-term effect of fluticasone
appeared to be more pronounced in subjects
with bronchial hyperresponsiveness. No long-term
beneficial effects of fluticasone treatment on
secondary health outcomes (i.e., bronchial hyper-
responsiveness, exacerbations, respiratory symp-
toms, and health status) could be demonstrated.
We considered the post-bronchodilator FEV1 to
be the main outcome parameter in our study.
Contrary to our initial hypothesis but in accordance
wit h the resul ts of previou s lon g-term studies in
subj ects in diffe rent stage s of COPD, 9 –12 the post-
bronchodilator FEV1 decline was not decelerated by
inhaled steroid treatment. One could argue that
the value of FEV1 measurements in early or
pre clinica l stage s of COP DFas w e woul d like to
describe our study populationFis doubtful. How-
ever, we observed a slight and statistically sig-
nificant increase of FEV1 in favor of fluticasone
treatment after 3 months of study. A short-term
increase of the FEV1 during treatment with inhaled
steroids, followed by a progressive decline parallel
to placebo has also been reported by other
autho rs. 9,11 Althoug h the FEV1 has been widely
accepted as the gold standard for measuring
bronchial obstruction and thus of the severity of
COPD, the value of FEV1 measurements in very
early stages of COPD is doubtful. The explorative
subgroup analysis suggested that in the subjects
with bronchial hyperresponsiveness, the short-term
FEV1 response due to fluticasone treatment was
significa ntly larger than in subjects wit hout bron-
chial hyperresponsiveness; this observation corre-
sponds with findings reported for patients with
mani fest COPD. 4–7 However, the presence (or
absence) of bronchial hyperresponsiveness at base-
line did not seem to influence the efficacy of
fluticasone relative to placebo treatment with
regard to the annual FEV1 decline.
A substantial part of the FEV1 measurements was
performed in the general practices, and our
find ings re ly hea vily on the qua lity of the se
measurements. Repeated instructions of the prac-
tices’ staff resulted in reliable performances, with
an averag e test re produci bility of 4%. 23 Reanalyzin g
the data with onl y th e me asurem ents of the lung
function laboratory did not change the main
conclusions.
It has been hypothesized that subjects with mild
obstructive airways disease, whose pathophysiolo-
gic abnormalities are predominantly present in the
small airways, may remain undetected if no flow
rates at low lung volu mes are measur ed.28 Ind eed,
at the start of the trial the mid-expiratory flow
(MEF) values were slightly impaired (below 70% of
predicted values in both treatment groups), in-
dicating (mild) obstruction of the peripheral air-
ways. However, when we assessed the course of the
pulmonary function on the MEF25, MEF50, or MEF75
values, no effects of fluticasone in comparison to
placebo on these indices were observed (results not
presented).
In COPD, other characteristics of disease pro-
gression or monitoring of treatment like health
status and exacerbations attract more and more
atte ntion. 29 Impaired qual ity of lif e is more direc tly
related to the use of general practitioners’ facil-
ities than respiratory symptoms or a reduced lung
functi on, 30 and impaire d quality of life may also be
pre sent in COPD w ith nea r norm al spirome try. 29 In
the current study, no improvement in generic
hea lth status dur ing treatme nt w ith fluticas one
was observed, but this is probably due to the
virtu ally undist urbed hea lth statu s of the study
subjects at the start of the trial. The rate of acute
exacerbations was very low in both treatment
groups, which may be expected in subjects who
were not previously known by their GP as suffering
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from chronic respiratory disease. Therefore, there
was hardly any room for improvement on this
particular outcome. The salient and statistically
significant difference in the number of episodes
with increased symptomsFone of the secondary
study outcomesFin favor of placebo treatment
was unexpected and we have no explanation for
this observation. We conclude that, in the current
study, we were unable to demonstrate significant
long-term health benefits of early introduction
of inhaled steroid treatment in subjects with
early symptoms and signs of COPD. Primary care
physicians should be careful to base maintenance
treatment with inhaled steroids in subjects at risk
for, or in an early stage of COPD on a single
spirometric evaluation after 3 months. Implemen-
tation of screening or case-finding programs to
detect subjects with early COPD cannot be justified
on the basis of this study.
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P.N.R. Dekhuijzen , E.F.M. Wouters , H. van den Hoogen ,
C.P. van Schayck , C. van Weel
Summary Objective: The objective of the study was to assess the probability, and
explore determinants of adverse respiratory outcome after discontinuation of inhaled
corticosteroid (ICS) treatment in subjects with chronic obstructive pulmonary disease
(COPD) diagnosed and treated in general practice. Design: Prospective unblinded ICS
withdrawal study. Subjects: 201 ICS treated COPD patients with various degrees of air-
ﬂow limitation from 45 Dutch general practices. Main outcome measures: Probability
of and time to exacerbation or unremitting worsening of respiratory symptoms after
ICS discontinuation. Results: Mean age was 60.6 (S.D. 9.5) years, post-bronchodilator
forced expiratory volume in 1 s (FEV1) 65.6 (S.D. 15.7) % predicted. Overall probabil-
ity of adverse respiratory outcome after ICS discontinuation was 0.37 (95% conﬁdence
interval (CI) 0.31, 0.44). Survival analysis showed that age, gender, smoking status
and reversibility of airﬂow limitation were independent predictors of adverse respi-
ratory outcome. For females, the adjusted hazard ratio was 2.14 (95% CI 1.31, 3.50)
compared to males. For age, the hazard ratio was 1.05 (95% CI 1.02, 1.08) per year
lived. Conclusion: Discontinuation of inhaled corticosteroids may harm patients with
COPD. The probability of an adverse respiratory outcome may be higher in women,
elderly patients, smokers and patients with higher bronchodilator reversibility while
on inhaled steroid treatment.
Introduction
Despite a number of recent clinical studies [1—4],
the beneﬁts of inhaled corticosteroids in patients
with chronic obstructive pulmonary disease (COPD)
are still debated. No effect on lung function decline
has been established, but inhaled steroids seem to
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slow-down health status deterioration and reduce
acute exacerbations [1,4]. According to recent
global guidelines for COPD management, inhaled
steroids should be reserved for symptomatic pa-
tients with a documented spirometric response to
steroids and for those with moderate to severe air-
ﬂow limitation and repeated exacerbations which
require antibiotic and/or prednisolone treatment
[5]. At this time, however, many more patients
with COPD in general practice are treated with
inhaled corticosteroids, most of them for a num-
ber of years already [6,7]. Regular inhaled steroid
treatment is probably superﬂuous in a considerable
number of patients and ought to be discontinued.
This may cause problems, however, as adverse ef-
fects of withdrawal of inhaled steroid therapy in
patients with COPD have been reported [8—10],
making it likely that at least some patients are
harmed. For that reason, the possibility to pre-
dict adverse respiratory outcome would enable a
more rational and safe way of withdrawing inhaled
steroids in order to modify current ineffective
prescription practices. Therefore, the objectives
of this study were to assess the probability of an
adverse respiratory outcome after discontinuation
of regular inhaled steroid treatment in primary
care patients with COPD, and to explore patient
characteristics associated with the probability
of exacerbation or relapse after inhaled steroid
withdrawal.
Methods
Subjects and recruitment
We studied 232 subjects with COPD diagnosed
and treated by their general practitioner (GP)
(Fig. 1). All subjects entered the washout phase
of the COPD on Primary Care Treatment (COOPT)
trial [11], which investigates the effective-
ness of inhaled ﬂuticasone propionate and oral
N-acetylcysteine in COPD. Study participants
were recruited from 45 general practices in the
south-eastern part of The Netherlands. Eligibility
criteria were: chronic dyspnea, sputum production
and cough for at least three consecutive months
per year during the previous 2 years [12]; cur-
rent or former smoker; either post-bronchodilator
forced expiratory volume in 1 s (FEV1) <90% of
the predicted value, or FEV1/FVC <88% of the
predicted value (89% for women) [12]; never
treated for asthma, allergic rhinitis or atopic
rash; no severe comorbid conditions. Subjects
with a FEV1 <35% of the predicted value were
excluded.
Study procedures and measurements
The study was approved by the medical ethics
review board of the University Medical Centre,
Nijmegen. All subjects gave written informed con-
sent. In order to be able to assess eligibility of
subjects for the subsequent clinical trial, those
on inhaled steroids had to go through a steroid
washout of at least 3 months. Trial candidates
requiring a washout were categorized as: low
inhaled steroid dosage (<500g ﬂuticasone pro-
pionate, <800g budesonide or beclomethasone
dipropionate per day); intermediate dosage (ﬂu-
ticasone propionate 500—1000g, budesonide or
beclomethasone dipropionate 800—1600g); high
dosage (≥1000g ﬂuticasone propionate,≥1600g
budesonide or beclomethasone dipropionate).
Subjects were instructed to contact their GP if
they noted a worsening of their respiratory symp-
toms for at least three consecutive days. Subjects
had to had been clinically stable for at least 6
weeks prior to steroid withdrawal, i.e. should not
have had an exacerbation during this period. The
steroid washout formally terminated on the day of
the visit at the lung function laboratory where the
eligibility criteria for trial participation were ver-
iﬁed. Adverse respiratory outcome was deﬁned as
either
(1) The occurrence of an acute exacerbation
of COPD, diagnosed and treated with pred-
nis(ol)one and/or a course of antibiotics by a
general practitioner or chest physician; or
(2) an episode of unremitting worsening of respi-
ratory symptoms of at least three consecutive
days which led the subject to seek medical at-
tention from his or her general practitioner and
which resulted in relapse into inhaled steroid
treatment.
General practices staffs were trained in per-
forming spirometry before the study and were
equipped with an electronic spirometer (Micro
Medical Ltd., Rochester, Kent, UK) and spirometry
software (Spirare®, Diagnostica Ltd., Oslo, Nor-
way). Spirometry was performed before and after
administration of 400g salbutamol dosisaerosol
by spacer (Volumatic®, GlaxoSmithKline, Zeist,
The Netherlands). Reversibility of airﬂow limi-
tation was calculated as the percentage change
between pre- and post-bronchodilator FEV1 val-
ues and as the difference between the pre- and
post-bronchodilator percentage predicted FEV1
[13]. European Community for Steel and Coal ref-
erence values were used to calculate predicted
values [13].
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Figure 1 Subject recruitment and drop out during inhaled steroid washout (*) including 11 subjects lost to follow-up,
17 subjects without conﬁrmation of inhaled steroid discontinuation and 3 subjects where a general practitioner or
chest physician advised against inhaled steroid withdrawal (†) including (n = 75) adverse respiratory outcome.
Statistical analysis
SPSS for Windows (Release 9.0.1) was used for
analyses. Appropriate statistical tests were used to
compare baseline characteristics between steroid
dosage subgroups and subjects with and without
adverse respiratory outcome. The relationship be-
tween the time to adverse respiratory outcome
after steroid withdrawal and a number of explana-
tory variables was analysed using multivariable
Cox proportional hazards modelling [14]. Survival
time was deﬁned as the number of days between
the start of steroid withdrawal and onset of ad-
verse respiratory outcome. Those withstanding the
washout period without adverse respiratory events
were treated as right censored cases. Explanatory
variables included in the multivariable model were:
age; gender; smoking status (current/former); du-
ration of disease; self-reported exacerbation rate
in the previous 2 years (0, 1, or ≥2 exacerbations);
FEV1 as percentage predicted; FVC as percent-
age predicted; FEV1/FVC ratio ≥70% or <70%;
reversibility of FEV1 <9% or ≥9%. Backward elimi-
nation was used to remove covariates with a Wald
statistic test probability ≥0.10 from the model.
A priori, we suspected confounding by indication
[15] with regard to the dosage of inhaled steroids
before discontinuation: subjects on a high dose of
inhaled steroids were more likely to be in a worse
respiratory condition than subjects using a low or
intermediate dosage. Therefore, a proportional
hazards model containing all ﬁrst order interaction
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terms with baseline inhaled steroid dosage and
the explanatory variables was considered ﬁrst. Be-
cause this model showed signiﬁcant interaction
for age, reversibility and FEV1/FVC, we decided to
construct separate models for each of the three in-
haled steroid dosage subgroups, next to the model
applicable to the total study population.
Results
Population characteristics and inhaled
steroid withdrawal
Discontinuation of inhaled steroid treatment was
intended in 232 subjects (Fig. 1). Eleven (5%) sub-
jects were lost to follow-up. In 17 (7%) subjects,
the actual discontinuation of inhaled steroid treat-
ment could not be conﬁrmed. In three (1%) sub-
jects, withdrawal of inhaled steroids was advised
against by a consulting chest physician. Table 1
shows baseline characteristics of the remaining 201
subjects by subgroup of inhaled steroid dosage.
Most subjects (54%) were on a moderately high
dosage of inhaled steroids. Signiﬁcant airﬂow limi-
Table 1 Baseline characteristics of subjects with a general practice-based diagnosis of COPD and conﬁrmed
discontinuation of inhaled steroid treatment by baseline dosage of inhaled steroids. Values are means (S.D.) unless
stated otherwise.
Baseline dosage of inhaled steroids Total P-valuea
Low Intermediate High
No 38 109 54 201
Gender (% female) 42 27 35 32 0.174
Age (years) 59.0 (10.2) 61.6 (9.4) 59.7 (9.1) 60.6 (9.5) 0.569
Diseased lifeyearsb (%) 8.1 (7.8) 7.6 (6.7) 7.0 (6.4) 7.5 (6.8) 0.631
Smokers (% current) 47 51 36 49 0.867
Simultaneous NAC withdrawal (%) 7.9 7.3 9.3 8.0 0.913
Exacerbations in previous 2 yearsc (%)
None 31.6 22.9 20.4 23.9
1 7.9 21.1 20.4 18.4
≥2 60.5 56.0 59.3 57.7 0.377
FEV1 pre-bronchodilator (l) 2.02 (0.70) 1.70 (0.68) 1.68 (0.58) 1.76 (0.67) 0.024
Percentage of predicted value (%) 67.6 (16.3) 58.0 (17.4) 56.9 (17.0) 59.5 (17.5) 0.006
FEV1 post-bronchodilator (l) 2.18 (0.68) 1.89 (0.64) 1.85 (0.60) 1.93 (0.64) 0.028
Percentage of predicted value (%) 72.8 (13.3) 64.5 (15.6) 62.7 (17.1) 65.6 (15.7) 0.006
FEV1 reversibility from baseline (%) 9.6 (12.8) 14.0 (15.2) 11.4 (9.9) 12.4 (13.5) 0.309
FVC post-bronchodilator (l) 3.31 (1.08) 3.13 (0.84) 3.01 (0.77) 3.13 (0.88) 0.324
FEV1/FVC post-bronchodilator (%) 66.9 (10.5) 60.5 (12.6) 61.3 (12.3) 61.9 (12.3) 0.019
NAC: N-acetylcysteine; FEV1: forced expiratory volume in one second; FVC: forced vital capacity.
a Signiﬁcance level of difference between inhaled steroid dosage subgroups.
b Number of years since initial diagnosis of COPD as a proportion of age.
c Self-reported by study subjects.
tation (post-bronchodilator FEV1 <80% of predicted
value) was present in 156 (78%) subjects. Forty-six
(23%) subjects had mild, 105 (52%) moderate,
and 50 (25%) severe airﬂow limitation. Baseline
steroid dosage was signiﬁcantly related to pre-
and post-bronchodilator FEV1 and FEV1/FVC values
(Table 1).
Adverse respiratory outcome
Of the 201 study subjects, 86 (43%) dropped out
after inhaled steroid treatment was discontinued,
75 (87%) due to respiratory causes and 11 (13%)
for other reasons. Other reasons for dropping out
were: lack of motivation (8); acute and serious ill-
ness of spouse (1); intervening elective surgery (1);
and diagnosed malignancy (1). Of the respiratory
dropouts, 54 (72%) were due to an acute exacer-
bation and 21 (28%) due to unremitting worsen-
ing of respiratory symptoms. Of all adverse res-
piratory outcomes, 11 (15%) occurred in the low,
43 (57%) in the intermediate and 21 (28%) in the
high steroid dosage subgroup (Table 2). The over-
all probability of dropping out due to respiratory
causes was 0.37 (95% conﬁdence interval (CI) 0.31,
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Table 2 Univariate comparison of subjects with and without an adverse respiratory outcome after discontinuation
of inhaled steroid treatment. Values are means (S.D.) unless stated otherwise.
Adverse respiratory outcome P-value
Yes (n = 75) No (n = 126)
General characteristics
Gender (% female) 40.0 27.0 0.054
Age (years) 62.5 59.4 0.028
Smokers (% current) 47.6 50.7 0.676
Years since diagnosisa (%) 11.6 (9.2) 13.4 (13.2) 0.266
Exacerbations in past 2 yearsb (%)
None 23.0 25.3
1 17.5 20.0
2 or more 59.5 54.7 0.793
Withdrawal of medication
Dosage inhaled steroids at time of withdrawal (%)
Low 14.7 21.4
Intermediate 57.3 52.4
High 28.0 36.2 0.495
Simultaneous NAC withdrawal (%) 10.7 6.3 0.274
Lung function
FEV1 reversibility (baseline) (%) 14.9 (16.5) 11.0 (11.3) 0.047
FEV1 reversibility (predicted) (%) 7.13 (7.38) 5.48 (5.66) 0.076
FEV1 pre-bronchodilator (l) 1.69 (0.68) 1.85 (0.64) 0.010
Percentage of predicted value (%) 57.1 (17.8) 60.9 (17.2) 0.138
FEV1 post-bronchodilator (l) 1.79 (0.66) 2.01 (0.62) 0.018
Percentage of predicted value (%) 64.3 (16.7) 66.4 (15.5) 0.360
FVC pre-bronchodilator (l) 2.64 (0.90) 2.98 (0.81) 0.006
Percentage of predicted value (%) 76.1 (17.2) 79.0 (15.6) 0.223
FVC post-bronchodilator (l) 2.93 (0.90) 3.25 (0.84) 0.011
Percentage of predicted value (%) 84.4 (16.3) 86.0 (15.2) 0.476
FEV1/FVC pre-bronchodilator (%) 60.7 (13.1) 62.0 (11.9) 0.493
Percentage of predicted value (%) 79.4 (17.0) 80.5 (14.9) 0.618
FEV1/FVC post-bronchodilator (%) 61.5 (12.5) 62.2 (12.2) 0.685
Percentage of predicted value (%) 80.3 (15.9) 80.8 (15.2) 0.827
NAC: N-acetylcysteine; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.
a Number of years since initial diagnosis of COPD as a proportion of age.
b Self-reported by study subjects.
0.44). Within the low, intermediate and high steroid
dosage subgroups this probability was 0.29 (95% CI
0.15, 0.43), 0.39 (95% CI 0.30, 0.48), and 0.39 (95%
CI 0.26, 0.52), respectively. The median (interquar-
tile range) number of days until adverse respira-
tory outcome was 43 (66), 42 (49) and 22 (53) for
the low, intermediate and high steroid dosage sub-
groups (P = 0.456), respectively.
Explanatory variables associated with
adverse respiratory outcome
Univariately, gender, age, reversibility of airﬂow
limitation and pre- and post-bronchodilator FEV1
and FVC values differed between those with and
without adverse respiratory outcome (Table 2).
Subjects experiencing an adverse respiratory out-
come tended to be more often female, were older,
showed a higher baseline bronchodilator reversibil-
ity and had lower FEV1 and FVC values.
Multivariable survival analysis indicated that the
risk of adverse respiratory outcome was higher
for females and that the risk increased with pro-
gressing age (Fig. 2). The hazard ratio for females
was 2.14 (95% CI 1.31, 3.50) compared to males
(Table 3). For age, the hazard ratio was 1.05 (95%
CI 1.02, 1.08) per year of increased age. When
analysed separately for the baseline inhaled steroid
dosage subgroups, age, gender, smoking status and
reversibility were independent predictors for ad-
verse respiratory outcome in one or more subgroups
(Table 3).
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Figure 2 Adjusted survival curves after discontinuation of inhaled steroid treatment in subjects with a general
practice based diagnosis of COPD (n = 201) by age quartile.
Table 3 Results of multivariable proportional hazards analyses.
Explanatory
variable
Reference
category
β coefﬁcient P-value Hazard
ratio
95% CI
Total study population (n = 201)
75 (37%) adverse outcome Age 1 year increase 0.048 <0.001 1.05 1.02, 1.08
Gender Male 0.762 0.002 2.14 1.31, 3.50
By inhaled steroid dosage subgroup
Low dosage (n = 38) Age 1 year increase 0.109 0.008 1.11 1.03, 1.20
11 (29%) adverse outcome
Intermediate dosage (n = 109) Age 1 year increase 0.056 0.005 1.06 1.02, 1.10
43 (39%) adverse outcome Gender Male 0.810 0.022 2.25 1.13, 4.49
Smoking Non-smoker 0.718 0.030 2.05 1.07, 3.93
High steroid dosage (n = 54) Gender Male 0.970 0.033 2.64 1.08, 6.45
21 (39%) adverse outcome Reversibility Irreversible 1.166 0.013 3.21 1.28, 8.05
CI: conﬁdence interval.
Discussion
This study adds information to the limited body
of knowledge with regard to the effects and risks
of discontinuation of inhaled steroid treatment in
patients with COPD. To our knowledge, no previ-
ous withdrawal studies have been performed in
a primary care COPD population. All subjects in
our study matched the ‘classic’ clinical proﬁle of
COPD, i.e. reported chronic sputum production and
persistent cough for at least the previous 2 years.
Moreover, some degree of persistent airﬂow limita-
tion was present in all subjects and all were current
or former smokers. We aimed to avoid inclusion of
subjects with unambiguous asthma by excluding
those previously treated for asthma, allergic rhini-
tis or atopic rash. Still, as both COPD and asthma
show a high prevalence in the general practice
population and smoking occurs in both groups of
patients [16,17], coexistence of COPD and clinical
features of asthma in the same subject is likely
to have occurred in this study. Because asthma
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and COPD share clinical similarities, it is virtually
impossible to differentiate patients with chronic
bronchitis and/or emphysema who have partially
reversible airway obstruction and bronchial hyper-
reactivity from patients with asthma whose airﬂow
obstruction does not remit completely [18]. There-
fore, when it comes to deciding if inhaled steroid
treatment is apposite in a particular subject with
apparent chronic obstructive airways disease, a
pragmatic approach–—which does not necessarily
require deﬁnite diagnostic labelling–—is needed to
support GPs’ decision-making.
In the current study, neither patients nor GPs
were ‘blinded’, so both were well aware of the fact
that inhaled steroid treatment was discontinued.
Although from a methodological point of view a
double-blind withdrawal trial would have been the
preferred design, the results of such a trial would
not reﬂect what happens in daily general practice if
inhaled steroid treatment is discontinued in a sub-
ject with apparent COPD. As a consequence of our
unblinded design patients may have been more per-
ceptive to changes in respiratory symptoms which
they normally would have ignored had their regular
pharmacotherapy not recently been modiﬁed.
After inhaled steroid withdrawal, more than
one-third (39%) of our study subjects experienced
an adverse respiratory outcome. This ﬁgure is very
similar to ﬁndings reported by Jarad et al. [8], who
observed that in a group of patients with COPD 38%
experienced an exacerbation within 8 weeks after
regular inhaled steroid treatment had been discon-
tinued in an unblindedmanner. In their double-blind
randomised controlled ﬂuticasone propionate with-
drawal trial, van der Valk et al. [10] observed a
48% exacerbation rate and an increased risk of
recurrence during 6 month follow-up of their 142
patients with moderate to severe COPD recruited
from hospital and outpatient records. O’Brien et al.
[9] found that in elderly patients with severe irre-
versible airﬂow limitation, withdrawal of inhaled
steroid therapy led to deterioration in ventilatory
function and increased exercise-induced dyspnea.
However, the heterogeneous primary care COPD
population in our study will generally suffer from
less severe disease and is likely to comprise more
subjects with coexisting asthma features.
So far, only one subgroup analysis with regard
to adverse effects of inhaled steroid withdrawal
in COPD has been reported [8]. In this study of
272 patients with apparently irreversible COPD, no
demographic or lung function variables predicted
the risk of exacerbation after discontinuation of
inhaled steroid treatment. Several large prospec-
tive placebo-controlled trials have explored the
relative efﬁcacy of inhaled steroids in subgroup
analyses [1—3]. These subanalyses all considered
heterogeneity of treatment effect with regard to
the progressive FEV1 decline, but never explored
the occurrence or frequency of exacerbations as an
outcome of interest. In one study it was observed
that inhaled steroids decelerated FEV1 decline in
the subgroup with the least smoking history [2].
Other subject characteristics like age, gender,
baseline FEV1, presence of serum IgE antibodies,
reversibility of airﬂow limitation, or response to
an oral corticosteroid trial did not predict the
long-term treatment result of inhaled steroids in
COPD, at least not in terms of FEV1 decline [1—3].
A small study performed in a mixed primary care
population of patients with COPD and asthma indi-
cated that current smoking, higher bronchodilator
reversibility, low FEV1/FVC ratio and high annual
lung function decline were related to a more pro-
gressive decline of FEV1 while on inhaled steroid
treatment [19]. A recent subgroup analysis of a
large inhaled steroid trial in secondary care pa-
tients suggest that the effects of inhaled steroids
on exacerbations may be seen predominantly in pa-
tients with moderate-to-severe COPD who experi-
ence recurrent exacerbations [20]. Considering all
published evidence on subject characteristics re-
lated to inhaled steroid treatment efﬁcacy, there is
some overlap with our ﬁndings: we observed that–
—next to gender and age–—smoking status, degree
of reversibility of airﬂow limitation and FEV1/FVC
at the time of inhaled steroid withdrawal were
related to adverse respiratory outcome.
In conclusion, when treatment with inhaled
steroids is discontinued in patients with COPD, the
probability of an adverse respiratory outcome is
rather high, but it may be mediated by age, gen-
der, smoking status and degree of reversibility of
airﬂow limitation. Although the severity of airﬂow
obstruction and the past exacerbation rate did
not determine the probability of adverse outcome
in our population, other studies have shown that
these factors may be important determinants of
relapse after inhaled steroid withdrawal as well. If
in a patient with COPD discontinuation of inhaled
steroid treatment is intended, a thorough prior
assessment of potential determinants and care-
ful monitoring of early signs and symptoms of an
adverse respiratory response is well-advised.
Announcement
As a GP you will learn from our paper that . . .
discontinuation of prophylactic inhaled steroid
treatment may harm patients with COPD, and that
certain patient characteristics (i.e. age, gender,
smoking status, severity and reversibility of airﬂow
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limitation, past exacerbation rate) may predict
adverse outcome after discontinuation of inhaled
steroids in this group of patients.
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Abstract 
 
Objective - To investigate the occurrence rate, treatment, and healthcare costs of 
exacerbations in patients with chronic obstructive pulmonary disease (COPD) in Dutch 
general practice. 
Methods – Baseline data from the COPD on Primary Care Treatment (COOPT) trial were 
used. Details on the occurrence and management of exacerbations were collected by 
systematic medical record review for the 2-year period preceding trial inclusion. 
Results - Mean age of the 286 study subjects involved was 59.2 (SD 9.6) years, 
postbronchodilator FEV1 67.1% (SD 16.2) of predicted. Following ERS criteria, subjects 
suffered from: no (26%); mild (19%); moderate (40%); or severe (15%) airflow obstruction. 
Overall mean and median annual exacerbation rates were 0.88 (SD 0.79) and 0.5 (IQR 1.0), 
respectively. Eexacerbation rate was not related to severity of airflow obstruction (p=0.628). 
Mean annual exacerbation costs per subject were €40, €53, €61 and €92 for the respective 
severity subgroups (p=0.012). The increase of costs in the more severe subgroups was mainly 
attributable to more physician consultations, diagnostic procedures, and prescription of 
reliever medication (e.g., bronchodilators, cough preparations). 
Conclusion – Occurrence of exacerbations did not depend on the severity of airflow 
obstruction, whereas the healthcare cost associated to exacerbations increased along with the 
severity of the disease. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and 
mortality world-wide(1). In Western countries, the burden of COPD on society is expected to 
increase substantially over the next decades(2;3). Apart from the accelerated decline in lung 
function, an important and characteristic clinical feature of COPD is the occurrence of 
exacerbations, i.e. recurrent episodes of acute deterioration of the disease caused by infectious 
agents or other trigger factors(4). Exacerbations have been shown to contribute substantially 
to the impaired health status observed in patients with COPD(5-7). Moreover, several studies 
suggest that the occurrence of exacerbations may influence the long-term prognosis in terms 
of lung function and health status decline, and survival(8-11). Published reports indicate that 
there may be large variation in the occurrence rate of exacerbations among patients with 
COPD. Estimates range from one to three exacerbations per patient per year(12-18), although 
there is evidence of substantial underreporting by patients(14). Differences in the populations 
studied and the absence of a definition for exacerbations generally agreed upon hampers 
direct comparison of studies. 
Acute exacerbations are responsible for a large proportion of the healthcare cost due to COPD 
and disease severity seems to be the major driver of costs, especially while expenditures for 
physician time, emergency room visits, hospital admissions, oxygen therapy, and nursing 
home stays increase as the disease becomes more severe(19-22). However, most published 
studies have recruited patients in secondary care settings and, consequently, predominantly 
included patients suffering from severe to end-stage COPD. This subgroup of patients, which 
comprise only a relatively small proportion of all patients with COPD in the general 
population, suffer from frequent and severe exacerbations and are responsible for a substantial 
part of the healthcare cost attributable to COPD. Patients with mild to moderate disease, 
which are much larger in number, are typically treated in primary care and are less well 
studied with regard to their exacerbations. 
Therefore, the objectives of the current study were to investigate the occurrence rate and 
management of acute exacerbations in patients with COPD treated in Dutch general practices, 
and to assess the exacerbation related healthcare cost in different stages of severity of airflow 
obstruction. 
 
 
131
Methods 
 
Study subjects and design  
The study consisted of a systematic medical record review over the past 2 years in 286 
subjects with physician-diagnosed COPD recruited from 46 general practices in the 
Netherlands. All subjects participated in the COPD on Primary Care Treatment (COOPT) 
study, a randomised controlled trial evaluating the effectiveness of N-acetylcysteine and 
fluticasone propionate in a primary care COPD population(23). General practitioners (GPs) 
identified subjects with a diagnosis of COPD using existing diagnostic labels and drug 
prescription records. Subjects identified as suffering from COPD were invited for a screening 
visit to the general practice. Subsequently, eligibility for trial participation was verified in a 
certified pulmonary function laboratory. Trial inclusion criteria were: age 35-75 yrs; current 
or ex-smoker; chronic dyspnea, sputum production and cough for at least three consecutive 
months per year during the previous two years(24); either post-bronchodilator (BD) FEV1 
(forced expiratory volume in one second) <90% of the predicted value or post-BD FEV1/FVC 
<88% (89% for women) of the predicted value; no previous treatment for asthma, allergic 
rhinitis or atopic rash; no severe comorbid conditions. Subjects with FEV1 <40% of predicted 
post-BD were excluded. The study was approved by the medical ethics review board of the 
University Medical Centre Nijmegen, the Netherlands. All subjects gave written informed 
consent. 
 
Data collection 
GPs identified all contacts related to acute deterioration of the respiratory condition during the 
two years preceding the date of trial inclusion from the subjects’ medical record using a 
standardised data extraction form. For each study subject the exact time frame was 
individually marked out by providing the GP with the begin and end dates of the observation 
period. Inquired details for each contact were: date, time, and type of contact (office 
consultation, telephone consultation, home visit); changes in respiratory symptoms (i.e., 
increased dyspnea, cough, amount of sputum); objective signs (sputum colour, sputum 
consistency, fever); drugs prescribed (dosage and brand of oral glucocorticoids, antibiotic 
agents, inhaled steroids, bronchodilators, mucolytics, cough preparations); diagnostic tests 
(chest X-rays, pulmonary function tests, sputum cultures, blood tests); referrals to respiratory 
consultants; emergency room visits; and hospital admissions (including length of stay). The 
information on changes in respiratory symptoms as recorded in the GPs files was often 
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incomplete and therefore not used in the current evaluation. Separate contacts pertaining to 
one and the same exacerbation episode were marked as such by the reporting GP. 
Completeness of the reported contacts was verified by one of the investigators in a ten percent 
(n=29) random sample of study subjects. In this sample, completeness of reporting turned out 
to be 100%. 
Spirometry was performed in a pulmonary function laboratory in all subjects following the 
European Respiratory Society (ERS) standards(25). Following the protocol of the subsequent 
clinical trial (23), subjects were categorised according to severity of airflow obstruction using 
criteria issued by the ERS (postbronchodilator FEV1 as percentage of predicted value ≥80%: 
no obstruction; ≥70% and <80%: mild obstruction; ≥50% and <70%: moderate obstruction; 
<50%: severe obstruction)(24). History of cigarette smoking was assessed by standardised 
interview and quantified as the number of packyears smoked. 
 
Cost calculations 
Use of healthcare resources was assessed by counting the number of units consumed. 
Subsequently, units were converted into monetary values. Drug prescriptions were converted 
to costs using the March 2000 table of the Royal Dutch Association for the Advancement of 
Pharmacy and included taxes and pharmacist fee. Cost of diagnostic tests were calculated 
using tariffs published by the Dutch Council of Health Insurances(26;27). Referrals to 
respiratory consultants, emergency visits, and hospital admissions were valued using results 
of a cost investigation from a secondary care population of patients with COPD(28). Cost of 
referrals included the time spent by respiratory consultants and additional diagnostic 
procedures requested by the consultants. Costs were calculated as the cost per exacerbation 
episode as well as the annual exacerbation cost per subject. All cost are expressed in Euro’s 
(€). The year 2001 was taken as the index year for all cost, regardless of the calendar year in 
which an exacerbation had actually occurred. 
 
Analyses 
The SAS statistical software package (version 6.12 for Windows) was used for analysis. 
Differences in baseline characteristics between the categories of obstruction severity were 
analysed using analysis of variance (ANOVA) and χ2 tests. Mean and median annual 
exacerbation rates were calculated for the four categories of obstruction severity and 
compared by ANOVA and Kruskal-Wallis tests. Differences in the occurrence of 
exacerbations by calendar month were analysed by χ2 test. Although the cost data distribution 
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was skewed towards the left, t test based 95 percent confidence intervals (95% CIs) were 
calculated for total cost and separate cost components(29). Differences in exacerbation related 
cost between obstruction severity subgroups were compared using ANOVA. 
 
 
Results 
 
Study population 
Demographic and clinical characteristics of the study population are given in table 1. Age and 
packyears of smoking were highest for the subjects with more severe obstruction (both 
p<0.001), whereas the body mass index (BMI) was lowest in the more severe subgroups 
(p=0.042). Reversibility as percentage of predicted FEV1 ranged from 5.5 (SD 6.2) percent in 
subjects without obstruction to 8.0 (SD 5.8) percent in subjects with moderate obstruction 
(p=0.044). Long-acting bronchodilators and inhaled steroids were more often prescribed in 
the more severely affected subgroups (p=0.003 and p=0.019, respectively). Comorbidity was 
present in 109 (38%) subjects, hypertension being the most prevalent condition (16% of all 
subjects) followed by ischaemic heart disease (15%), atherosclerosis (11%), cardiac 
arrhythmia (6%), and diabetes mellitus (5%). Presence of relevant comorbid conditions did 
not differ between the categories of obstruction severity. 
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Table 1. Demographic and clinical characteristics of the study population (n=286) by severity 
of airflow obstruction* at the end of the 2-yr retrospective observation period. Values are 
means (standard deviation) unless stated otherwise. 
  
No 
obstruction 
 
Mild 
obstruction 
 
Moderate 
obstruction 
 
Severe 
obstruction 
 
Total 
 
p† 
General characteristics       
n (%) 75 (26) 53 (19) 114 (40) 44 (15) 286 (100)  
Age, years 56.6 (9.8) 57.6 (9.6) 59.7 (8.8) 64.3 (9.2) 59.2 (9.6) <0.001 
Males (%) 54 (72) 32 (60) 90 (69) 32 (73) 209 (73) 0.097 
Paid work (%) 32 (43) 15 (28) 36 (32) 6 (14) 89 (31) 0.011 
Current smokers (%) 42 (56) 33 (62) 60 (53) 26 (59) 160 (56) 0.675 
Cigarette smoke exposure, 
Packyears 
25 (14) 24 (14) 29 (20) 37 (17) 28 (17) <0.001 
Body mass index, kg/m2 26.8 (4.5) 27.6 (5.1) 25.8 (3.7) 25.5 (4.6) 26.4 (4.4) 0.042 
Comorbid conditions (%)       
None 53 (71) 31 (58) 73 (64) 20 (45) 177 (62)  
1 12 (20) 12 (23) 24 (21) 15 (34) 66 (23)  
2 or more 7  (9) 10 (19) 17 (15) 9 (21) 43 (15) 0.181 
Medication use       
On inhaled corticosteroids (%) 26 (35) 27 (51) 51 (45) 28 (64) 132 (46) 0.019 
Bronchodilator treatment (%)       
No bronchodilator 30 (40) 10 (19) 24 (21) 5 (11) 69 (24)  
Short-acting  37 (49) 34 (64) 63 (55) 26 (59) 160 (56)  
Long-acting‡ 8 (11) 9 (17) 27 (24) 13 (30) 57 (20) 0.003 
Pulmonary function       
Prebronchodilator FEV1, litres 2.54 (0.56) 2.06 (0.51) 1.61 (0.39) 1.03 (0.26) 1.85 (0.68) <0.001 
as % predicted 81.6 (8.7) 68.1 (7.5) 51.9 (8.8) 36.4 (7.4) 60.3 (17.8) <0.001 
Postbronchodilator FEV1, litres 2.72 (0.55) 2.26 (0.47) 1.85 (0.36) 1.20 (0.24) 2.05 (0.66) <0.001 
as % predicted 87.1 (6.1) 74.9 (3.1) 59.8 (5.6) 42.2 (5.7) 67.1 (16.2) <0.001 
Postbronchodilator FVC, litres 3.95 (0.97) 3.36 (0.85) 3.21 (0.82) 2.45 (0.56) 3.32 (0.96) <0.001 
as % predicted 102.4 (14.5) 90.6 (13.7) 82.7 (14.3) 68.8 (13.0) 87.2 (17.9) <0.001 
Postbronchodilator FEV1/FVC, 
% 
69.9 (7.6) 68.4 (9.1) 59.1 (10.3) 50.4 (11.8) 62.3 (11.9) <0.001 
FEV1 reversibility, %§  5.5 (6.2) 6.8 (8.0) 8.0 (5.8) 5.9 (4.3) 6.8 (6.2) 0.044 
Annual exacerbation rate       
Mean rate 0.75 (0.63) 0.85 (0.76) 0.97 (0.88) 0.89 (0.78) 0.88 (0.79) 0.303 
Median rate (IQR) 0.5 (1.0) 0.5 (0.7) 0.7 (1.0) 0.5 (1.4) 0.5 (1.0) 0.627 
 
* no obstruction: FEV1 >80% of predicted value; mild obstruction: FEV1 70-80% of predicted value; 
moderate obstruction: FEV1 50-69% of predicted value; severe obstruction: FEV1 <50% of predicted 
value(24) 
† p-values indicate significance levels of differences between obstruction severity subgroups 
‡ with or without additional short-acting bronchodilator 
§ difference in FEV1 % predicted between prebronchodilator and postbronchodilator measurement 
IQR = interquartile range 
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Occurrence of exacerbations 
A total of 507 exacerbations comprising 732 GP contacts were reported for the 286 subjects 
studied. In 227 (45%) exacerbations more than one contact with the GP had taken place. The 
number of GP contacts per exacerbation ranged from 1 to 7, with an average of 1.5 (SD 0.91) 
contacts. 220 subjects (77%) experienced at least one exacerbation during the two year period. 
Mean and median annual exacerbation rates did not differ between the severity subgroups 
(table 1). There was a dissimilar distribution in the occurrence of exacerbations throughout 
the year, with the majority of exacerbations reported in the months October through March 
(59% of all exacerbations) and July (χ2 test, p=0.014, figure 1). 
 
Figure 1. Occurrence of exacerbations by calender month in 286 subjects with COPD 
managed in general practice. The solid line represents the overall mean number of 
exacerbations per calender month; the figure above each bar is the proportion of all reported 
exacerbations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Management of exacerbations 
A course of oral corticosteroids was prescribed in 26% of all exacerbations. Within the set of 
all reported exacerbations, the probability of an oral corticosteroid prescription increased 
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roughly along with the severity of obstruction of the subject concerned (no obstruction: 0.18, 
mild: 0.28; moderate: 0.28; severe: 0.32; χ2 test: p=0.040). Forty-seven percent of the 
exacerbations were treated with one or more antibiotic drugs, tetracyclines being the most 
frequently prescribed class of antibiotics (56%), followed by penicillins (27%), macrolides 
(12%), sulfonamides (4%), and quinolones (1%). Unlike oral corticosteroid prescriptions, the 
probability of an antibiotic being prescribed did not increase as obstruction became more 
severe (χ2 test, p=0.747). Hospital admission was reported for only one exacerbation; one 
other exacerbation necessitated an emergency room visit. Spirometry was performed in 173 
(34%) of all exacerbations (94% performed in general practice, 6% in a pulmonary function 
laboratory). Chest radiographs were requested in 63 (12%) exacerbations, sputum cultures in 
3 (1%). Referral to a respiratory consultant was reported for 25 (5%) exacerbations. 
 
Exacerbation related healthcare cost 
Table 2 shows the mean cost per exacerbation and the mean annual exacerbation cost per 
study subject. The total cost per exacerbation aggregated to €66 (95% CI 56, 76). The annual 
cost per subject attributable to exacerbations aggregated to €59 (95% CI 48, 69). Exclusion of 
the hospital admission cost resulted in €62 (95% CI 57, 67) per exacerbation, and €51 (95% 
CI 44, 57) for the annual exacerbation cost. There was no significant association between the 
annual exacerbation cost and age (Spearman: r=0.027, p=0.654) or gender (Mann-Whitney U, 
p=0.492). A consistent tendency towards increasing annual exacerbation cost within the more 
severely obstructed subgroups was observed (figure 2, p=0.024, and p=0.060 with the hospital 
admission cost excluded). The increasing cost were merely due to more GP consultations, 
diagnostic procedures requested, and prescriptions for reliever medication. 
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Table 2. Mean (95% CI) healthcare cost (in Euro’s) for exacerbations, and mean annual cost 
attributable to exacerbations in subjects with COPD. 
  
no of 
units 
Cost per 
exacerbation 
(n=507) 
Annual exacerbation 
cost per subject 
(n=286) 
GP consultations     
Office visits 681   22.6 (21.3, 23.8) 19.9 (17.7, 22.2) 
House calls 35    1.7 (1.0, 2.5)   1.5 (0.8, 2.2) 
Phone consultations 16    0.2 (0.1, 0.3)   0.2 (0.1, 0,3) 
Total GP consultation cost  24 (23, 26) 22 (19, 24) 
 
Drug prescriptions 
   
Antibiotic agents 260    5.7 (5.0, 6.4)   5.0 (4.1, 5.9) 
Oral corticosteroids 149    1.6 (1.4, 1.9)   1.4 (1.1, 1.8) 
Inhaled corticosteroids 106 *   7.1 (5.4, 8.7)   6.1 (4.3, 7.9) 
Bronchodilators 179 †   5.7 (4.6, 6.8)   4.9 (3.7, 6.1) 
Other reliever medication 17    0.4 (0.2, 0.7)   0.4 (0.2, 0.6) 
Total drug prescription cost  20 (18, 23) 18 (15, 21) 
 
Diagnostic procedures 
   
Chest X-rays 63    4.9 (3.7, 6.0)   4.3 (3.2, 5.4) 
Lung function tests 173    5.7 (4.7, 6.8)   5.1 (3.9, 6.3) 
Sputum cultures 3    0.1 (0, 0.2)   0.0 (0.0, 0.1) 
Total diagnostic procedure cost  11 (9, 12)   9 (8, 11) 
 
Secondary care 
   
Consultation of respiratory consultant 25 § 6.0 (3.7, 8.3)   5.3 (3,2, 7.4) 
Emergency room visits 1 ll 0.3    0.6 
Hospital admissions 1 & 4.4   7.8 
Total secondary care cost  11 (2, 20)   10 (2, 17) 
    
Total healthcare cost  66 (56, 76) 59 (48, 69)  
 
 
*  76 (72%) new prescriptions, 30 (28%) increased dosage 
†  130 (73%) new prescriptions, 49 (27%) increased dosage 
§  including cost of diagnostic procedures requested by the consultant 
ll  cost of the ER visit were €161 
&  cost of the hospital admission were €2237  
 
 
Discussion 
In this study we assessed the occurrence of exacerbations in a group of patients with COPD 
treated in Dutch general practice, and estimated the healthcare cost arising from these acute 
episodes. The noticeable observation that hospitalisations, emergency room visits and chest 
physician consultations were exceptional events illustrates the typical primary care nature of 
the patient population studied. The results also indicate that the healthcare cost induced by 
exacerbations of COPD in (Dutch) primary care may depend on the severity of airflow 
obstruction, whereas the occurrence rate of exacerbations itself does not seem to do so. The 
latter observation is in contrast with an earlier COPD study conducted in the Spanish primary 
care setting, in which an association was found between the severity of airflow obstruction 
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Figure 2. Distribution of exacerbation related annual healthcare cost by subgroup of severity 
of airflow obstruction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* p=0.060 with the hospital cost excluded 
† bronchodilators, mucolytics, and cough preparations 
 
 
and the risk of frequent exacerbations(30). On the other hand, our findings are in line with a 
study performed in a UK secondary care setting, in which patients with frequent or infrequent 
exacerbations were indistinguishable in terms of lung function(31). In the current study, the 
patients with more severe obstruction did not so much experience more exacerbations but 
once they suffered from one, the healthcare costs involved were higher than in those with less 
severe obstruction. The higher cost were caused primarily by more consultations, diagnostic 
tests, and prescription of reliever medication (i.e., bronchodilators, mucolytics, cough 
preparations) in the GPs management of exacerbations. A relationship between FEV1 
impairment and increased drug prescription in stable COPD has been reported previously(12), 
but our data suggest that this relationship may also apply to the primary care cost of treating 
acute exacerbations of the disease. 
Studies in patients with COPD treated in secondary care have shown that the treatment cost of 
exacerbations are largely due to hospitalisations, emergency room visits, and domestic 
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oxygen therapy(10;19). Compared to these studies the exacerbation related costs in our study 
were rather low. This is easily explained by the fact that among all 507 reported exacerbations 
only one hospital admission and one emergency room visit had occurred. This further 
demonstrates the typical primary care nature of our study population: in the Netherlands, 
patients treated by GPs generally suffer from less severe disease and, consequently, require 
less intensive medical attention in case of an exacerbation compared to patients treated by 
secondary care chest physicians. The Confronting COPD survey has also demonstrated that 
the rate of unscheduled healthcare contacts is relatively low in the Netherlands(32). 
One of the main reasons for Dutch GPs to refer patients with COPD to a chest physician 
appears to be the occurrence of recurrent or unresolving exacerbations(33). Once a patient 
with COPD has been admitted to hospital because of a (severe) exacerbation, it is rather 
common practice that a chest physician temporarily or permanently takes over the patients’ 
treatment after discharge from hospital. Because patients who were treated by chest 
physicians were less likely to be invited by the GPs for participation in the upcoming trial and 
because patients with FEV1 <40% of predicted were excluded, those with frequent or severe 
exacerbations were probably underrepresented in our study population. 
In order to avoid being forced to choose between existing definitions for exacerbations 
beforehand, we instructed the GPs to report any contact in which study subjects sought 
medical attention because of acute deterioration of their respiratory condition. Because of the 
differing definitions for exacerbation used in the literature(34), direct comparison of the 
exacerbation rate observed in our study with rates reported from previous studies is impeded. 
One method is to use prescriptions for courses of oral corticosteroids and antibiotics as a 
proxy measure for exacerbations(35). However, had we only used this proxy definition in the 
current study, we would have missed a substantial number of exacerbations, as in only a 
quarter of all episodes an oral corticosteroid was prescribed. With addition of antibiotic 
prescriptions to the proxy definition based oral corticosteroid prescriptions alone(13), 59 
percent of all episodes would have been detected. Still, a substantial part (41 percent) of all 
episodes was managed without a course of oral corticosteroids or antibiotics, but merely with 
a -transient- increase of the dosage of inhaled corticosteroids and/or bronchodilators, or 
prescription of other reliever medication (i.e., mucolytics, cough preparations). 
In the Netherlands each inhabitant can only be registered in a single general practice. Because 
of this, it is unlikely that we missed many exacerbations by using GP records as the only data 
source. However, we can only speculate on the number of exacerbations which were ‘self-
managed’ by patients and were therefore not included in the GPs’ medical records. It has been 
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reported that patients with COPD may seek medical attention in only fifty percent of 
exacerbations(14). From a healthcare expenditure perspective these events are irrelevant as 
they do not result in any medical costs. However, the ‘productivity’ cost due to work 
absenteeism or incapacity for work may be relevant in these episodes. Because of the 
retrospective nature of our method for data collection we were not able to include the 
exacerbation related productivity cost in our calculations. 
In conclusion, in the typical primary care population of patients with COPD studied we 
observed that patients with increasing severity of airflow obstruction did not experience more 
frequent, but more expensive exacerbations. The additional costs were mainly due to more 
physician consultations, requested diagnostic tests, and new prescriptions or adjustment of 
existing medication for relieve of respiratory symptoms. Although the probability of an oral 
corticosteroid prescription increased roughly along with the severity of airflow obstruction, a 
substantial number of exacerbations was not treated with either oral corticosteroids or 
antibiotics, which makes this healthcare utilisation based proxy measure a rather unreliable 
instrument for assessing exacerbation occurrence rates in primary care COPD studies. 
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General discussion 
General discussion 
 
The introduction of this thesis provided an inventory of the evidence regarding the efficacy 
(i.e., treatment effects in ideal experimental conditions) and effectiveness (actual treatment 
effect in real life conditions) of several interventions for COPD and asthma as established in 
1997, and assessed the impact of a number of barriers towards optimal delivery of health care. 
Naturally, not all of the areas covered in the introduction could be elaborated on in this thesis. 
The two central topics that were investigated more profoundly in the preceding chapters were 
(I) aspects of utilization of spirometry in general practice; and (II) treatment with inhaled 
corticosteroids in different groups of patients with, or at high risk of chronic respiratory 
disease. These two topics are discussed below in the light of the results of the studies reported 
in this thesis. 
 
I. Utilization of spirometry in general practice 
Although it is obvious that spirometry does not capture the full impact of chronic airways 
disease on patients’ health, it remains the gold standard for diagnosing airflow obstruction and 
monitoring its progression.1 Spirometry is generally considered to be the best standardized and 
most reproducible measurement for this purpose currently available. Equipment is no longer a 
limiting factor for spirometry utilization in general practice, as rather inexpensive and reliable 
electronic spirometers have become available. According to the guidelines of the Dutch 
College of General Practitioners (NHG)2 and professional organisations in the field of 
respiratory care (e.g., the Global Initiative on Obstructive Lung Disease – GOLD1) spirometry 
constitutes an essential tool to determine the presence and severity of airflow obstruction, and 
to distinguish between reversible and irreversible obstruction. The NHG guideline on COPD 
states that “the general practitioner (GP) can test and treat most patients with mild or 
moderately severe COPD, provided that the practice is in the possession of a spirometer and the 
GP is capable of interpreting the results of the lung function test”.3 
The first six chapters of this thesis dealt about different aspects of spirometry utilization in 
general practice. In the literature review reported in Chapter 1 it was concluded that application 
of spirometry in general practice may lead to better differentiation between COPD and asthma, 
which may bring about more adequate treatment targeting and, as a consequence, improved 
health status in patients.4 However, several years after the first chapter was written, there still is 
no firm scientific evidence that supports the presumption that the health of patients is indeed 
improved when GPs consistently apply spirometry while diagnosing and monitoring chronic 
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respiratory disease. Particularly the usefulness of monitoring spirometric indices as a routine 
part of the management of COPD may be exaggerated and has yet to be determined. 
Spirometry as an isolated tool for diagnosing and monitoring is unlikely to have an impact on 
patients’ health if the test results do not entail appropriate modification of the patients’ 
management. Because the treatment options recommended for COPD and asthma more and 
more diverge as new (pharmacological) interventions are introduced (e.g., long-acting 
bronchodilators) and established treatments and health care services are targeted to specific 
subgroups of patients partly on the basis of spirometric indices (e.g., indication for inhaled 
corticosteroids5, referral to secondary care - see Chapter 7), the relevance of broad 
implementation of spirometry in general practice increases. 
If one is willing to accept the proposition that intensified use of spirometry for diagnostics and 
monitoring in primary care is indeed to the benefit of patients or to the efficiency of the health 
care system, one should at the same time be convinced of the feasibility of this type of lung 
function testing in the general practice setting. This point has been - and should remain to be – 
an important point of attention. After all, inadequate spirometric tests are likely to produce 
indices that are either too low (like, for instance, the FEV1) or too high (the FEV1/FVC ratio), 
which may result in false-positive or false-negative diagnoses or in overestimation or 
underestimation of the severity of airflow obstruction. 
Chapter 1 highlighted some essential pre-conditions that should be met in a general practice 
when spirometry is to be implemented adequately. Whether general practice based spirometric 
tests are actually valid was the subject of investigation in the study reported in Chapter 2. In 
this study an effort was made to create the necessary pre-conditions in the involved general 
practices by providing spirometry training for practice staff, dispensing good quality 
spirometers, and arranging regular check-up of and maintenance service for the equipment. 
Contrary to our a priori expectations the results of the study showed that a general practice 
spirometric test was on average not inferior to the same test conducted in a pulmonary function 
laboratory in the same patient when the same procedures and equipment were used. 
Apparently, with sufficient training of those executing the tests the current practice of 
performing spirometry in the general practice setting seems justifiable. This is an important 
observation, which provides a basis for initiatives to intensify the use of spirometers by GPs. 
Chapter 6 elaborated on some alternatives to arrange for spirometry facilities in primary care, 
and discussed the pros and cons of these alternatives. 
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Spirometry quality assurance 
Ongoing spirometry quality standards are difficult to bring into the daily routine of general 
practice. Therefore, one should be aware of the fact that dwindling attention to quality 
assurance is a likely cause of declining quality of spirometric tests in general practice in the 
course of time.6 Even if those who execute the tests have been well trained initially, the 
relatively low rate of tests requested by GPs, the (often) limited number of staff members who 
have been trained to perform spirometry, the (often) limited attention to equipment calibration 
and maintenance, and the lack of any feedback on the quality of test performance are potential 
causes of decline of test quality. 
Whether or not intensified guidance of the execution of tests could prevent the anticipated 
decline, a subanalysis of the study reported in Chapter 2 was performed to explore the effects 
of periodic supervision by lung function technicians on the achievements of general practices 
with regard to their spirometric tests. Intensified supervision and feedback has been shown to 
be effective in clinical trial settings7 and epidemiological studies.8 The results of the 
subanalysis reported in Chapter 4 indicate that even without additional quality assurance 
measures the overall performance of spirometric testing in general practice was quite 
acceptable a year after the initial training program. Nonetheless, periodic educational outreach 
visits did seem to contribute to maintaining the validity of the spirometric tests. Because of the 
labour-intensive nature of outreach visits, alternative options to maintain test validity may be 
more attractive. Making use of the possibilities that present-day spirometry software packages 
have to offer with regard to quality assurance may be an efficient way to keep those responsible 
for the execution of tests focussed on the quality of their work. The results of the small-scale 
study in healthy volunteers reported in Chapter 3 suggest that a simple intervention like 
exposing practice assistants to information from flow-volume curves may already lead to some 
improvement of spirometric test quality. Thus, even if a GP does not use flow-volume curves 
in his or her diagnostic evaluation of patients, the quality of spirometric tests is likely to benefit 
from critical assessment of the curves while executing a test. Therefore, if a general practice 
considers purchasing a spirometer, the device chosen should preferably display a real-time 
flow-volume curve. Another option for guidance of general practice spirometry quality 
assurance would be to receive feedback on tests that are send to a local lung function laboratory 
for judgement by an experienced technician. There are examples of general practices in the 
field that have established such a structure. Arrangements between a general practice and a 
local laboratories also offers the opportunity to institute periodic practice-teaching of nurse 
practitioners and practice assistants, and would also enable regular check-up and calibration of 
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spirometers. There are indications that primary care professionals fail to appreciate the 
importance of calibration, maintenance, and cleaning of spirometric equipment9, especially in 
comparison with the stringent procedures that ought to be employed in lung function 
laboratories.10 Whether this apparent lack of attention towards equipment performance has 
consequences for the reliability of spirometric tests and, ultimately, for patient care in general 
practice is not known. 
 
Implementation of spirometry 
The maximum benefit of spirometry for primary care can only be achieved when GPs 
consistently integrate spirometric testing into their routine for diagnosing and managing 
patients with chronic respiratory disease. The apparent underutilization of spirometry in 
primary care11 is also illustrated by our experience that in a substantial number of subjects who 
are labelled by GPs as having COPD, no lung function testing has ever been carried out.12 In 
these subjects the assignment of the diagnosis COPD is not formally justified, as the presence 
of airflow obstruction has not been demonstrated. The degree to which spirometry is (under-
)utilized is likely to vary from practice to practice and even from GP to GP.13 Implementation 
of spirometry could be enhanced by clearing away barriers that impede GPs to use spirometry. 
The essential first step is to aim for facilities for quality spirometry to be widely available and 
easily accessible: GPs and other primary health care professionals who are involved in the care 
for patients with respiratory disease should have access to spirometry, either for diagnosing and 
severity staging, for periodic monitoring of lung function, or both. It will depend on the local 
circumstances and preferences how spirometry can best be organized for a particular general 
practice: either in the practice itself, by means of centralized services like primary care group 
commissioned services, nurse-run asthma clinics or mobile community-based spirometry 
services, by arranging open access to pulmonary function laboratories, or a combination of 
these options (see Chapter 6). The transcripts of the discussion sessions with pulmonologists on 
which Chapter 7 was based also pointed to the indispensableness of spirometry to support GPs’ 
decisions whether or not to refer a patient to a pulmonologist, and the pulmonologists’ decision 
to pass on the patients’ management back to the GP when this is appropriate. 
If a GP does not want to take up full diagnostic spirometry, he or she should at least consider 
the use of office screening spirometry, an approach that is also known as ‘exclusion 
spirometry’.14;15 A normal result from a (valid) screening test is probably sufficient to exclude 
respiratory impairment, except in asthma. An abnormal outcome of a screening test would 
require verification of the test outcome, or even additional diagnostic lung function testing by 
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using one of the services mentioned above (including a full diagnostic spirometry in the general 
practice itself). Although the diagnostic characteristics of this stepwise approach of using 
spirometry need to be evaluated before it can be recommended, it may be a rather efficient 
mode of applying spirometry in general practice. Screening spirometry can also be used to 
actively detect undiagnosed subjects with COPD in high-risk populations like, for instance, all 
former or current smokers, or smokers above a certain age. Although studies on the effects of 
this ‘case-finding’ approach are emerging16-19, further research is needed to determine which 
combination of subject characteristics constitutes the most predictive and efficient profile to 
detect undiagnosed cases of COPD. Both the ethical and economic aspects of COPD case-
finding in general practice also warrant further research attention. 
Even with good accessibility of services there is no guarantee that GPs will indeed use 
spirometry in all cases in which this would be indicated. Little is known about the reasons why 
GPs choose to use spirometry or to refrain from it, but it is likely that a number of factors may 
play a role. The capability to organize spirometry, the possibility of delegation of tasks by GPs 
to practice assistants or practice nurses, the guaranteed availability of equipment on every 
occasion that it is needed, and lack of time are factors that are likely to be involved.13 Another 
factor which appears to be relevant is that a GP may simply be not convinced that spirometry 
adds relevant information to the usual routine of medical history taking and physical 
examination that he or she is acquainted with.20;21 Lack of self-confidence with regard to the 
interpretation of spirometric tests may also cause GPs to be reluctant to take up spirometry. In 
Chapter 5 of this thesis the achievements of GPs to interpret spirometric tests were investigated 
and although this simulation study does not necessarily reflect what happens in real life, some 
interesting observations were made. The results suggest that by using spirometry GPs may 
reduce their diagnostic uncertainty (or, in other words, narrow their differential diagnosis) but 
may also be inclined to confirm their diagnosis by requesting additional diagnostic testing, or 
by referring the patient to a pulmonologist. Whether remote support by a pulmonologist or by a 
computerized spirometry expert system can prevent this from happening in cases where it is not 
really necessary is currently being investigated in our department. Finally, the health economic 
consequences of enhanced implementation of spirometry in primary care are unclear. The 
question whether the extra costs of performing more spirometric tests in general practice are 
compensated by savings in other domains or by actual health benefits in patients has not been 
answered yet. 
It will take time before all GPs have adopted spirometry as a self-evident part of their 
diagnostic repertory. The time that spirometers are as commonly used in general practices as 
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devices for measuring blood pressure is probably still years ahead of us. Facilitation of this 
development by means of financial and other incentives would be helpful to speed up this 
process. 
 
 
II.  Inhaled steroids in chronic respiratory disease 
 
Asthma 
 
Adherence and asthma self-management 
Inhaled corticosteroids have been available for well over two decades now. For asthma the 
efficacy of these anti-inflammatory drugs has been demonstrated conclusively in the early 
nineties of the past century22-25 and the actual effectiveness has been confirmed in a large 
population based cohort study.26 Although new anti-inflammatory drugs have more recently 
been added to the available modes of therapy (e.g., leukotriene receptor antagonists) inhaled 
steroids still constitute the cornerstone of asthma management and are likely to keep this 
position for a number of years to come. 
In a situation like this, in which a highly effective prophylactic drug is available for a particular 
chronic disease, GPs and other primary care professionals involved should try to optimize the 
actual utilization of these drugs in their practice population. In the case of inhaled steroids this 
can be achieved by neutralizing barriers that impede asthma patients to take maximum benefit 
from this prophylactic treatment, as was touched upon in the Introduction of this thesis. One of 
the barriers appears to be the well established observation that a substantial number of asthma 
patients do not use their inhaled steroids appropriately in terms of treatment adherence,27;28 or 
even quit using their prophylactic medication completely after a while.29-32 Although the 
evidence that this type of conduct actually compromises patients health mainly comes from 
retrospective and case-control studies in patients with rather severe asthma33-35, it is likely that 
non-adherence towards prescribed inhaled steroid treatment does indeed result in – potentially 
avoidable - morbidity. Thus, improving the actual utilization of inhaled steroids from the first 
prescription on in those patients that really need it is generally considered to be one of the main 
points of impact for improving asthma care.36 
A contemporary way to achieve this is to try and involve patients with asthma more closely in 
the management of their disease by equipping them with self-management skills.37 According 
to a recent meta-analysis the evidence on the isolated contribution of written self-management 
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plans in the known beneficial effects of comprehensive asthma care has not been firmly 
established.38 On the other hand, it has also been put forward that the use of individualised 
action plans is a pivotal factor in the success of self-management programs, especially when 
the action points for patients are based on personal best peak expiratory flow (PEF) rates and 
comprise inhaled as well as oral corticosteroid self-treatment of exacerbations.39 
The self-management study reported in Chapters 8 and 9 of this thesis included a written action 
plan that was based on personal best PEF and bronchial symptoms, and showed that the 
implemented self-management program was at least equally effective as the asthma treatment 
usually provided by Dutch GPs. Even while the actual benefit of the intervention of doubling 
the dose of inhaled steroids when asthma control starts to deteriorate has recently been 
questioned40, self-management does seem to improve – or at least maintain - asthma patients’ 
health all the same. Moreover, it has been shown that by including a ‘step-down’ approach for 
the dose of inhaled steroids in the action plan a significant reduction in the use of inhaled 
steroids41 and bronchodilators42 can be achieved without compromising asthma control. (The 
sparing effect on inhaled steroids was also observed in the study reported in Chapters 8 and 9, 
whereas the effect on the use of bronchodilators was not.) The observation that patients 
continue to use self-management skills to one degree or another years after they have acquired 
these skills43 makes the initial investment worthwhile, as the cost of a self-management 
intervention seem to be recovered by savings in years thereafter.44 In the study in patients with 
mild to moderate asthma reported in Chapters 8 and 9 these savings were mainly due to the 
reduced use of inhaled steroids and the lower number of days with restricted activities. In 
patients with more severe asthma – a relatively small group in general practice - savings can 
also be expected in emergency visits and hospital admissions.45;46 
Combined with the argument that the self-management approach fits well in the present-day 
concept that patients should be more autonomous with regard to their treatment 47, the observed 
equivalence of self-management with, or even dominance over usual asthma care should be 
reason enough to facilitate implementation of self-management programs in general practice. 
By doing so, barriers of the constitutive kind (i.e., attitudes of patients and primary care 
professionals)48-50 and organizational kind (i.e., time, money, tools)51 that impede 
implementation can be expected. Practice nurses, a discipline that is increasingly seen in Dutch 
general practices52 and is expected to change usual general practice care for patients with 
chronic (respiratory) disease significantly, can play a central role in the implementation of self-
management interventions for patients with asthma or other chronic diseases. The 2001 asthma 
treatment guidelines of the Dutch College of General Practitioners53 do not yet recommend the 
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use of written self-management action plans, but given the current state of evidence - to which 
the study reported in this thesis contributed – the guideline appears to be outdated on this 
specific point. 
Even so, self-management will not be a suitable approach for all patients with asthma.54 Ideally 
GPs should consider the appropriateness of a self-management intervention for each asthma 
patient in their practice population, but directing self-management to those patients that are 
likely to become successful ‘self-managers’ would be a more efficient and convenient way to 
utilize this type of intervention. Although some work has been done in this area55-57, further 
research is needed to establish the psychological, behavioural and other characteristics that 
discriminate successful from unsuccessful self-managers among the patients with asthma 
treated in general practice. 
Self-management interventions have also been investigated in COPD, but the goals that are 
pursued in COPD patients are quite different than for asthma, as are the points of impact that 
patients have to self-manage their disease. For instance, inhaled steroid dose-adjustment when 
disease control starts to deteriorate is not applicable in COPD, whereas in asthma this is one of 
the core elements of self-management. In COPD self-management the focus is mainly on 
teaching patients how to carry out their physical activities optimally given their physiological 
impairment, and to prevent or decrease the severity of exacerbations through life style 
modification.58 A recent meta-analysis concluded that the current body of literature contains 
insufficient data to give evidence-based recommendations on the efficacy of self-management 
in COPD.59 Further research in this area is needed, particularly to establish the value of self-
management programs for patients with mild to moderate disease, who constitutes the major 
part of all patients with COPD managed in general practice.12 
 
Asthma self-management and combination treatment 
The recent introduction of inhalation devices that contain the combination of an inhaled steroid 
and a long-acting β2-agonist may be an attractive alternative treatment option in patients who 
are not eligible for self-management. Although the final results of several recently finished 
‘landmark’ trials will have to be awaited, evidence is accumulating that ‘single inhaler’ 
combined treatment with an inhaled steroid and a long-acting β2-agonist provides a superior 
level of asthma control in the asthma populations studied.60-63 Although unquestionably more 
convenient for the patient, a combination formulation has the potential to decrease the 
flexibility required to successfully manage asthma over long periods of time.64 Thus, the 
availability of single inhaler treatment requires asthma self-management interventions to be 
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repositioned. After all, the aim of guided self-management is to give patients the ability to 
control their own disease with guidance from a health care professional36, and one of the keys 
to achieve this is to self-regulate the use of respiratory medication to the most adequate (or 
minimal) level that is required at a particular time. This implies that patients should have the 
possibility to be flexible in deciding how much of which drug is required. By using a single 
inhaler that contains two drugs with different treatment targets (inflammation and 
bronchodilation, respectively), this flexibility is no longer practicable because patients can no 
longer vary the dose of the prophylactic compound (the inhaled steroid) without simultaneously 
adjusting the compound for symptom relieve (the long-acting bronchodilator). This seriously 
limits patients’ liberty to self-manage their disease. Because the regular use of a long-acting β2-
agonist in itself already seems to improve the adherence towards inhaled steroid treatment54;65, 
the concern that this adherence will decrease under concomitant use of a long-acting β2-agonist 
appears to be unfounded. Therefore, single inhaler treatment may better be reserved for those 
patients in whom other options – including self-management and the use of separate inhalers 
for administering inhaled steroids and (long-acting) β2-agonists – fail or are inappropriate for 
other reasons, like for instance in case of insufficient and incorrigible perception of asthma 
control, or the presence of important comorbidity. 
 
 
II.B. COPD 
 
Inhaled steroids and exacerbations 
In contrast with asthma, patients with COPD are generally much less responsive to the anti-
inflammatory actions of inhaled steroids. Despite a number of large clinical studies that have 
been conducted in recent years the efficacy of inhaled steroids in COPD has not been 
established quite as unambiguously as in asthma. Two recent meta-analyses of published 
studies have indicated that there may be a small effect of inhaled steroids on the FEV1 decline 
of 5 to 8 millilitres per year66;67, but the clinical relevance of an effect this size remains 
questionable. The study reported in Chapter 10 indicates that initiating regular inhaled steroid 
treatment in an earlier or pre-clinical stage of the disease does not seem to provide a solution as 
well, as the progressive deterioration of lung function and other respiratory health outcomes 
were not beneficially affected. Chapter 11 and 12 presented data from the COPD on Primary 
Care Treatment (COOPT) study, a randomised controlled clinical trial performed by the 
departments of general practice of the University Medical Centre Nijmegen and Maastricht 
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University.68 This particular study aims to evaluate the effectiveness of an inhaled steroid 
(fluticasone propionate 500 microgram b.i.d.) and the anti-oxidative agent N-acetylcysteine 
(600 milligram o.d.) in former or current smokers with mild to moderate COPD or persistent 
symptoms of chronic bronchitis. The COOPT study concludes in 2004 and will provide 
complementary evidence on the position of inhaled steroids and N-acetylcysteine in the 
management of COPD. 
In recent years, investigators involved in the evaluation of pharmacologic and non-
pharmacologic treatment in COPD have shifted their attention from lung function decline as 
the primary outcome of interest to the occurrence of acute exacerbations and changes in health 
status.69 This shift was partly driven by the observation that inhaled fluticasone propionate was 
ineffective in decelerating the annual FEV1 decline, but at the same time was effective in 
preventing acute exacerbations and slowing the deterioration of health status.70 The data on 
exacerbations reported in Chapter 12 show that in patients with COPD or chronic bronchitis 
who are treated in (Dutch) general practice, the annual occurrence rate of exacerbations is 
rather low. With a mean rate of less then one exacerbation per year and a quarter of all patients 
not suffering from a single exacerbation in the 2-year retrospective observation period, the 
room for improvement for any prophylactic treatment seems limited in this patient population. 
On the other hand, it has been reported that many COPD exacerbations are not documented in 
medical records because patients do not necessarily contact their physician in case of 
worsening of their disease.71 This seems unfortunate, because timely intervention does seem to 
improve the course and recovery of exacerbations72, which may subsequently affect the course 
of patients’ health status.73;74 However, exacerbation rate is a difficult outcome to measure in 
clinical studies, especially while proxy definitions based on health care utilization (which are 
quite frequently used) do not seem to be adequate.75 Therefore, better methods to assess the 
occurrence of exacerbations and to express their severity are required.76 
 
Indications for inhaled steroid treatment in COPD 
As was noted in Chapter 7 priority should be given to identifying the (relatively small) group of 
patients with COPD that do benefit from regular inhaled steroid treatment. Current COPD 
management guidelines1;3;77;78 specify criteria for regular inhaled steroid treatment in patients 
with COPD. The table below summarizes the recommendations with regard to inhaled steroid 
treatment in the various guidelines. 
155
Indications for regular inhaled steroid treatment in COPD guidelines 
    
 Guideline Year Indication for regular inhaled steroid treatment 
    
A Global Initiative for 
Chronic Obstructive 
Lung Disease (GOLD)1 
2003 Based on publications appearing since June 2000, the 2003 
Report recommends use of inhaled glucocorticosteroids only 
in patients with severe or very severe (Stages III and IV) 
COPD and frequent exacerbations. 
    
B National Institute for 
Clinical Excellence 
(NICE)77 
2004 Inhaled corticosteroids should be prescribed for patients 
with an FEV1≤ 50% predicted who are having two or more 
exacerbations requiring treatment with antibiotics or oral 
corticosteroids in a 12-month period. 
    
C American Thoracic 
Society (ATS) and 
European Respiratory 
Society (ERS)(3200} 
2004 In patients with more advanced disease (usually classified as 
an FEV1 <50% predicted) there is evidence that the number 
of exacerbations per year and the rate of deterioration in 
health status can be reduced by inhaled corticosteroids in 
COPD. 
… When therapy is thought to be ineffective, a trial of 
withdrawing treatment is reasonable. Some patients will 
exacerbate when this occurs, which is a reason for re-
instituting this therapy. 
    
D Dutch College of 
General Practitioners 
(NHG)3 
2001 History of asthma and/or atopy, non-smoker: continue in 
case of (subjective) effect, discontinue when no effect. 
Frequent exacerbations (≥3 in last winter or year): continue 
in case of improvement (i.e., reduction of number of courses 
of prednisone or antibiotics or hospital admissions for 
COPD); discontinue if no effect. 
    
 
The table shows that the guidelines that have recently been issued by leading respiratory 
professional organisations (A, B, and C) are consistent in recommending that inhaled steroids 
should be prescribed in patients with advanced COPD who experience frequent exacerbations. 
It should be mentioned that For Dutch GPs this would mean that - at the most - one out of 
every five patients with COPD would have an indication for inhaled steroid treatment12, and it 
is quite likely that in many of these cases pulmonologists have already taken over the patients’ 
treatment. Moreover, the clinical studies on which the recommendations in the guidelines are 
based have predominantly included patients with moderate to (very) severe disease. As a 
consequence, the milder side of the COPD severity spectrum has been underexposed while 
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establishing the efficacy of inhaled steroids in terms of prevention of exacerbations and other 
outcomes. 
Still, it is rather unsatisfactory that the severity of airflow obstruction and the past rate of 
exacerbations should determine whether or not a patient with COPD should be prescribed an 
inhaled steroid. The question as to why patients with more severe disease show a treatment 
response and patients with less severe disease do not has not been answered. Apparently, with 
the current state of knowledge it is not possible to give more specific indications based on 
characteristics of the actual inflammatory process underlying the disease in a particular COPD 
patient.79 Meanwhile, the perception among Dutch pulmonologists that the presence of 
bronchial hyperresponsiveness in a COPD patient is a useful criterion to base regular inhaled 
steroid treatment on (see Chapter 7) does not seem to be well-founded. Bronchial 
hyperresponsiveness, which is often considered to be discriminative between asthma and 
COPD, can actually be present in both conditions.80 A 6-month follow-up study in COPD 
patients with bronchial hyperresponsiveness showed that fluticasone did have a positive effect 
on lung function indices compared with placebo, but that the hyperresponsiveness itself was 
not significantly reduced.81 This finding runs parallel with the subgroup analysis of the study 
reported in Chapter 10, in which it was observed that subjects with an accelerated lung function 
decline and bronchial hyperresponsiveness showed an FEV1 response on fluticasone during the 
first few months, but no subsequent modifying effect of continued fluticasone treatment on the 
annual FEV1 decline was observed. Thus, the limited evidence currently available contradicts 
the notion that it is useful to include the presence of bronchial hyperresponsiveness in the 
decision to prescribe inhaled steroid treatment in a particular patient with COPD.  
Despite the lack of effect in terms of bronchial hyperresponsiveness, it has been shown that 
inhaled steroids may affect specific cellular and molecular aspects of the inflammation in the 
airways of patients with COPD. Beneficial effects on the numbers of mast cells, neutrophils 
and macrophages present in the bronchial wall tissue and bronchoalveolar lavage fluid as well 
as on levels of inflammatory mediators have been reported82-86, although other authors have 
produced evidence against an anti-inflammatory action of inhaled steroids in COPD.87 During 
the last decade sputum induction has offered a rather save and noninvasive method to study the 
inflammatory process in the airways of patients with COPD.88 Induced sputum analysis can be 
used to distinguish between asthma and COPD89, and there is some evidence that the absence 
of sputum eosinophilia is associated with steroid resistance.90 Determination of the presence of 
sputum eosinophilia or levels of specific inflammatory mediators may help physicians to 
identify the subgroup of COPD patients who are particularly responsive to inhaled steroid 
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treatment.91 Although the health outcomes of pharmacogenetics - an evolving and promising 
field of research92 - are largely untested, this technology may also have the potential to identify 
inhaled steroid responsive COPD patients. Hopefully, in future guideline revisions it will be 
possible to include a more sophisticated profile of those patients with COPD that are likely to 
benefit from long-term inhaled steroid treatment. 
  
Discontinuation of inhaled steroids  
From the discussion above it follows that regular inhaled steroid treatment is only indicated for 
a limited number of patients with COPD. Interestingly, it has recently been reported that GPs 
and pulmonologists in Belgium prescribe inhaled steroids considerably more often than 
guidelines recommend11, although this finding is not per se generalizable to other countries.93 
Even so, it is not surprising that in the year 2002 a substantial proportion (~60%) of all patients 
with COPD in the Netherlands received inhaled steroids on a regular basis.94 Chapter 11 of this 
thesis presented the results of a study in which inhaled steroid treatment was discontinued in a 
general practice population of patients with COPD and (ex-) smokers with chronic bronchitis. 
In this study 37% of the patients experienced an adverse outcome during the first three months 
after withdrawal, and although the study did not include a control group of patients who 
continued the use of their inhaled steroids, a relapse rate of ~40% has also been reported in 
another uncontrolled study95 and two studies that did include a cross-over control condition96 or 
a parallel control group.97 
Two of the guidelines referred to above provide recommendations on how to deal with 
discontinuation of inhaled steroid treatment in patients with COPD.3;78 In both guidelines a 
‘trial and error’ approach is recommended. As long as the determinants of a long-term inhaled 
steroid treatment response are insufficiently underpinned, such a pragmatic approach - which 
does not necessarily require definite diagnostic labelling of patients– is required. A step-down 
scheme which permits an early check of whether an adverse response to inhaled steroid 
discontinuation is to be expected may be well-advised. Until better indications can be 
formulated to support the discontinuation (or, more importantly, the initiation) of inhaled 
steroid treatment in COPD, educational or other interventions aimed at GPs and 
pulmonologists are needed to reduce the number of patients in which this treatment is 
superfluous. 
 
 
 158
 
References 
 
 
 1.  Global Initiative for Chronic Obstructive Lung Disease (GOLD). www.goldcopd.com. Date accessed: 
July 19 2004.  
 
 2.  Geijer RMM, Thiadens HA, Smeele IJM, Sachs APE, Bottema BJAM, van Hensbergen W et al. [NHG 
Standard COPD and asthma in adults: diagnostics.] Huisarts Wet 2001;44:107-17. 
 3.  Geijer RMM, van Schayck CP, van Weel C, Sachs AP, Bottema BJAM, Smeele IJM et al. [NHG 
Standard COPD: treatment.] Huisarts Wet 2001;44:207-19. 
 4.  Spann SJ. Impact of spirometry on the management of chronic obstructive airway disease. J Fam Pract 
1983;16:271-5. 
 5.  Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate 
on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73. 
 6.  Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in primary care practice: the 
importance of quality assurance and the impact of spirometry workshops. Chest 1999;116:416-23. 
 7.  Enright PL, Johnson LR, Connett JE, Voelker H, Buist AS. Spirometry in the Lung Health Study. 1. 
Methods and quality control. Am Rev Respir Dis 1991;143:1215-23. 
 8.  Upton MN, Ferrell C, Bidwell C, McConnachie A, Goodfellow J, Davey Smith G et al. Improving the 
quality of spirometry in an epidemiological study: The Renfrew-Paisley (Midspan) family study. Public 
Health 2000;114:353-60. 
 9.  Dowson LJ, Yeung A, Allen MB. General practice spirometry in North Staffordshire. Monaldi Arch 
Chest Dis 1999;54:186-8. 
 10.  American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 
1995;152:1107-36. 
 11.  Decramer M, Bartsch P, Pauwels R, Yernault JC. Management of COPD according to guidelines. A 
national survey among Belgian physicians. Monaldi Arch Chest Dis. 2003;59:62-80. 
 12.  Lips EJI, Feenstra TL, Schermer TRJ, Rutten-van Molken MP. Severity distribution of physician-
diagnosed COPD in the Netherlands. Eur Respir J 2003;22 suppl 45:67s. 
 13.  Poels PJP, Schermer TRJ, Jacobs JE, Honigh J, Hartman J, Akkermans RP et al. Determinants for 
implementation of spirometry by Dutch general practitioners. Eur Respir J 2004. 
 14.  Almirall J, Begin P. Exclusion spirometry: an initiative to increase lung function assessment in primary 
care. Can Respir J 2004;11:195-6. 
 15.  Burton MA, Burton DL, Simpson MD, Gissing PM, Bowman SL. Respiratory function testing: The 
impact of respiratory scientists on the training and support of primary health care providers. Respirology 
2004;9:260-4. 
 16.  Van Schayck CP, Loozen JM, Wagena E, Wesseling GJ, Wesseling GJ. Detecting patients at a high risk 
of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding 
study. BMJ 2002;324:1370. 
 17.  Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection 
of COPD in general practice: the DIDASCO Study. Chest 2004;125:1394-9. 
 18.  Zielinski J,.Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. 
Chest 2001;119:731-6. 
159
 19.  Vrijhoef HJ, Diederiks JP, Wesseling GJ, van Schayck CP, Spreeuwenberg C. Undiagnosed patients and 
patients at risk for COPD in primary health care: early detection with the support of non-physicians. J 
Clin Nurs 2003;12:366-73. 
 20.  Choudhury A, Griffiths CJ, Packe GE. Diagnosis of chronic obstructive pulmonary disease (COPD) - are 
guidelines being implemented in primary care. Eur Respir J 2001;18 Suppl 33:347s. 
 21.  O'Dowd LC, Fife D, Tenhave T, Panettieri RA, Jr. Attitudes of physicians toward objective measures of 
airway function in asthma. Am J Med 2003;114:391-6. 
 22.  Haahtela T, Jarvinen E, Kava T, Kiviranta K, Koskinen S, Lehtonen K et al. Comparison of a b2-agonist, 
terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 
1991;325:388-92. 
 23.  Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K et al. Effects of reducing or 
discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5. 
 24.  Sears MR, Taylor DR, Print CG, Lake DC, Herbison GP, Flannery EM. Increased inhaled bronchodilator 
vs increased inhaled corticosteroid in the control of moderate asthma. Chest 1992;102:1709-15. 
 25.  Lorentzson S, Boe J, Eriksson G, Persson G. Use of inhaled corticosteroids in patients with mild asthma. 
Thorax 1990;45:733-5. 
 26.  Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of 
hospitalisation for asthma. Thorax 2002;57:880-4. 
 27.  Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-
agonists with corticosteroids improve compliance? Eur Respir J 1994;7:504-9. 
 28.  Anonymous. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use 
of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 
1996;9:687-95. 
 29.  Ekedahl A,.Mansson N. Unclaimed prescriptions after automated prescription transmittals to pharmacies. 
Pharm World Sci 2004;26:26-31. 
 30.  Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients' problems with new medication for 
chronic conditions. Qual Saf Health Care 2004;13:172-5. 
 31.  Van Staa TP, Cooper C, Leufkens HG, Lammers JW, Suissa S. The use of inhaled corticosteroids in the 
United Kingdom and the Netherlands. Respir Med 2003;97:578-85. 
 32.  Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM. Adherence to prescribed treatment 
for asthma: evidence from pharmacy benefits data. J Asthma 2003;40:93-101. 
 33.  Van Ganse E, Hubloue I, Vincken W, Leufkens HG, Gregoire J, Ernst P. Actual use of inhaled 
corticosteroids and risk of hospitalisation: a case-control study. Eur J Clin Pharmacol 1997;51:449-54. 
 34.  Birkhead G, Attaway NJ, Strunk RC, Townsend MC, Teutsch S. Investigation of a cluster of deaths of 
adolescents from asthma: evidence implicating inadequate treatment and poor patient adherence with 
medications. J Allergy Clin Immunol 1989;84:484-91. 
 35.  Osman LM, Friend JA, Legge JS, Douglas JG. Requests for repeat medication prescriptions and 
frequency of acute episodes in asthma patients. J Asthma 1999;36:449-57. 
 36.  Anonymous. Global strategy for asthma management and prevention revised 2002.  National Institutes of  
Healt, National Heart, Lung, and Blood Institute. NIH Publication No 02-3659. 2002.  
 37.  Lahdensuo A. Guided self management of asthma--how to do it. BMJ 1999;319:759-60. 
 38.  Toelle B, Ram F. Written individualised management plans for asthma in children and adults. Cochrane 
Database Syst Rev 2004;2:CD002171. 
 160
 
 39.  Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. 
Thorax 2004;59:94-9. 
 40.  Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to 
prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363:271-5. 
 41.  Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled 
corticosteroids in asthma: randomised controlled trial. BMJ 2003;326:1115. 
 42.  Harrison TW, Oborne J, Wilding PJ, Tattersfield AE. Randomised placebo controlled trial of beta agonist 
dose reduction in asthma. Thorax 1999;54:98-102. 
 43.  Caplin DL, Creer TL. A self-management program for adult asthma. III. Maintenance and relapse of 
skills. J Asthma 2001;38:343-56. 
 44.  Trautner C, Richter B, Berger M. Cost-effectiveness of a structured treatment and teaching programme 
on asthma. Eur Respir J 1993;6:1485-91. 
 45.  Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P et al. Randomised comparison of 
cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ 
1998;316:1138-9. 
 46.  Osman LM, Calder C, Godden DJ, Friend JA, McKenzie L, Legge JS et al. A randomised trial of self-
management planning for adult patients admitted to hospital with acute asthma. Thorax 2002;57:869-74. 
 47.  Wensing M, Baker R. Patient involvement in general practice care: a pragmatic framework. Eur J Gen 
Pract 2003;9:62-5. 
 48.  Jones A, Pill R, Adams S. Qualitative study of views of health professionals and patients on guided self 
management plans for asthma. BMJ 2000;321:1507-10. 
 49.  Thoonen BPA, Schermer TRJ, Akkermans RP, den Otter JJ, Grol RP, van Schayck CP. Willingness of 
patients to perform self-management of asthma and the role of inhaled steroids. Scan J Prim Health Care 
2002;20:60-4. 
 50.  Barner JC, Mason HL, Murray MD. Assessment of asthma patients' willingness to pay for and give time 
to an asthma self-management program. Clin Ther 1999;21:878-94. 
 51.  Thoonen BPA, Jones KP, van Rooij HA, van den Hout AC, Smeele I, Grol R et al. Self-treatment of 
asthma: possibilities and perspectives from the practitioner's point of view. Fam Pract 1999;16:117-22. 
 52.  Van den Berg M and De Bakker D. [Introduction of practice support on higher vocational level in Dutch 
general practice. Meta-analysis. Utrecht, Netherlands Institute for Health Services Research (NIVEL). 
2003. 
 
 53.  Geijer RMM, van Hensbergen W, Bottema BJAM, van Schayck CP, Sachs APE, Smeele IJM et al. 
[NHG Standard asthma in adults:  Treatment.] Huisarts Wet 2001;44:153-64. 
 54.  Osman LM. How do patients' views about medication affect their self-management in asthma? Patient 
Educ Couns 1997;32:S43-S49. 
 55.  Abdulwadud OA, Abramson MJ, Forbes AB, Walters EH. The relationships between patients' related 
variables in asthma: iplications for asthma management. Respirology 2001;6:105-12. 
 56.  Van der Palen J, Klein JJ, Seydel ER. Are high generalised and asthma-specific self-efficacy predictive 
of adequate self-management behaviour among adult asthma patients? Patient Educ Couns 1997;32:S35-
S41. 
 57.  Geden E, Isaramalai SA, Taylor S. Influences of partners' views of asthma self-management and family 
environment on asthmatic adults' asthma quality of life. Appl Nurs Res 2002;15:217-26. 
161
 58.  Bourbeau J, Nault D, Dang-Tan T. Self-management and behaviour modification in COPD. Patient Educ 
Couns 2004;52:271-7. 
 59.  Monninkhof E, van der Valk P, van der Palen J, van Herwaarden C, Partridge MR, Zielhuis G. Self-
management education for patients with chronic obstructive pulmonary disease: a systematic review. 
Thorax 2003;58:394-8. 
 60.  Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence 
with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J 
Allergy Clin Immunol 2004;113:245-51. 
 61.  Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B et al. Budesonide and formoterol in 
a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults 
with mild-to-moderate asthma. Chest 2003;123:1480-7. 
 62.  Buhl R, Creemers JP, VONDRA V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol 
in a single inhaler in adults with moderate persistent asthma. Respir Med 2003;97:323-30. 
 63.  Kavuru M, Melamed J, Gross G, LaForce C, House K, Prillaman B et al. Salmeterol and fluticasone 
propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, 
double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:1108-16. 
 64.  Bensch G,.Prenner BM. Combination therapy: appropriate for everyone? J Asthma 2003;40:431-44. 
 65.  Van der Woude HJ,.Aalbers R. Compliance with inhaled glucocorticoids and concomitant use of long-
acting beta2-agonists. Respir Med 2001;95:404-7. 
 66.  Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients 
with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003;138:969-73. 
 67.  Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression 
of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003;58:937-41. 
 68.  Chavannes NH, Schermer TRJ, Wouters EF, van Weel C, van Schayck CP. Treatment of COPD in 
general practice: the COOPT study. Eur Respir J 2001;18 Suppl 33:348s. 
 69.  Van Schayck CP. Is lung function really a good parameter in evaluating the long-term effects of inhaled 
corticosteroids in COPD? Eur Respir J 2000;15:238-9. 
 70.  Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind 
placebo controlled study of fluticasone propionate in patiens with moderate to severe chronic obstructive 
pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303. 
 71.  Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of 
exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 
2000;161:1608-13. 
 72.  Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves 
outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 
2004;169:1298-303. 
 73.  Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of 
health status in COPD. Eur Respir J 2004;23:698-702. 
 74.  Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F et al. Effect of exacerbations on 
quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 
2004;59:387-95. 
 75.  Burge S,.Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 
2003;41:46s-53s. 
 162
 
 76.  Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E et al. COPD exacerbations: the 
importance of a standard definition. Respir Med 2004;98:99-107. 
 77.  National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national 
clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and 
secondary care. Thorax 2004;59 (Suppl I). 
 78.  American Thoracic Society, European Respiratory Society. Standards for the diagnosis and management 
of patients with COPD. http://www.ersnet.org. Date accessed: July 19 2004.  
 
 79.  Dekhuijzen PN. [Inhaled corticosteroids for COPD]. Ned Tijdschr Geneeskd 2003;147:1398-404. 
 80.  Grootendorst DC, Rabe KF. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive 
pulmonary disease. Proc Am Thorac Soc 2004;1:77-87. 
 81.  Verhoeven GT, Hegmans JPJJ, Mulder PGH, Bogaard JM, Hoogsteden HC, Prins JB. Effects of 
fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002;57:694-700. 
 82.  Hattotuwa HL, Gizycki MJ, Ansari TW, Jeffery BK, Barnes NC. The effects of inhaled fluticasone on 
airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy 
study. Am J Respir Crit Care Med 2002;165:1579-80. 
 83.  Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory 
cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57:799-803. 
 84.  Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghe B et al. Inhaled corticosteroids 
reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. 
Thorax 1998;53:583-5. 
 85.  Balbi B, Majori M, Bertacco S, Convertino G, Cuomo A, Donner CF et al. Inhaled corticosteroids in 
stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? 
Chest 2000;117:1633-7. 
 86.  Yildiz F, Kaur AC, Ilgazli A, Celikoglu M, Kacar OS, Paksoy N et al. Inhaled corticosteroids may reduce 
neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 
2000;67:71-6. 
 87.  Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled 
steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med 1999;160:1635-9. 
 88.  Vlachos-Mayer H, Leigh R, Sharon RF, Hussack P, Hargreave FE. Success and safety of sputum 
induction in the clinical setting. Eur Respir J 2000;16:997-1000. 
 89.  Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-
alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J 
Respir Crit Care Med 1996;153:530-4. 
 90.  Hargreave FE,.Leigh R. Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med 1999;160:S53-S57. 
 91.  Brightling CE, Monteiro W, Ward R, Parker D, Morgan MDL, Wardlaw AJ et al. Sputum eosinophilia 
and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised 
controlled trial. Lancet 2000;356:1480-5. 
 92.  Haga SB,.Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA 2004;291:2869-
71. 
 93.  Rudolf M. The reality of drug use in COPD: the European perspective. Chest 2000;117:29S-32S. 
 94.  Herings RMC. [More asthma and COPD; better treated]. Pharm Weekbl 2002;137:17-9. 
163
 95.  Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid 
withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161-6. 
 96.  O'Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M et al. Effects of withdrawal 
of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 
2001;164:365-71. 
 97.  Van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation 
of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J 
Respir Crit Care Med 2002;166:1358-63. 
 
 
 164
 
Summary 
Summary 
 
The introduction gives a summary of a comprehensive literature review on the efficacy and 
effectiveness of health care interventions for COPD (chronic obstructive pulmonary disease) 
and asthma. Barriers associated with the primary process of care delivery were also identified. 
These barriers comprised, among others, delayed contact of patients with the health care 
system, diagnosis of the respiratory condition, indications for pharmacological and non-
pharmacological interventions, the actual execution of care and treatment compliance by 
patients. The literature review was performed as a part of the 1997 Public Health Status and 
Forecasts (PHSF) project enforced by the National Institute of Public Health and the 
Environment (RIVM). 
 
In Chapter 1 the need for widespread use of spirometry in primary healthcare is appraised 
through a more specific literature review. The added value of spirometry for and the quality of 
measurements made by general practitioners (GPs), and the economic consequences of 
intensified use of spirometry in primary care are discussed. Appropriate application of 
spirometry in general practice may lead to improved health status of patients with COPD or 
asthma, but consistent attention to quality assurance measures is vital. If good quality cannot 
be guaranteed in the general practice setting, the reliability and validity of the tests is 
uncertain. Pulmonary function laboratories, nurse-run asthma clinics, primary care group 
commissioned and mobile community-based spirometry services may be other choices, but it 
depends on local availability as to which choice is most suitable for organising primary care 
spirometry. 
 
The aim of the study reported in Chapter 2 was to investigate the validity of spirometric tests 
performed in general practice. A within-subject comparison of spirometric tests with a ‘gold 
standard’ (spirometric tests performed in a pulmonary function laboratory) was performed in 
388 patients with COPD. GPs and practice assistants took part in a baseline spirometry 
workshop. Within subject differences in forced expiratory volume in 1 second (FEV1) and 
forced vital capacity (FVC) between laboratory and general practice tests were determined. 
Relevant spirometric indices measured by trained general practice staff were marginally but 
statistically significantly higher than those measured in pulmonary function laboratories, 
indicating consistently higher values for general practice measurements. The proportion of 
non-reproducible tests was very similar for the laboratory and general practice tests. Because 
of the limited agreement between laboratory and general practice values the use of these 
measurements interchangeably is probably better avoided, but with sufficient training of 
practice staff the current practice of performing spirometric tests in the general practice 
setting seems justifiable. 
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The study reported in Chapter 3 was performed to explore the effect of periodic educational 
outreach visits by lung function technicians on the validity of general practice spirometry in 
patients with COPD.  ‘Intervention group’ practices were periodically visited by a lung 
function technician, who focussed on optimization of spirometric test performance. 
‘Reference group’ practices were not visited. A baseline spirometry workshop was offered to 
both groups of practices. Outcomes were the within-subject differences in forced expiratory 
volume in 1 second (∆FEV1) and forced vital capacity (∆FVC) between laboratory and 
general practice tests (practice minus laboratory value). Intervention and reference group 
practices differed in number and age of practice assistants and GPs’ attendance at the baseline 
spirometry workshops. In the first year evaluation the mean ∆FEV1 and ∆FVC favoured the 
general practice tests in both groups. A year later, ∆FEV1 and ∆FVC were higher in 
intervention group patients compared to reference group patients. Although initially the 
validity of spirometric tests was sufficient in the intervention as well as reference group 
practices, periodic educational outreach visits by lung function technicians seemed to prevent 
regression of test validity over time, especially in terms of FVC values. 
 
In Chapter 4 it was investigated whether the use of feedback information provided by 
flow/volume curves during spirometry as performed by practice assistants improves 
spirometry test quality. To address this issue, a randomised controlled crossover study was 
performed in which general practice assistants performed spirometry in healthy volunteers in 
two different measurement conditions, one allowing viewing flow/volume curves during the 
tests (‘unblinded’), the other not (‘blinded’). Outcomes were differences in the most relevant 
spirometric indices and the repeatability and number of manoeuvres per test. Higher PEF 
(peak expiratory flow) values were observed for the unblinded condition, but the other 
outcomes (i.e., FEV1, FVC, FEV1/FVC) showed no differences. Two lung function 
technicians judged that the flow/volume curves obtained in the unblinded condition were 
somewhat better. This study in healthy subjects suggests that the use of information from 
flow/volume curves leads to a modest quality improvement of spirometric tests performed by 
practice assistants. 
 
The aim of the study reported in Chapter 5 was to compare the achievements of trained GPs 
in spirometric diagnosis with an expert consensus panel, and to assess the influence of 
spirometry on the GPs decision-making. Twelve paper cases including a range of 
flow/volume curves were interpreted by 39 GPs as well as a by an expert panel. The results 
showed that normal curves and obstructive curves were reasonably well diagnosed, while rare 
and mixed disease patterns achieved considerably lower scores. Intermediate scores were 
obtained in the recognition of incorrect test manoeuvres. Spirometry influenced GPs decision-
making in reducing the number of alternative diagnoses, but also increased referral rates to 
pulmonologists as well as the use of diagnostic predniso(lo)ne courses considerably. Trained 
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GPs were able to differentiate between normal and obstructive disease patterns, while curves 
suggestive of rare and mixed pathology were often missed. Spirometry also seems to 
influence the decision-making process of the GP. 
 
Chapter 6 is an editorial on the annual World COPD Day which has been instituted by the 
Global Initiative for Chronic Lung Disease (GOLD). On this particular day people worldwide 
are encouraged to review their respiratory health status and consult a doctor in case of certain 
symptoms, especially when they are smokers. Spirometry would be regarded as an integral 
component of this consultation. Thus, a likely and desirable outcome of World COPD Day 
could be a considerable and perhaps dramatic increase in demand for spirometry. An essential 
requirement would seem to be the development of high quality spirometry by family 
physicians on a large scale. World COPD Day aims to promote public awareness of COPD, 
and it is to be hoped that early diagnosis of COPD will facilitate the prevention of further 
damage to the airways and lungs, predominantly by focusing on smoking cessation. Thus, 
spirometry, in conjunction with a commitment to smoking cessation initiatives, has the 
potential to impact significantly on global health. However, its true potential will only be 
achieved by ensuring that quality spirometry is widely available in primary care. 
 
In Chapter 7 the prevailing views of pulmonologists regarding referral and consultation in 
asthma and COPD are explored and compared with published referral guidelines for GPs and 
pulmonologists. Twenty-nine Dutch pulmonologists working at non-university hospitals or 
specialised chest clinics participated in group discussion sessions. The outcome of the 
discussions and the published referral guidelines for GPs and pulmonologists showed 
considerable similarity, but also some marked discrepancies. The main points of disagreement 
among the pulmonologists were: 1) should GPs or pulmonologists add long-acting 
bronchodilators (β2-agonists) to asthma treatment regimens; 2) should the current cut-off 
point for severity of airflow obstruction (‘predicted FEV1 <50%’) for referral of patients with 
COPD be increased; and 3) should an annual exacerbation rate of two episodes a year be used 
as an undifferentiated referral criterion for COPD patients? For asthma, proposed back-
referral (i.e. from pulmonologist to GP) criteria rested on: required dose of inhaled steroids, 
persistent need for long-acting β2-agonists, duration of clinical stability and persistence of 
airflow obstruction. Back-referral criteria for COPD rested on age, blood-gas abnormalities 
and ventilatory limitations. Primary care monitoring facilities and ‘shared-care’ constructions 
were considered to be facilitating conditions for back-referral. Overall, this explorative study 
provided insights into how pulmonologists visualise a rational referral policy for patients with 
asthma or COPD. These insights can be included in future revisions of guidelines for GPs and 
pulmonologists. 
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In Chapter 8 a study to determine the effectiveness of asthma self-management in general 
practice is reported. Nineteen general practices were randomly allocated to usual care or self-
management and 214 adult asthma patients were included in the study. In the two year follow-
up the proportion of successfully treated weeks per patient in the usual care group was 72% 
compared with 78% in the self-management group. The mean number of limited activity days 
was 1.2 in the self-management group and 3.9 in the usual care group. Lung function indices 
(i.e., FEV1, reversibility) and bronchial hyperresponsiveness did not change. There was a 
saving of 217 puffs of inhaled steroid per patient in favour of the SM group. It was concluded 
that self-management lowers the burden of illness as perceived by patients with asthma and is 
at least as effective as the treatment usually provided in Dutch primary care. Moreover, self-
management appears to be a safe basis for intermittent treatment with inhaled corticosteroids 
in patients with asthma. 
 
Chapter 9 describes an extensive economic evaluation of the asthma self-management study 
reported in Chapter 8. We hypothesized that introducing self-management would not 
compromise asthma control while the cost would be equal to or lower than in usual care. 
Patient-specific cost data were collected, health preferences were assessed, and incremental 
cost per quality-adjusted life year (QALY) and per successfully treated week gained were 
calculated. Self-management patients gained more QALYs and experienced more 
successfully treated weeks during the 2-year observation period. Self-management patients 
consumed less puffs of budesonide compared to usual care patients. The productivity cost due 
to limited activity days were lower among self-management patients. When all costs were 
included, self-management was cost-effective on all outcomes studied. Thus, guided self-
management is a safe and efficient alternative approach compared with asthma treatment 
usually provided in Dutch primary care. 
 
In Chapter 10 the clinical effects of early introduction of inhaled corticosteroids (fluticasone 
propionate) in subjects showing early signs and symptoms of COPD without a prior clinical 
diagnosis were investigated in a randomised clinical trial. Subjects with an accelerated annual 
lung function decline and persistent respiratory symptoms were detected in a general 
population screening and monitoring program. Forty-eight subjects were randomized (24 
fluticasone, 24 placebo). After 3 months, the forced expiratory volume in 1 second (FEV1) 
before and after administration of a bronchodilator had increased in the fluticasone relative to 
the placebo group. However, the subsequent decline of the FEV1 was not beneficially 
modified by fluticasone treatment. There were no differences in respiratory symptoms, 
functional status, or exacerbations favouring fluticasone treatment. The presence of bronchial 
hyperresponsiveness modified the initial FEV1 response on fluticasone, but not the subsequent 
annual FEV1 decline. Early initiation of inhaled steroid treatment does not seem to affect the 
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progressive deterioration of lung function or other respiratory health outcomes in subjects 
with early signs and symptoms of COPD. 
 
The objective of the study reported in Chapter 11 was to assess the probability and explore 
determinants of an adverse respiratory outcome (exacerbation or increase of respiratory 
symptoms) after discontinuation of inhaled corticosteroid (ICS) treatment in patients with 
COPD. A prospective unblinded ICS withdrawal study was performed in 201 patients with 
COPD with various degrees of airflow limitation who were diagnosed and treated in general 
practice. The overall probability of an adverse respiratory outcome within three months after 
ICS discontinuation was 0.37. Age, gender, smoking status and reversibility of airflow 
limitation were predictors of adverse respiratory outcome. It was concluded that 
discontinuation of inhaled corticosteroids may harm some patients with COPD. The 
probability of an adverse respiratory outcome may be higher in women, elderly patients, 
smokers and patients with higher bronchodilator reversibility while on inhaled steroid 
treatment. 
 
Chapter 12 reports on the occurrence rate, treatment, and healthcare costs of exacerbations in 
patients with COPD in Dutch general practice. The baseline data from the COPD on Primary 
Care Treatment (COOPT) trial were used. Details on the occurrence and management of 
exacerbations were collected by systematic medical record review for the 2-year period 
preceding trial inclusion. Following international criteria, subjects had chronic bronchitis 
without obstruction (26%), mild airflow obstruction (19%), moderate obstruction (40%) or 
severe obstruction (15%). The overall mean annual exacerbation rates was 0.88. Exacerbation 
rate was not related to severity of airflow obstruction. The mean annual exacerbation costs per 
patient were €40, €53, €61 and €92 for the respective severity subgroups. The increase of 
costs in the more severe subgroups was mainly attributable to more physician consultations, 
diagnostic procedures, and prescription of reliever medication (e.g., bronchodilators, cough 
preparations). It was concluded that in a general practice population of patients with COPD 
the occurrence of exacerbations does not depend on the severity of airflow obstruction, 
whereas the healthcare cost associated to exacerbations increase along with the severity of 
airflow obstruction. 
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Samenvatting 
Samenvatting 
 
De Introductie geeft een samenvatting van een uitgebreide literatuurstudie naar de 
werkzaamheid en doeltreffendheid van zorginterventies bij patiënten met chronic obstructive 
pulmonary disease (COPD, of ‘chronisch obstructief longlijden) en astma. Tevens werden 
barrières in het primaire proces van zorgverlening geïdentificeerd. Deze barrières omvatten 
onder andere verlaat contact van patiënten met het zorgsysteem, de diagnostiek van 
chronische luchtwegaandoeningen, indicatiestelling voor medicamenteuze en niet-
medicamenteuze interventies, de feitelijke uitvoering van zorg en de therapietrouw van 
patiënten. De literatuurstudie was onderdeel van de Volksgezondheid Toekomst Verkenning 
1997, uitgevoerd door het Rijksinstituut voor Volksgezondheid en Milieu (RIVM). 
 
Aan de hand van een andere literatuurstudie wordt in Hoofdstuk 1 de behoefte van brede 
toepassing van spirometrie in de eerstelijns gezondheidszorg belicht. Spirometrie wordt steeds 
meer toegepast in huisartspraktijken en biedt daar een meerwaarde bij vooral de (vroeg-
)detectie en behandeling van obstructieve longaandoeningen. De betrouwbaarheid van 
spirometrie verricht in de huisartspraktijk is minder gegarandeerd dan in longfunctie- of 
huisartsenlaboratoria, waardoor spirometrie in eigen beheer van de huisarts minder geschikt 
lijkt voor het monitoren van het longfunctiebeloop. Spirometrie kan wel een waardevol en 
haalbaar instrument zijn voor huisartsen, onder voorwaarde dat de uitkomsten adequaat 
geïntegreerd worden in het huisartsgeneeskundig denken en handelen. De economische 
consequenties van wijdverspreide toepassing van spirometrie in de huisartspraktijk zijn 
vooralsnog onduidelijk. Als een huisartspraktijk de kwaliteitsbewaking onvoldoende kan 
garanderen, kunnen longfunctie- en huisartsenlaboratoria een belangrijke plaatsvervangende 
of ondersteunende rol spelen. 
 
Het doel van de studie in Hoofdstuk 2 was de betrouwbaarheid van spirometrietests zoals 
uitgevoerd in Nederlandse huisartspraktijken nader te bepalen. Hiertoe werden van 388 
patiënten met COPD uit 61 huisartspraktijken de spirometrietests uit de huisartspraktijken 
vergeleken met de bestaande ‘standaardtest’: een spirometrietest verricht in een 
longfunctielaboratorium. Voor aanvang van het onderzoek volgden huisartsen en 
praktijkassistenten een spirometriecursus. Binnenpersoonsverschillen tussen laboratorium- en 
huisartspraktijktests in het geforceerde expiratoire volume in 1 seconde (∆FEV1) en de 
geforceerde vitale capaciteit (∆FVC) werden per patiënt berekend als effectmaten. Uit de 
resultaten bleek dat de meetwaarden uit  huisartspraktijken consistent hoger waren en dat het 
percentage niet-reproduceerbare tests, een kwaliteitsindicator, niet verschilde tussen de 
laboratorium- en huisartspraktijktests. De conclusie van het onderzoek luidde dat relevante 
spirometrische meetwaarden door getrainde medewerkers in huisartspraktijken bepaald, 
marginaal (maar wel statistisch significant) hoger waren dan dezelfde waarden gemeten in een 
 172
 
longfunctielaboratorium. Vanwege de beperkte overeenstemming tussen de 
spirometrieuitslagen uit laboratoria en huisartspraktijken kan het afwisselend gebruik van 
metingen uit deze verschillende locaties beter worden vermeden. De resultaten van dit 
onderzoek lijken een ondersteuning voor de inmiddels wijdverspreide ontwikkeling om 
spirometrie in eigen beheer van de huisartspraktijk uit te voeren. 
 
In Hoofdstuk 3 wordt het effect van periodieke begeleidingsbezoeken door een 
longfunctielaborant op de betrouwbaarheid van spirometrietests bij COPD-patiënten in de 
huisartspraktijk bestudeerd. Praktijken in een ‘interventiegroep’ werden periodiek bezocht 
door een longfunctielaborant die zich richtte op het optimaliseren van de uitvoering van 
spirometrietests. Praktijken in een ‘referentiegroep’ werden niet bezocht. Huisartsen en 
praktijkassistenten uit beide groepen praktijken kregen vooraf een spirometrietraining 
aangeboden. Binnenpersoonsverschillen tussen laboratorium- en huisartspraktijktests in het 
geforceerde expiratoire volume in 1 seconde (∆FEV1) en de geforceerde vitale capaciteit 
(∆FVC) werden per patiënt berekend als effectmaten en vergeleken tussen de interventie- en 
referentiegroepen. In een aantal opzichten (bijv. aantal en leeftijd van praktijkassistenten, 
bijwonen van de spirometrienascholing) waren de praktijken in de interventie- en 
referentiegroepen niet volledig met elkaar vergelijkbaar. In het eerste jaar van de evaluatie 
vielen de effectmaten (∆FEV1 en ∆FVC) in beide groepen ten gunste van de 
huisartspraktijken uit. Een jaar later waren de effectmaten echter beter in de interventiegroep 
dan in referentiegroep. Geconcludeerd werd dat - hoewel de betrouwbaarheid van de 
spirometrietests feitelijk toereikend was in beide groepen praktijken -  periodieke begeleiding 
door een longfunctielaborant een terugval in de betrouwbaarheid van spirometrietests in de 
loop der tijd mogelijk kan voorkomen. 
 
In Hoofdstuk 4 werd onderzocht in hoeverre het gebruik van informatie die tijdens de 
uitvoering van spirometrietests voortkomt uit flow/volume curven de kwaliteit van door 
doktersassistenten uitgevoerde tests ten goede komt. Om dit te onderzoeken werd een 
gerandomiseerd, gecontroleerd experiment verricht. Daarin verrichten 
huisartspraktijkassistenten bij gezonde proefpersonen spirometrie onder twee verschillende 
meetcondities. Bij de ene conditie was de flow/volume curve zichtbaar tijdens de test 
(‘ongeblindeerd’), bij de andere conditie niet (‘geblindeerd’). Effectmaten waren de 
verschillen tussen de twee condities in de belangrijkste meetwaarden uit spirometrie, de 
reproduceerbaarheid van tests en het aantal blaaspogingen per test. Onder ongeblindeerde 
omstandigheden werden hogere piekstroomwaarden (PEF) gemeten; voor de overige 
effectmaten (d.w.z. FEV1, FVC, en FEV1/FVC) werden géén verschillen gevonden. Twee 
longfunctielaboranten oordeelden dat de flow/volume curven die waren verkregen onder de 
ongeblindeerde omstandigheden iets vaker van betere kwaliteit waren. Deze studie bij 
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gezonde proefpersonen duidt erop dat het gebruik van informatie uit flow/volume curven leidt 
tot enige kwaliteitsverbetering bij spirometrietests zoals uitgevoerd door doktersassistenten. 
 
Het doel van het in Hoofdstuk 5 beschreven onderzoek was om de prestaties van huisartsen 
bij het diagnosticeren en interpreteren van spirometrie te vergelijken met de interpretatie van 
een panel van deskundigen en de invloed van spirometrie op het proces van besluitvorming 
van huisartsen vast te stellen. Twaalf ‘papieren’ casus, die een variëteit aan flow/volume 
curven omvatten, werden door 39 huisartsen beoordeeld; onafhankelijk daarvan deed het 
deskundigenpanel hetzelfde. De resultaten lieten zien dat normale curven en obstructieve 
afwijkingen redelijk goed door de huisartsen werden herkend, terwijl dat bij minder 
voorkomende en gemengde ziektebeelden veel minder het geval was. Redelijke prestaties 
werden gevonden voor het herkennen van slecht uitgevoerde spirometrietests. Spirometrie 
beïnvloedde het beslisproces van huisartsen, wat tot uiting kwam in een afname van het aantal 
alternatieve diagnosen, een aanzienlijke stijging van het aantal verwijzingen naar longartsen 
en het gebruik van diagnostische prednisontests. Geconcludeerd werd dat in spirometrie 
nageschoolde huisartsen goed in staat bleken te differentiëren tussen normale curven en 
obstructieve afwijkingen, terwijl curven die passen bij weinig voorkomende of gemengd 
ziektebeelden relatief vaak verkeerd werden beoordeeld. Spirometrie leek tevens invloed te 
hebben het beslisproces van huisartsen in termen van verwijzing en aanvullende diagnostiek. 
 
Hoofdstuk 6 betreft een redactioneel artikel over de World COPD Day (‘Wereld COPD 
Dag’), die is uitgeroepen door de Global Initiative for Chronic Lung Disease (GOLD). Op 
deze jaarlijks terugkerende dag worden mensen wereldwijd aangemoedigd om aandacht te 
schenken aan de toestand van hun longen en luchtwegen en om bij bepaalde symptomen een 
arts te consulteren, vooral wanneer zij (nog) roken. Spirometrie maakt vervolgens integraal 
onderdeel uit van zo’n consult. De - wenselijke - uitkomst van World COPD Day is derhalve 
een substantiële toename in de vraag naar spirometrie. Een essentiële voorwaarde daarbij is 
dat er op grote schaal hoogwaardige spirometriefaciliteiten voor huisartsen beschikbaar zijn. 
‘Wereld COPD Dag’ richt zich op het stimuleren van de publieke aandacht voor COPD, 
waarmee mogelijk door vroege herkenning en diagnostiek van COPD verdere schade aan de 
longen en luchtwegen kan worden voorkomen. In combinatie met een verhoogde aandacht 
voor stop-roken initiatieven heeft spirometrie de potentie om een forse impact te hebben op de 
volksgezondheid van de wereldbevolking. Dit streven kan echter alleen worden gerealiseerd 
indien er voldoende kwalitatief goede spirometriefaciliteiten voor de eerste lijn beschikbaar 
zijn. 
 
In Hoofdstuk 7 werden de visies van longartsen op verwijzing en consultatie bij astma- en 
COPD-patiënten verkend en vergeleken met gepubliceerde transmurale richtlijnen voor huis- 
en longartsen. Negenentwintig Nederlandse longartsen uit niet-academische ziekenhuizen en 
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gespecialiseerde longrevalidatiecentra namen deel aan groepsdiscussies. De uitkomsten van 
de discussies en de gepubliceerde richtlijnen ten aanzien van verwijzing lieten duidelijke 
overlap zien, maar ook enkele duidelijke discrepanties. De belangrijkste verschillen in 
inzichten tussen de longartsen onderling waren: 1) moet de huisarts of de longarts een 
langwerkende luchtwegverwijder (β2-agonist) toevoegen aan het behandelbeleid bij astma; 2) 
moet het huidige afkappunt voor de ernst van luchtwegobstructie (‘voorspelde FEV1<50%’) 
voor verwijzing van patiënten met COPD omhoog worden bijgesteld; en 3) moet een 
exacerbatiefrequentie van twee per jaar wel als een ongedifferentieerd verwijscriterium 
gelden bij patiënten met COPD? Voor terugverwijzing van astmapatiënten door de longarts 
naar de huisarts werden als criteria voorgesteld: de benodigde onderhoudsdosering 
inhalatiesteroïden; een aanhoudende noodzaak voor gebruik van langwerkende β2-agonisten; 
duur van de periode waarin een patiënt ‘klinisch stabiel’ is; en het bestaan van een 
persisterende luchtwegobstructie. Als criteria voor terugverwijzing bij COPD werden 
genoemd: leeftijd, afwijkende bloedgaswaarden en ventilatoire beperkingen. Faciliteiten voor 
monitoring in de eerste lijn en het bestaan van ‘shared-care’ constructies werden door de 
longartsen beschouwd als omstandigheden die terugverwijzing van patiënten naar de huisarts 
zouden bevorderen. Deze exploratieve studie verschafte inzicht in hoe longartsen aankijken 
tegen een rationeel verwijsbeleid bij patiënten met astma of COPD. Deze inzichten kunnen 
worden betrokken in toekomstige revisies van richtlijnen voor huis- en longartsen. 
 
Hoofdstuk 8 betreft de evaluatie van een gerandomiseerde studie naar de effectiviteit van een 
zelfmanagementprogramma voor patiënten met astma in de huisartspraktijk. Negentien 
huisartspraktijken verstrekten ofwel ‘gebruikelijke huisartsenzorg’, ofwel ‘zelfmanagement’. 
In totaal namen 214 volwassen astmapatiënten deel aan de studie. Tijdens de 
observatieperiode van twee jaar bedroeg het gemiddelde percentage ‘succesvol behandelde 
weken’ per patiënt 72% in de groep die gebruikelijk zorg ontving; in de zelfmanagementgroep 
was dit 78%. Het aantal dagen waarop patiënten beperkingen in hun dagelijkse activiteiten 
ondervonden was gemiddeld 1,2 bij zelfmanagement en 3,9 bij gebruikelijke zorg. 
Longfunctiewaarden (d.w.z. FEV1, reversibiliteit) en bronchiale hyperreactiviteit veranderden 
niet. De conclusie luidde dat zelfmanagement tenminste even effectief was als de 
gebruikelijke behandeling van astma die in de eerstelijns gezondheidszorg wordt verstrekt. 
Zelfmanagement lijkt daarmee voor patiënten met astma een veilige basis te zijn voor 
intermitterende behandeling met inhalatiecorticosteroïden. 
 
Hoofdstuk 9 beschrijft een uitgebreide economische evaluatie van het 
zelfmanagementprogramma voor astmapatiënten dat ook onderwerp van studie was in 
Hoofdstuk 8. De hypothese vooraf was dat het introduceren van zelfmanagement niet ten 
koste zou gaan van de mate van astmacontrole, terwijl de kosten gelijk of lager zouden zijn 
dan bij gebruikelijke zorg. Er werden onder meer patiëntspecifieke kostengegevens verzameld 
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en gezondheidsvoorkeuren gemeten. De meerkosten per gewonnen quality-adjusted life year 
(QALY) en per gewonnen ‘succesvol behandelde week’ werden berekend. Patiënten in de 
zelfmanagementgroep wonnen meer QALYs en hadden meer succesvol behandelde weken 
tijdens de 2-jaars observatieperiode. Er was sprake van een besparing in het gebruik van 
inhalatiecorticosteroïden in de zelfmanagementgroep. De kosten door verzuim van arbeid en 
andere dagelijkse activiteiten waren ook lager in de zelfmanagementgroep. Indien de 
medische kosten en de kosten door productiviteitsverlies werden meegenomen was 
zelfmanagement kosteneffectief voor alle bestudeerde effectmaten. Geconcludeerd werd 
daarom dat zelfmanagement een veilig en efficiënt alternatief is voor de astmazorg zoals die 
doorgaans vanuit de huisartspraktijk wordt verleend. 
 
In Hoofdstuk 10 werden de effecten onderzocht van het vroegtijdig starten van een 
behandeling met inhalatiecorticosteroïden (fluticason propionaat) bij personen met 
beginnende tekens en symptomen van COPD, maar bij wie deze diagnose nog niet was 
gesteld. Personen met een versnelde jaarlijkse daling van de longfunctie en aanhoudende 
luchtwegsymptomen werden door middel van een gericht bevolkingsonderzoek en 
daaropvolgende monitoring opgespoord. Achtenveertig personen werden betrokken in een 
placebo-gecontroleerd experiment; de ene helft werd twee jaar lang met fluticason behandeld, 
de andere helft met placebo. Na drie maanden was de eensecondewaarde (FEV1) meer 
toegenomen in de fluticasongroep dan in de placebogroep. De daaropvolgende jaarlijkse 
daling van de FEV1 werd echter niet gunstig beïnvloed door fluticason, noch had deze 
behandeling een gunstig effect op luchtwegsymptomen, kwaliteit van leven of het optreden 
van exacerbaties. Na de eerste drie maanden verbeterde de FEV1 bij mensen die 
hyperreactiviteit van de luchtwegen vertoonden wel in de fluticasongroep, maar niet in de 
placebogroep. Bij de jaarlijkse FEV1-daling had aanwezigheid van bronchiale 
hyperreactiviteit echter geen modificerende rol ten aanzien van de effectiviteit van de 
behandeling. Geconcludeerd werd dat vroegtijdige behandeling met inhalatiesteroïden geen 
gunstige invloed had op de progressieve longfunctiedaling of op andere respiratoire 
effectmaten bij personen met beginnend COPD. 
 
Het doel van de in Hoofdstuk 11 beschreven studie was te bepalen in hoeverre het stopzetten 
van een behandeling met inhalatiecorticosteroïden bij patiënten met COPD op de korte 
termijn leidt tot een negatieve uitkomst (d.w.z. een exacerbatie of verergering van 
luchtwegklachten). Het betrof een prospectieve ongeblindeerde stopstudie voor 
inhalatiesteroïden bij 201 COPD-patiënten met verschillende mate van ernst van 
luchtwegobstructie. De patiënten waren gediagnosticeerd en werden behandeld in de 
huisartspraktijk. De kans op een negatieve uitkomst in de eerste drie maanden na het stoppen 
van de inhalatiesteroïden was 0.37. Leeftijd, geslacht, rookstatus en reversibiliteit van 
luchtwegobstructie voorspelden de kans op een negatieve uitkomst. De conclusie luidde dat 
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het staken van een behandeling met inhalatiesteroïden bij een deel van de COPD-patiënten 
een negatief effect kan hebben. In dit onderzoek was de kans op een negatieve uitkomst groter 
voor vrouwen, ouderen en rokers en bij patiënten met een reversibele obstructie. 
 
In Hoofdstuk 12 werden de frequentie van optreden en de behandeling en medische kosten 
van exacerbaties bij patiënten met COPD in huisartspraktijken bestudeerd. Gegevens over het 
optreden en de behandeling van exacerbaties werden verzameld door middel van systematisch 
medisch dossier onderzoek over een periode van 2 jaar. Volgens internationale criteria hadden 
patiënten chronische bronchitis zonder obstructie (26%), milde luchtwegobstructie (19%), 
matige obstructie (40%) of ernstige obstructie (15%). De gemiddelde exacerbatiefreqeuntie 
was 0.88 exacerbaties per jaar. De frequentie van exacerbaties was niet gerelateerd aan de 
ernst van de luchtwegobstructie. De gemiddelde jaarlijkse exacerbatiekosten per patiënt 
bedroegen €40, €53, €61 en €92 in de opeenvolgende subgroepen qua ernst van obstructie. De 
stijging van de kosten in de subgroepen met ernstigere problematiek was vooral toe te 
schrijven aan hogere kosten door consulten bij een arts (huis- of longarts), diagnostische tests 
en recepten voor medicijnen ter verlichting van symptomen (met name luchtwegverwijders, 
hoestpreparaten). De conclusie luidde dat in de groep COPD-patiënten die behandeld wordt in 
de huisartspraktijk het vóórkomen van exacerbaties niet afhangt van de ernst van de 
luchtwegvernauwing, maar dat de kosten die gepaard gaan met deze exacerbaties wel stijgen 
naarmate de longfunctie ernstiger gestoord is. 
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Dankwoord 
Dankwoord 
 
In de afgelopen jaren heb ik ervaren hoe complex en arbeidsintensief het doen van 
wetenschappelijk onderzoek in de Nederlandse huisartspraktijk is. De diverse onderzoeken 
waaruit dit proefschrift is voortgekomen hadden onmogelijk uitgevoerd kunnen worden 
zonder de toewijding en inzet van een groot aantal mensen. Ik ben de patiënten, huisartsen, 
praktijkassistenten, longfunctielaboranten en longartsen en alle andere mensen die bij de 
verschillende onderzoeksprojecten betrokken waren zeer erkentelijk voor hun onmisbare - en 
vaak belangeloze – inzet. 
 
Daarnaast wil ik een aantal mensen speciaal bedanken voor hun rol bij de totstandkoming van 
dit proefschrift. 
 
Beste Chris (van Weel), ik waardeer het enorm dat je mij als ‘niet-huisarts’ het 
vertrouwen en de ruimte hebt gegeven om de onderzoekslijn voor COPD- en astma binnen de 
afdeling Huisartsgeneeskunde grotendeels naar eigen inzicht voort te kunnen zetten. Door je 
brede visie op de huisartsgeneeskunde en het wetenschappelijk onderzoek daarbinnen ben je 
voor mij een onmisbaar klankbord. Ondanks het feit dat je in de komende jaren waarschijnlijk 
minder tijd zult gaan krijgen voor directe betrokkenheid bij het onderzoek, hoop ik nog jaren 
voor en met je te kunnen werken. 
Beste Onno (van Schayck), jou wil ik bedanken voor het feit dat je mij in 1996 wist 
over te halen om na mijn grote stage voor Gezondheidswetenschappen bij de ‘CARA-groep’ 
te blijven. Zonder de kansen en inzichten die jij me destijds hebt gegeven zou ik nu niet zijn 
waar ik ben. Hoewel ons contact de laatste jaren qua aard en frequentie duidelijk veranderd is, 
denk ik nog vaak terug aan de dynamiek van de tijd dat jij nog het Nijmeegse gezicht van het 
COPD- en astmaonderzoek was. 
Beste Richard (Dekhuijzen), jij bedankt voor het feit dat ik altijd bij je terecht kon (en 
kan) met vragen. Je ‘no-nonsense’ houding helpt dingen snel tot de essentie terug te brengen. 
Ik zie uit naar de voortzetting van de samenwerking met jou en met de andere Nijmeegse 
longartsen, zowel binnen de lopende projecten als bij het uitwerken van de nieuwe 
onderzoeksplannen. 
Beste Bart (Thoonen), de jaren dat we samen aan het ZBA-onderzoek werkten waren 
bijzonder enerverend. Na een periode van minder intensief contact bieden de recente 
ontwikkelingen op onderzoeksgebied de mogelijkheid om onze contacten en samenwerking 
weer nieuw leven in te blazen.  
Beste Reinier (Akkermans), zonder jouw deskundigheid op het gebied van 
(geavanceerde) statistische analyses zou het onderzoekerswerk voor mij – en voor veel andere 
onderzoekers binnen ons instituut - een stuk lastiger zijn.  
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Beste Riet (Cretier), Joke (Grootens), Joliet (Hartman), Annie (Hendriks), Lea (Peters) 
en Gita (Siebers), jullie wil ik bijzonder bedanken voor jullie jarenlange inzet bij de diverse 
onderzoeken waarop delen van dit proefschrift zijn gebaseerd (COOPT, HASPIR, ZBA, 
DIMCA). Ik heb grote waardering voor het feit dat jullie – op één uitzondering na - allemaal 
zonder enige ervaring in het wetenschappelijk onderzoek begonnen zijn op onze afdeling en 
in een aantal jaren tijd zijn uitgegroeid tot doorgewinterde onderzoeksassistenten. 
Beste Twanny (Jeijsman-Rouwhorst), jij bedankt voor je rol als steun en toeverlaat 
voor de CARA-groep. Ik kan me niet herinneren ooit vergeefs een beroep op je te hebben 
gedaan. En natuurlijk bedankt voor je bijdrage aan dit proefschrift en het mij herinneren aan 
de verplichtingen die een promotie nu eenmaal met zich meebrengt. 
Beste Hans (Folgering), van jou heb ik ontzettend veel geleerd over longfunctie en 
luchtwegaandoeningen. De samenwerking in het kader van het kenniscentrum ‘Opgelucht 
werken’ was heel stimulerend. Ik vind het erg jammer dat door je recente ‘afzwaaien’ de 
samenwerking nu grotendeels is gestopt. 
Beste Lilian (Bierman), ruim een decennium ben je op het Universitair Longcentrum 
Dekkerswald de steun en toeverlaat geweest voor een reeks onderzoekers van de afdeling 
Huisartsgeneeskunde, waaronder ikzelf. Mijn hartelijke dank daarvoor! 
Beste Gerhard (Zielhuis), hoewel je het je waarschijnlijk niet realiseert, was het jouw 
optreden tijdens de open dag van de opleiding Gezondheidswetenschappen in 1990 die mij 
deed besluiten om in Nijmegen verder te gaan studeren. Dat je 15 jaar later de voorzitter van 
de commissie was die mijn manuscript beoordeelde maakt een cirkel rond. 
Beste collega’s van de afdeling Huisartsgeneeskunde en de afdeling IVES, in het 
bijzonder Wil van den Bosch, Wim de Grauw, Henk van den Hoogen, Waling Tiersma en 
Willem van Gerwen, bedankt voor jullie adviezen en bijdragen aan de onderzoeken van de 
CARA-groep. 
Lieve mam en pap, bedankt voor het feit dat jullie het, jaren na het afronden van mijn 
studie Fysiotherapie, mede mogelijk hebben gemaakt om de studie 
Gezondheidswetenschappen in Nijmegen te kunnen doen. Het blijkt dat dat destijds een hele 
goede keuze is geweest. 
Lieve Nien, Jelt en Wyk, het is de afgelopen jaren soms moeilijk geweest om werk en 
privé gescheiden te houden. Misschien dat me dat na 6 april beter gaat lukken …. 
 
Tenslotte wil ik het Nederlands Astma Fonds, GlaxoSmithKline, Novartis Pharma, 
Boehringer Ingelheim en AstraZeneca bedanken voor hun financiële bijdrage aan de kosten 
van het drukken van het proefschrift en van de promotie als geheel. 
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Tjaarda Roland Jacob Schermer was born on 23 January 1967 in Ede, the Netherlands. In 
1984 he obtained his secondary school diploma in Zevenaar and started a vocational 
physiotherapy training program in Arnhem one year later. After graduation as a 
physiotherapist in 1989 he practised physiotherapy full-time for three years. From 1991 to 
1996 he studied Biomedical Health Sciences at the Medical Faculty of the Radboud 
University Nijmegen while still working part-time as a physiotherapist. During his study in 
Nijmegen he developed a special interest in the epidemiology of chronic diseases. In 1996 he 
started working for the COPD & Asthma Research Unit of the Department of General 
Practice of the Radboud University Nijmegen Medical Centre, first as a research assistant but 
after one year as a researcher. At present he is the coordinator of the COPD & Asthma 
Research Unit and executive project leader of a number of studies in the field of COPD and 
asthma. 
He has a registered partnership with Nienke Bruins. Together they have to children, Jelte 
(1998) and Wyke (2001). They live in the city of Arnhem in the eastern part of the 
Netherlands. 
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